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 Abstract 
 (+)-Myriceric acid A, [(+)-1.1], is a natural product isolated in 0.01% yield from the 
southern bayberry, myrica cerifera twigs.   It is a specific ETA receptor antagonist because it 
selectively inhibits the endothelin-1 (ET-1) induced increase in [Ca2+] (IC50 = 11 + 2 nM) and 
antagonizes the binding of ET-1 (Ki = 66 + 15 nM), in rat aortic smooth muscle cells.  ET-1 is a 
potent vasoconstrictor peptide released by the vascular endothelial cell.  Over production of this 
peptide causes vasospasm, which may lead to heart attack, stroke, pulmonary hypertension, and 
congestive heart failure.  
My research involved the development of a total synthesis of (+)-myriceric acid A.  This 
is a triterpenoid compound that has five six-member rings, seven stereo-centers, a carboxylic 
acid group, and a trans-caffeoyl ester side chain.  The synthesis was planned to be accomplished 
by adding the D and E rings to the known ABC ring compound (4a'S,4b'R,8a'R)-1',1',4a',8a'-
tetramethyldecahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-2.1].   
Many model studies, both convergent and linear syntheses, were conducted to determine 
the best approach to construct the D and E rings.  From these studies it was determined that a 
linear synthesis was best.   
After the ABCD ring compound (4aR,4bR,6aR,10bR)-1,1,4a,10b-tetramethyl-
4,4a,4b,5,6,6a,7,8,10b,11,12,12a-dodecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolan]-9(3H)-one 
[(-)-3.41a] was synthesized, several approaches were investigated for the functionalization of the 
D ring.  The best method turned out to be one in which the C14 position of 3.41a was 
functionalized by a Michael addition of a nitrile group.  Conversion of the nitrile to the aldehyde 
proved to be problematic, but was overcome by the formation of an interesting cyclic hemiiminal 
which hydrolyzed cleanly to the aldehyde (4aR,4bR,6aR,10aS,10bR,12aR)-1,1,4a,10b-
tetramethyl-9-oxohexadecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbaldehyde 
(4.22) when treated with acid. 
Herein, the studies that led to the tetra-cyclic aldehyde 4.22, a key intermediate for the 
synthesis of (+)-myriceric acid A, will be discussed. 
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Abstract 
 
(+)-Myriceric acid A, [(+)-1.1], is a natural product isolated in 0.01% yield from the 
southern bayberry, myrica cerifera twigs.   It is a specific ETA receptor antagonist because it 
selectively inhibits the endothelin-1 (ET-1) induced increase in [Ca2+] (IC50 = 11 + 2 nM) and 
antagonizes the binding of ET-1 (Ki = 66 + 15 nM), in rat aortic smooth muscle cells.  ET-1 is a 
potent vasoconstrictor peptide released by the vascular endothelial cell.  Over production of this 
peptide causes vasospasm, which may lead to heart attack, stroke, pulmonary hypertension, and 
congestive heart failure.  
My research involved the development of a total synthesis of (+)-myriceric acid A.  This 
is a triterpenoid compound that has five six-member rings, seven stereo-centers, a carboxylic 
acid group, and a trans-caffeoyl ester side chain.  The synthesis was planned to be accomplished 
by adding the D and E rings to the known ABC ring compound (4a'S,4b'R,8a'R)-1',1',4a',8a'-
tetramethyldecahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-2.1].   
Many model studies, both convergent and linear syntheses, were conducted to determine 
the best approach to construct the D and E rings.  From these studies it was determined that a 
linear synthesis was best.   
After the ABCD ring compound (4aR,4bR,6aR,10bR)-1,1,4a,10b-tetramethyl-
4,4a,4b,5,6,6a,7,8,10b,11,12,12a-dodecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolan]-9(3H)-one 
[(-)-3.41a] was synthesized, several approaches were investigated for the functionalization of the 
D ring.  The best method turned out to be one in which the C14 position of 3.41a was 
functionalized by a Michael addition of a nitrile group.  Conversion of the nitrile to the aldehyde 
proved to be problematic, but was overcome by the formation of an interesting cyclic hemiiminal 
which hydrolyzed cleanly to the aldehyde (4aR,4bR,6aR,10aS,10bR,12aR)-1,1,4a,10b-
tetramethyl-9-oxohexadecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbaldehyde 
(4.22) when treated with acid. 
Herein, the studies that led to the tetra-cyclic aldehyde 4.22, a key intermediate for the 
synthesis of (+)-myriceric acid A, will be discussed. 
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CHAPTER 1 - Introduction: isolation, partial synthesis and 
biological importance of (+)-myriceric acid A 
1.1  Isolation and characterization of (+)-myriceric acid A 
 
 In 1996 Fujimoto et al.1, at Shionogi Research Laboratories in Japan, reported the 
isolation of (+)-myriceric acid A [(+)-1.1] from the plant Myrica cerifera.   This triterpene was 
the first non-peptide endothelin A receptor antagonist from a plant.1 
 Endothelin-1-induced increase of cytosolic free Ca2+ was inhibited by the methanol 
extract from the fresh twigs of Myrica cerifera.1   Further extraction from chloroform and water 
showed increased activity of the chloroform fraction.  Silica gel chromatography gave an active 
fraction that showed one major peak on reverse phase HPLC.  Semi-preparative reverse phase 
HPLC produced (+)-myriceric acid A [(+)-1.1].1 
 The molecular formula, C39H52O7, was deduced from mass spectrometry analysis of the 
crystalline (+)-1.1.1   1H-NMR and 13C-NMR of (+)-1.1 suggested the presence of a trans-
caffeoyl group, six tertiary methyl groups, a CH2OR group, a double bond, a carbonyl group, and 
a carboxyl group.1  
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Figure 1.1: Myriceric acid A and oleanoic acid1 
 
 These NMR spectral data indicated that it was a derivative of 3-oxoolean-12-en-28-oic 
acid (1.2) with one of the methyl groups substituted by a trans-caffeoyloxo group (Figure 1.1).1 
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Scheme 1.1: Synthesis of acetate (+)-1.4 from (+)-myiceric acid A1 
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a.) i. CH2N2/ether, MeOH  ii. NaOH, MeOH, 50oC 1.5 h  b.) Ac2O, pyridine overnight rt. 
 
Methylation followed by basic hydrolysis of (+)-1.1 produced hydroxy methyl ester (+)-
1.3.1   Acetylation of the hydroxymethel group in (+)-1.3 produced acetate (+)-1.4 (Scheme 1.1), 
from which its crystal structure was obtained (Figure 1.2).1 
 
 
Figure 1.2:  Crystal structure of (+)-1.41 
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 The crystal structure of (+)-1.4 confirmed the proposed structure of (+)-myriceric acid A, 
(+)-1.1. 
 
1.2 Partial synthesis of myriceric acid A from oleanolic acid2 
 
 After their isolation of myriceric acid A, Konoike et al.1,2, wanted to do further 
pharmacological evaluations and study the structure-activity relationships of myriceric acid A 
and its derivatives.2  Because the content of (+)-1.1 in the plant was only 0.01%, in 1997 they 
reported the development of an efficient 14 steps synthesis of (+)-1.1 from the natural compound 
oleonolic acid 1.7.2 
  
Scheme 1.2: Retro-synthesis of myriceric acid A [(+)-1.1] from oleanolic acid (1.7) 2 
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 As illustrated in their retrosynthetic analysis of (+)-1.1 (Scheme 1.2), two key 
intermediates were needed to accomplish the synthesis of (+)-1.1 from oleanolic acid (1.7).2   
Oleanolic acid (1.7) already has all the stereocenters required in (+)-1.1, the major differences 
are that 1.7 has a hydroxy group at C3 which should be a ketone in (+)-1.1 and the C14 methyl 
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group in 1.7 is replaced by a trans-caffeoyloxymethyl group in (+)-1.1.  Intermediate, 
myricerone (1.6) was obviously a key compound necessary for obtaining these required 
functionalities.2   Because direct acylation of the C27 hydroxy group was not efficient and failed 
when attempted with 3,4-di-O-acetylcaffeic acid, Konoike et al.2 developed a new procedure that 
required the key intermediate phosphonate 1.5.  This would be used in a Horner-Wadsworth-
Emmons (HWE) olefination3 with a dihydroxy-benzaldehyde derivative.  Phosphonate 1.5 was 
very versatile and could be used with other aldehydes so other derivatives were possible from 
this intermediate.2   
 
Scheme 1.3: Synthesis of nitrite 1.10 from oleanolic acid (1.7) 2 
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a.) Jones oxidation; b.)  O3, MeOH, -50oC, 79% yield; c.)  NOCl, pyridine, -40oC, 30 min., 94% yield.2 
 
A key step in the conversion of 1.7 to the intermediate 1.6 was introduction of the C27 
hydroxy group using the Barton reaction4.  Three steps, from oleanolic acid (1.7), were required 
to make the starting compound 1.10 for the Barton reaction.  Oxidation of the C3 hydroxy group 
was accomplished by Jones oxidation of 1.7 to produce oleanoic acid (1.8).2   Introduction of 
ozone to a crude solution of 1.8 produced the 12α-hydroxy lactone 1.9 in which the 12α-
hydroxy group was the scaffold for the Barton reaction.  Nitrite 1.10 was formed by treatment of 
hydroxy lactone 1.9 with nitrosyl chloride in pyridine.2   To prevent decomposition of nitrite 
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1.10, it was necessary for the work up and crystallization to be done in the presence of pyridine 
(Scheme 1.3).2 
Several reaction conditions were investigated for the Barton reaction of nitrite 1.10 to 
produce oxime 1.11.2   From these investigations they determined that acetone was the best 
solvent and lower concentrations increased the yield.  Also, irradiation should be done between 
329-379 nm in less than one hour and exclusion of oxygen was essential.  Pyridine was not 
necessary but prevented decomposition of nitrite 1.10, and temperature did not affect the 
reaction.2   The photochemical reaction of 1.10 was done following the requirements stated 
above to produce oxime 1.11 (Scheme 1.4).2  
 
Scheme 1.4: Barton reaction of 1.10 to produce oxime 1.112 
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a.) acetone, pyridine, irridiation 329-379nm, 1 h under nitrogen atmosphere, 74% yield.2 
 
 Direct formation of its corresponding aldehyde 1.14 from oxime 1.11 was difficult 
because of steric hindrance around the C27 position, so they generated it through a three-step 
process starting by formation of imine 1.12 from oxime 1.11.2   Treatment of oxime 1.11 with 
TiCl3 produced imine 1.12, which was stable under normal hydrolysis conditions.2   Hydrolysis 
of imine 1.12 was accomplished by treatment with sodium nitrite in aqueous dioxane-acetic acid 
to produce a mixture of two compounds, hemiacetal acetate 1.13 and hydroxy aldehyde 1.14 in a 
2:1 ratio, respectively.  Treatment of the mixture of 1.13 and 1.14 with sodium hydroxide in 
methanol produced aldehyde 1.14 as the sole product (Scheme 1.5).2 
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Scheme 1.5: Seven step conversion of oxime 1.11 to myricerone (1.6)2 
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a.) 20% TiCl3, 10:1 dioxane:AcOH, 26oC 4 h, 88% yield.  b.) aqueous NaNO2, 10:1 dioxane:AcOH, 40oC 1 h  c.)  
NaOH, MeOH, 14-26oC, 2.5 h, 77% yield d.)  PPTS, ethylene glycol, Toluene, reflux 4 h  e.)  Ac2O, pyridine, 
DMAP, CH2Cl2 5 h, 96% yield 2 steps  f.)  THF, Li, NH3 (l), 45 min. g.)  HCl, THF, reflux 75 min., 99% yield 2 
steps.2 
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From aldehyde 1.14, four more steps were required to complete the synthesis of the key 
intermediate, myricerone (1.6).  The first step was protection of the C3 ketone in aldehyde 1.14, 
which was accomplished by treatment with PPTS and ethylene glycol to produce the ethylene 
ketal 1.15.  Treatment of ketal 1.15 with acetic anhydride in pyridine resulted in the acetylation 
of the C12 hydroxy group producing acetoxy ketal 1.16.2   Formation of the C12-C13 double 
bond was accomplished by reductive elimination of the acetoxy lactone moiety with lithium in 
liquid ammonia.  Interestingly, the C14 aldehyde was also reduced in the process producing the 
desired C14-hydroxy methyl group in compound 1.17.2   The ethylene-ketal protecting group in 
1.17 was removed by treatment with aqueous hydrochloric acid and resulted in the formation of 
the key intermediate myricerone (1.6).2 
 Synthesis of the second key intermediate, phosphonate 1.5, was accomplished in one step 
from 1.6.  Commercially available diethoxyphosphonoacetic acid was condensed with 
myricerone 1.6 by treatment with carbonyl diimidazole to give phosphonate 1.5 (Scheme 1.6) in 
39% yield, after 12 steps, from oleanolic acid 1.7.2 
 
Scheme 1.6: Synthesis of phosphonate 1.5 from myricerone (1.6) 2 
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a.) diethoxyphosphonoacetic acid, carbonyl diimidazole, CH2Cl2, rt 6 h, 84% yield.2 
 
 Since direct HWE olefination of 1.5 with 3,5-dihydroxybenzaldehyde (1.18) failed 
because the phenolic hydroxy groups deactivated the aldehyde.  They were protected as 
diphenylmethyl groups to produce aldehyde 1.19 (Scheme 1.7).2   
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Scheme 1.7: Synthesis of 1.19 from 1.182 
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a.) Ph2CHBr, K2CO3, DMF, 80oC 5 h, 23% yield.2 
 
 The HWE olefination of phosphonate 1.5 and aldehyde 1.19 produced compound 1.20 in 
95 % yield.  Treatment of 1.20 with triflouracetic acid in anisole removed the diphenyl methyl 
protecting groups and produced (+)-myriceric acid A [(+)-1.1] (Scheme 1.8).2 
 
Scheme 1.8: HWE olefination of 1.5 and deprotection of 1.20 to form myriceric acid A [(+)-
1.1] 2 
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a.)   DBU, LiCl, DMF rt 5 h, 95% yield  b.)  TFA, anisole, rt 1.5 h, 80% yield 2 steps.2 
 
 Synthesis of (+)-myriceric acid A [(+)-1.1] was accomplished in 14 steps and 31% yield 
starting from the natural product oleanolic acid (1.7).  No chromatographic purification was 
necessary until after the reaction of 1.20 to produce the final product (+)-1.1.2 
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1.3   Importance and biological activity of myriceric acid A. 
 
 After its isolation, (+)-myriceric acid A [(+)-1.1] showed inhibition of endothelin-1-
induced increase in cytosolic Ca2+ concentration (median inhibition concentration (IC50) = 11 + 2 
nM) and binding of endothelin-1 (ET-1) in rat aortic smooth muscle cells (binding constant (Ki) 
= 66 + 15 nM).1  Since it selectively antagonized binding of ET-1 but not ET-3 it was confirmed 
that it was a specific ETA receptor antagonist.1 
 
1.3.1  Endothelins 
 
 In 1988, Yanasigawa et al.5 reported that from the supernatant of porcine aortic 
endothelial cells (EC) they isolated and determined the amino acid sequence of a potent 21-
residue vasoconstrictor peptide.  This new peptide, now known as endothelin-1 (ET-1), has a 
relative molecular mass (Mr) of 2,492 and its four cystein residues form two intra-chain disulfide 
bonds (Cys1-Cys15 and Cys3-Cys11).5  Comparing its activity to other vasoconstrictors, ET-1 is 
the most potent mammalian vasoconstrictor peptide and its contraction is long lasting and 
difficult to wash out even more than angiotensin II.6   
 
Figure 1.3: Formation of ET-1 from preproET-16 
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Yanagisawa et al. also molecularly cloned the precursor peptide, which was a 203-residue 
preproendothelin sequence in pigs5 and 212 amino acids in humans6.  This precursor peptide 
undergoes three proteolytic steps to produce the mature ET-1.5,6  First it is cleaved between 
Lys51 and Arg52, then between Arg92 and Arg93 by dibasic endopeptidases to give a 38 amino 
acid (39 amino acids in humans) intermediate, big endothelin-1 (big ET-1).  An unusual specific 
cleavage between Trp73 and Val74 by an endothelin-converting enzyme (ECE) results in the 
formation of the mature ET-1 (Figure 1.3).5,6 
 Two other isopeptides, ET-2 and ET-3, were also identified after analysis of the human 
genomic library.1   The three isopeptides are very similar in sequence to each other and also to 
sarafotoxins, which are a family of peptides found in cobra venom.6   They all consist of 21 
amino acids, two disulphide bridges between Cys1-Cys15 and Cys3-Cys11, the charged 
tripeptide Asp8-Lys-Glu10, and the carboxy-terminal penta-peptide His16-Leu-Asp-Ile-Ile-
Trp21 (Figure 1.4).6   The free carboxylic C-terminal on Trp, and the disulphide bonds have been 
found to be necessary for biological activity and binding to the ETA receptor.  It was found that if 
the internal Cys3-Cys11 was replaced by alanines there was a slight loss of agonist activity on 
the other hand when Cys1-Cys15 was replaced almost all the activity was lost.6   
 
 
Figure 1.4: Similarities of ETs and sarafotoxins6 
  
 ET-1 is expressed in numerous vascular and non-vascular cells but it is the only one 
found in vascular endothelial cells, which explains why it is the primary circulating isoform.6   
For the other isoforms, ET-2 is mostly found in the gastrointestinal tract and ET-3 is found in the 
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neuronal tissues.6   Because it is one of the most potent and long lasting vasoconstrictors, ET-1 
has gotten most attention of the three isopeptides.6      
 
1.3.2  Endothelin receptors 
 
  The different potencies of the three isopeptides toward vasoconstrictory and 
vasodilatory activity: ET-1> ET-2 >> ET-3 for vasoconstriction and ET-1 = ET-2 = ET-3 for 
vasodilation indicated that these actions of ETs were mediated by different receptors.6   
Radioligand binding studies revealed that the vasoconstrictory receptor that prefers ET-1 was 
found in the vascular smooth muscle cells and the vasodilatory receptor that has the same affinity 
for both ET-1 and ET-3 was found on the endothelium.  These two receptors were termed the 
ETA and ETB receptors, respectively.6  
The ETA receptor was originally isolated, by Arai et al7, from bovine lung and was found 
to be a protein of 427 amino acids with a molecular mass of 48.5 kilodaltons with seven 
hydrophobic regions of 22-27 residues.6   The ETB receptor was originally isolated, by Sakuri et 
al8, from rat lung and was found to be a protein of 441 amino acids with a molecular mass of 47 
kilodaltons with seven hydrophobic regions.6   The ETA and ETB are ~60% homologous to each 
other and because their trans-membrane regions are highly homologous to that of G-protein 
coupled receptors (GPCR) they are considered members of the superfamily of GPCRs.6   
 
1.3.3  Vascular signal transduction mechanism for contraction 
 
 Two factors determine the contractile status of the vascular smooth muscle cells: the 
cytosolic Ca2+ concentration and the Ca2+ sensitivity of the myofilaments13.  The ETA receptor is 
coupled to phospholipase-C (PL-C)-coupled Gq proteins.10   Binding of ET-1 to the ETA receptor 
activates PL-C which stimulates formation of inositol triphosphate (IP3) and diacylglycerol 
(DAG) from phophatidylinsositol biphosphate (PIP2).10  IP3 then stimulates the sarcoplasmic 
reticulum to release Ca2+.10,11  The free Ca2+ binds to calmodulin (CaM), a calcium binding 
protein, and the Ca-CaM complex activates myosin light chain kinase (MLCK) that 
phosphorylates myosin light chain (MLC) in the presence of ATP.11   Phosphorylation of MLC 
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to MLC-P leads to cross-bridge formation of the myosin head and actin filaments, which results 
in contraction.11  PL-C activation also forms diacylglycerol (DAG), which activates protein 
kinase C10, which can also phosphorylate the MLC, which would result in contraction also 
(Figure 1.5).  
The Ca2+ sensitivity of the myofilaments depends on the activity ratio of MLCK and 
myosine light chain phospatase (MLCP).  MLCP dephosphorylates the MLC-P to produce the 
MLC.  
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Figure 1.5: Vascular signal transduction mechanism for contraction9,10,11 
   
Because of the significant presence of endothelin and/or receptors in many mammalian 
tissues it is believed that they may be involved many diseases like: stroke, migraine, and 
subarachnoid hemorrhage in the brain; congestive heart failure; pulmonary hypertension, and 
bronchial asthma in the lung to name a few6.  To further understand and possibly treat these 
diseases endothelin receptor antagonists need to be investigated. 
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1.4    Superfused spiral modiolar artery (SMA) of the gerbil as the bioassay 
for determining ETA receptor antagonistic activity of the synthetic 
intermediates 
 
 To evaluate the functional activities of our synthesized intermediates, as specific ETA 
receptor antagonists, we would use the well established bioassay, isolated in vitro superfused 
spiral modiolar artery (SMA) of the gerbil.  In 2001, Wangemann et al.13 demonstrated that ET-1 
induced, via the ETA receptors, a transient Ca2+ concentration [Ca2+] increase and a long lasting 
vasocontriction of the gerbil spiral modiolar artery (SMA).13  In the same study they also 
determined that Ca2+ mobilization was not necessary for the development of the 
vasoconstriction, but its maintenance was dependent on influx of extra-cellular calcium.13  It was 
concluded that other signaling mechanisms were also present which increased the sensitivity of 
the myofilaments resulting in lower [Ca2+] maintaining the constriction.13   
  
1.4.1  Spiral modiolar artery 
 
The spiral modiolar artery is an arteriole that provides the main blood supply to the 
cochlea.13   It has a diameter of 62 μm14 and loosely surrounds the eight cranial nerve in the 
cochlea of the inner ear.  The vascular diameter controls the blood flow and the diameter 
depends on the contractile state of the vascular smooth muscle cells.13   Access to the ETA 
receptor is ideal, on the SMA, because the wall contains only a single layer of vascular smooth 
muscle cells and a single layer of endothelial cells. 12  (Figure 1.6) 
 
 
Figure 1.6: Cross section through the wall of the SMA12 
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 This makes the isolated spiral modiolar artery (SMA) of the gerbil a suitable bioassay for 
determining ETA receptor antagonists. 
1.4.2  Isolation of the SMA and simultaneous measurement of  [Ca2+] and vascular 
diameter 
In this bio-assay the diameter of the SMA and the [Ca2+]i were measured simultaneously 
by video-microscopy and microflourometry.  Isolation of the SMA was achieved by micro-
dissection, in control solution, of the cochlea obtained from a gerbil.13 
 
 
Figure 1.7: Schematic for simultaneous measurement of [Ca2+] and vascular diameter by 
microflourometry and video microscopy13 
 
A segment of the isolated SMA was treated with molecular probes and transferred to a 
bath chamber (superfusion chamber), with control solution at 37oC, mounted on the stage of an 
inverted microscope.13   After illumination, changes in [Ca2+]i were determined by changes in the 
emission intensity.  Simultaneously, the outer diameter of the SMA was monitored and 
calibrated by video-edge detectors.  Changes were monitored on a chart recorder.13 (Figure 1.7) 
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1.4.3  Endothelin-1 effect on SMA 
 
Two experiments, a pulsatile and a cumulative experiment, were performed to study the 
effect of ET-1 on the [Ca2+] and the constriction of the SMA. 
In both experiments, the [Ca2+] and vascular diameter were normalized by increasing the 
[Ca2+] from 1 mM to 10 mM.  In the pulsatile experiment, in which a single dose of ET-1 was 
added, a transient [Ca2+] increase was observed along with a significant and long lasting 
vasoconstriction.  The [Ca2+] quickly returned to normal, however the vasocontriction remained 
even after the ET-1 was removed from the perfusate and the SMA was superfused with 1 mM 
Ca2+ solution.  In the cumulative experiment, an increasing dose of ET-1 showed a step-wise 
decrease of vascular diameter and no transient [Ca2+] increase was observed.13 (full procedure is 
described in chapter 5 and in the experimental section) 
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Figure 1.8: Top – (left) Pulsatile experiment; (right) cumulative experiment; Bottom – (left) 
Dose response curve for constriction; (right) dose response curve for [Ca2+]13 
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Comparison of the dose response curves obtained from both experiments show that the 
potency of the ET-1 toward constriction is the same in both experiments, however there is a 
significant difference in [Ca2+] increase.13   These data suggested that the transient increase in 
[Ca2+] was not necessary for the development of the contraction.  However, another experiment 
(not shown), indicated that influx of Ca2+ was necessary for the maintenance of the 
constriction.13   These results were consistent with the view that the sensitivity of the 
myofilaments toward Ca2+ was increased by ET-113, through a different signaling pathway. 
 
1.4.4  Effect of ETA receptor antagonists on ET-1 induced constrictions of the SMA 
 
A known selective ETA receptor antagonist is the synthetic cyclic peptide BQ-123 (1.21) 
(Figure 1.9).  In the SMA bioassay, when BQ-123 was present in the perfusate, no [Ca2+] 
increase or vasoconstriction was observed when a single dose of ET-1 was added.13,14  This 
indicated that the antagonist prevented both the [Ca2+] increase and the vasospasm by preventing 
the binding of the agonist, ET-1, to the ETA receptor. 
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1.21
BQ-123  
Figure 1.9: Structure of specific ETA receptor antagonist BQ-123 (1.21) 
 
Since it was able to prevent the vasospasm, determination of whether it could reverse it 
was investigated.  After the BQ-123 was washed out, the [Ca2+] increase and vasospasm were 
induced by a single dose of ET-1.  After the ET-1 was removed form the perfusate and the SMA 
was superfused with 1 mM Ca2+ solution, as expected, the vasospasm remained.  Addition of 
BQ-123 failed to reverse the vasospasm (Figure 1.10).14   
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Figure 1.10: Effect of ETA receptor antagonist BQ-123 in pulsatile experiment.  The 
antagonist was able to prevent the vasoconstriction but it failed to reverese it. 14 
 
It can be concluded from these results that the specific ETA receptor antagonists BQ-123 
can prevent the vasospasm but it is unable to reverse it.  While the SMA is superfused with the 
antagonist BQ-123, the antagonist binds to the ETA receptor and prevents the effect of the 
agonist, ET-1, and so prevents the vasospasm to occur.  After the ET-1 induced the vasospasm 
the antagonist was unable to reverse it because the maintainance of the constriction is not 
dependent on the binding of the agonist to the receptor.  The initial binding of the ET-1 to 
activate the receptor stimulates a different signaling mechanism that maintains the constriction.  
This mechanism is dependent on Rho-kinase inhibition of the myosin light chain phosphatase 
(MLCP) which results in sensitization of the contractile apparatus.  This results in a lower Ca2+ 
concentration maintaining the constriction.  So, ETA receptors are necessary for the initiation of 
the vasospasm but they may not be needed for the maintenance of the constriction.  
The affinity constant (KDB), which quantitatively indicate the effectiveness of the 
antagonist at preventing the effect of the agonist, of BQ-123 was determined to be 24 nM in the 
SMA bioassay.  To compare the effectiveness of (+)-myriceric acid A, an experiment in which 
ET-1 was added cumulatively in the presence of 1 μM (+)-myriceric acid A, was performed.  
From the shifts in the dose response curves, and the assumption that inhibition is competitive, the 
KDB of (+)-myriceric acid A was determined to be 500 nM (Figure 1.11). 
 
 17
  
Figure 1.11: Top - Effect of ETA receptor antagonist myriceric acid A in a cumulative 
addition of ET-1.   Bottom – Dose response curve of myriceric acid A 
 
This result show that myriceric acid A is an antagonist which prevents the vasospasm up 
to 3 nM of ET-1 when the SMA is superfused with 1 μM (+)-myriceric acid A, KDB = 500 nM.  
Because the KDB of (+)-myriceric acid A is 20 times less than that of BQ-123, KDB = 24 nM, a 
total synthesis of (+)-myriceric acid A is necessary from which synthetic intermediates can be 
evaluated and possibly a more active compound can be obtained. 
 
1.5  Conclusion:  
 
Because of the significant presence of endothelin and/or receptors in many mammalian 
tissues it is believed that they may be involved many diseases; like stroke, pulmonary 
hypertension and congestive heart failure.6   To treat and prevent these diseases, endothelin 
receptor antagonists need to be invesitigated.  A non-peptide that is a selective ETA receptor 
antagonist is myriceric acid A.1 It showed inhibition of endothelin-1-induced increase in 
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cytosolic Ca2+ concentration (IC50 = 11 + 2 nM) and binding of endothelin-1 (ET-1) in rat aortic 
smooth muscle cells (Ki = 66 + 15 nM).1  
Although the affinity constant of (+)-myriceric acid A (KDB = 500 nM) is 20 times less 
than that of the known specific ETA receptor antagonist BQ-123 (KDB = 24 nM), derivatives with 
higher activities may be obtained from a total synthesis.  This is evident in the structure-activity 
relationship study done by Fujimoto et al.1, after the isolation of (+)-myriceric acid A.  They 
synthesized three derivatives of myriceric acid A; 1.22, 1.23, and 1.24 which showed higher 
binding affinities Ki = 15, 3.4, and 41 nM, respectively (Figure 1.12) than (+)-myriceric acid A.1 
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Figure 1.12: Sulfonic derivatives of myriceric acid A1 
 
 Although the partial synthesis of myriceric acid A could allow for some structure-activity 
realationship studies, it was limited to derivatization of the existing functional groups on the 
pentacyclic backbone of the starting natural product oleanoic acid2.  For a more in depth 
structure-activity relationship study, a total synthesis of myriceric acid A is necessary, from 
which synthetic intermediates and novel analogs would be obtained.  
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CHAPTER 2 - Synthesis of the ABC rings of (+)-myriceric acid A 
and model studies for constructing the DE rings  
2.1 Retrosynthesis of (+)-myriceric acid A 
 
(+)-Myriceric acid A [(+)-1.1] is a pentacyclic triterpenoid isolated from the chloroform 
soluble fraction of the methanol extract of Myrica cerifera twigs.  It was the first non-peptide 
endothelin A receptor antagonist isolated from a plant1. It has seven stereo-centers, a double 
bond between C12 and C13, a caffeic ester side chain connected to a hydroxy methyl group 
(trans-caffeoyloxymethyl group) at C14 and a carboxylic acid at C17. 
 
Scheme 2.1: Retro synthesis of myriceric acid A from tricyclic compound (+)-2.2 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19 20 21
22
H
CO2H
H
H
O O
O
OH
OH23 24
25 26
27
28
29 30
A
B
C
D
E
H
HO
O
O
A
B
C
(+)-1.1 (-)-2.1
OH
A B
C
(+)-2.2
O
 
 
We planned to synthesize (+)-1.1 from the known tricyclic compounds (-)-2.1 which 
could be derived from (+)-2.215-19 (Scheme 2.1).  Compound (+)-2.2 and (-)-2.1 have been used 
as key intermediates for the synthesis of several terpenoids15-19.  Compound (-)-2.1 already has 
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the ABC rings with the C5, C8, C9, and C10 stereocenters of myriceric acid A.  The ketone at 
C14 in (-)-2.1 would be used to build the D and E rings.   
 
2.2  Synthesis of the ABC rings of (+)-myriceric acid A 
 
Compound 2.2 and 2.1 have been used by several research groups for the racemic and 
asymmetric synthesis of various natural products.15-19   This is because their synthesis initiates 
from simple, commercially available, and relatively inexpensive materials.  It also contains most 
of the stereo-centers of the ABC rings of many pentacyclic triterpenes.  Because of their proven 
versatility for the synthesis of several natural products15-19, 2.1 and 2.2 will be used as the ABC 
rings of (+)-myriceric acid A. 
 
2.2.1 Assymetric synthesis of the BC rings using an enantioselective intramolecular 
aldol condensation as a key step 
   
The synthesis of (-)-2.1 was initiated by a Michael addition reaction of 2-methyl-1,2-
cyclohexanedione (2.3) to ethyl vinyl ketone (EVK), catalyzed by potassium hydroxide in 
methanol, to give the symmetrical tri-ketone 2.4.  The intramolecular aldol condensation reaction 
of compound 2.4, using pyrrolidine in benzene, would result in the formation of racemic 2.5 as 
described by Heathcock et al.20.  To accomplish the planned asymmetric synthesis, chiral 
Wieland-Miescher ketone analogue (-)-2.5 needed to be obtained.  This was accomplished using 
Hagiwara et al.’s21 method in which they treated symmetrical triketone 2.4 with an equivalent of 
the unnatural amino acid D-phenylalanine as an organocatalyst, and 0.5 equivalents of D-
camporsulfonic acid in DMF to produce (+)-2.5 (Scheme 2.2), [α]D -125o, 89 % optical purity 
and after recrystallization [α]D -140o 21, 99.5 % optical purity.  The optical purity of this 
compound was determined by chiral HPLC of its p-bromobenzoylated derivative of (-)-2.9.21 
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Scheme 2.2: Hagiwara’s synthesis of chiral Wieland-Miescher ketone analogue, (-)-2.5 
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(a) KOH, MeOH, reflux, 100%; (b) D-phenylalanine, D-camphorsulfonic acid, DMF 68% yield after 2 steps. 
 
This enantioselective aldol condensation reaction was discovered independently by two 
groups, the Hajos22 group and Eder23 group, in the 1970’s.  In their reactions, proline catalyzed 
the enantioselective intramolecular aldol reaction of the symmetric triketone 2.6 to produce aldol 
compound 2.7 and condensation product 2.8 (Scheme 2.3).28   
 
Scheme 2.3: The Hajos-Parish-Eder-Sauer-Wiechert reaction and proposed transition 
states.22,23,28 
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Since then, three mechanisms28 for this reaction have been proposed: the hemiaminal 
intermediate A by Hajos in 197422; the proline enamine intermediate, that involves two prolines, 
in the transition state B by Agami in 198424; and the proline enamine intermediate C proposed by 
Houk25-27 in 2001. The Houk intermediate C is different from the Agami intermediate B because 
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C involves a single proline, in which the carboxyl group is hydrogen bonded to one of the 
enantiotopic ketones in the transition state, and B involves two prolines. 
Based on kinetic, stereochemical, and dilution experiments List et al. suggest that 
transition state C is the most acceptable mechanism for the asymmetric intramolecular aldol 
reaction of triketone 2.6.27   Following the same mechanism we believe that the Hagiwara et al. 
synthesis of the Wieland-Miescher ketone analogue 2.521, which uses D-phenylalanine instead of 
proline, follows a similar mechanism going through transition state D illustrated below (Figure 
2.1). 
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H
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Figure 2.1: Transition sate intermediates for intra-molecular aldol condensation.  D – 
favorable transition state; E – unfavorable transition state because of steric hindrance of 
the benzyl group 
 
Furthermore, transition state D which is pro R is favored over transition state E which is 
pro S, because in the latter the benzyl group contributes some steric hindrance.  On the other 
hand, in D the benzyl group is away from the enatiotopic carbonyl, so there is less steric 
hindrance in this transition state.  This results in the formation of R compound (-)-2.5.  
O
O
O
O
(-)-2.5
=5
6
5
 
Figure 2.2: Steric hindrance caused by the angular axial methyl group in (-)-2.5 
 
The newly formed stereo-center, with the angular axial methyl group at C5, helps to 
control the stereo-chemical outcome of the reactions that follow.  The axial methyl group blocks 
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the top face of the compound causing all reactants to come from the bottom face of (-)-2.5 
(Figure 2.2). 
 
2.2.2 Synthesis of key intermediate (+)-2.2 by addition of the A ring to the BC rings 
 
Continuing the synthesis, the saturated ketone at C6 in (-)-2.5 was regio- and stereo-
selectively reduced by treating (-)-2.5 with sodium borohydride in ethanol to produce (-)-2.9 
with 96% ee.  The stereo-selectivity of the reduction was achieved because the addition of 
hydride occurs from the less hindered bottom face in (-)-2.5 (Scheme 2.4).16-19 
 
Scheme 2.4: Synthesis of tricyclic compound (+)-2.2 
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(a)  NaBH4, ethanol 0oC, 87% yield, (b) NaOMe, MeOH, ethyl vinyl ketone, 69% yield 
 
Treatment of (-)-2.9 with sodium methoxide in methanol formed the thermodynamic 
dienolate (-)-2.9’ (Scheme 2.5).  This was reacted with EVK and resulted in a stereo-selective 
Robinson annulation reaction that produced (+)-2.2.  The axial methyl group at C5 controlled the 
stereo-selectivity of this reaction, again.  The structure of (+)-2.2 was confirmed by X-ray 
analysis of its crystal, which produced its crystal structure (Figure 2.3). 
OH
O
(+)-2.2  
Figure 2.3: Crystal structure of (+)-2.2, by single-crystal X-ray analysis 
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Interestingly after the reaction of (-)-2.9 to form (+)-2.2 the enantiomeric excess (ee) of 
(+)-2.2 had decreased significantly to 48% ee.  Honda et al17 and Takikawa et al19 report the 
same result and explain this by a retro-aldol reaction that competes with the formation of the 
dienolate (Scheme 2.5).17,19 
 
Scheme 2.5: Competing retro-aldol reaction17,19 
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The fact that the product is enriched with (+)-2.2, indicates that the dienolate formation is 
faster than the racemization.  Initially, a significant amount of the dienolate is formed which 
reacts with EVK to produce the enantiomer (+)-2.2.  However, as the reaction progresses, the 
realative concentration of (-)-2.9 decreases, and results in a slower formation of the dienolate, 
allowing for the racimization of (-)-2.9, through the retro-aldol, and consequently formation of 
the racemic (+)-2.2.  The initial formation of the high amount of (+)-2.2 is stable to the reaction 
conditions and results in the optical activity of the product.17 
To accomplish an asymmetric synthesis, a solution to the racimization was necessary.  
An obvious solution to this problem would be to protect the alcohol. Honda et al.17 and Takikawa 
et al.19 determined that this was an unsuccessful solution.  Honda et al.17 reported that they 
obtained racemic benzyl ether under benzylation conditions and the acetyl, pivaloyl, tert-
butyldimethylsilyl groups were removed under the Robinson annulation conditions.17  Similarly, 
Takikawa et al.19 reported that the benzyl and methoxymethyl (MOM) ethers failed to undergo 
the Robinson annulation reaction. 
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Takikawa el al.19 decided to do enzymatic resolution on (+)-2.2 using Chirazyme L-2 
(Roche Diagnostics Co.) to produce 50% of (-)-2.2 98.8% ee and 49% of acetate (+)-2.11 99.2% 
ee which was hydrolyzed to (+)-2.2 [α] D 22 +114 (c 0.128, CHCl3)19 (Scheme 2.6).   
 
Scheme 2.6: Enzymatic resolution of (+)-2.219 
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On the other hand Honda et al.17 continued the synthesis and they were able to increase 
the enantiomeric purity at a later stage in the synthesis17.  We decided to follow Honda et al.’s 
procedure17 as described below. 
 
2.2.3 Synthesis of the ABC ring ketone compound (-)-2.1 
 
Using (+)-2.2 with low ee we continued the synthesis by treating (+)-2.2 with lithium in 
liquid ammonia to do a Birch reduction of the enone moiety.  The resulting enolate was treated 
with iodomethane to give (+)-2.12 in 45-50% yield.  It was important in this reaction that after 
the iodomethane was added and the reaction was allowed to react for two hours and quenched 
with methanol to prevent reduction of the ketone.  Ketalization of (+)-2.12 was done by treating 
(+)-2.12 with ethylene glycol, catalytic amount of pyridinium p-toluenesulfonate (PPTS) in 
refluxing toluene with azeotropic distillation to give ketal (+)-2.13 (Scheme 2.7).  After column 
chromatography, (+)-2.13 was obtained with an optical activity of [α] D 27 +18 (c = 0.40, CHCl3).  
Honda et al.17 recrystallized the ketal to get an improved optical activity of [α] D 27 +22 (c 0.26, 
CHCl3) which after removal of the ketal formed (+)-2.12 [α] D 27 +47 (c 0.38, CHCl3).  The % ee 
of (+)-2.12 was determined to be 90% by 1H and 19F NMR, of the (-)-R-MTPA ester derivative 
of (+)-2.12.17 
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Scheme 2.7: Synthesis of ketal (+)-2.13 
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(a)  Li, NH3, THF 1 h, MeI 2 h, 45-50% yield; (b) PPTS, ethylene glycol, toluene reflux 2 h, 95% yield. 
   
Having the optically enriched ketal (+)-2.13 the synthesis was continued by reducing the 
double bond in (+)-2.13.  Treatment of (+)-2.13 with a catalytic amount of palladium on carbon 
in ethanol and one atmosphere of hydrogen gas produced the alcohol (-)-2.14.  Oxidation of the 
hydroxyl group of (-)-2.14 was accomplished by treatment with o-iodoxybenzoic acid (IBX) in 
dimethyl sulfoxide to give the ABC ring ketone compound (-)-2.1 (Scheme 2.8).18,19   
 
Scheme 2.8: Synthesis of the ABC ring ketone compound (-)-2.1 
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(a)  1 atm H2, 10% Pd-C, EtOH, 97% yield; (b)  IBX, DMSO overnight, 78% yield. 
 
Having ketone (-)-2.1 a plan for the construction of the D and E rings of (+)-myriceric 
acid A was needed.  Several plans that were investigated will be discussed in the next section. 
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2.3 Model studies for the construction of the D and E rings of (+)-myriceric 
acid A 
 
2.3.1 C ring model studies 
 
With the ABC rings of (+)-myriceric acid A constructed, we decided to use a model to 
study the construction of the D and E rings.  As a model we decided to use the simplest form of 
the C ring, cyclohexanone 2.15 (Figure 2.4).   
 
O
H
O
O
H
C
O
C'
12
13 12 '
13 '
(-)-2.1 2.15  
Figure 2.4: Cyclohexanone as the model of the C ring 
 
Two requirements were needed to continue our synthesis 1) the position α to the ketone at 
C13 needed to be functionalized with something that would activate this position and, 2) this 
functionality should allow for the formation of the double bond between C12 and C13 needed in 
the final product.  To accomplish these requirements we decided to functionalize the C13’ 
position of 2.15 with either a phenyl sulfide or phenyl selenide group.  Either of these would 
increase the acidity of the C13’ hydrogen and stabilize the resulting anion.  Another advantage of 
these groups was that when they are oxidized they form sulfoxides or selenoxides, respectively, 
which undergo syn-β-elimination to form the necessary double bond between C12 and C13.   
 
Scheme 2.9: Synthesis of β-keto-sulfide 2.16 and β-keto-selenide 2.17 
O O
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O O
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2.15 2.16 2.15 2.17
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(a)  LDA, THF, phenyl disulfide, -78oC, 62% yield;  (b) LDA, THF, phenyl selenyl bromide, -78oC, 86% yield 
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Cyclohexanone 2.15 was treated with freshly prepared lithium diisopropyl amine (LDA) 
to form the enolate.  The enolate was then reacted with phenyl disulfide to produce the α-phenyl 
sulfide 2.16 or phenyl selenyl bromide to give the α-phenyl selenide 2.17. (Scheme 2.9) 
 
2.3.2 Convergent approach for the formation of the D and E rings 
 
In our original plan we intended to do a convergent synthesis for the construction of the 
D’ and E’ rings.  Our plan is summarized in the retro-synthetic scheme below (Scheme 2.10).  
 
Scheme 2.10: Retro-synthesis of the model convergent synthesis plan 
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Robinson annulation of 2.16 or 2.17 to 2.20 E or Z would result in the formation of the D 
ring enone 2.19.  This compound has all the functional groups necessary in the D ring and the 
side chain at C18 could be used to form the E ring.  The ethyl ester at C17 makes the hydrogen at 
C17 more acidic and also it can easily be hydrolyzed to the required carboxylic acid in the final 
product.  The silyl protected hydroxyl group on C22 can be converted to a leaving group which 
would allow for the stabilized anion formed at C17 to do a substitution reaction to form the E 
ring.  The phenyl sulfide or phenyl selenide on C13 could then be oxidized to undergo a syn-β-
elimination to form the necessary double bond between C12 and C13.  Finally, C14 is the β 
position of a α,β-unsaturated ketone to which a Michael addition reaction can be used to 
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functionalize it.  The group that was added should be one that can be converted to the hydroxyl 
methyl group to which the caffeic ester chain is attached in (+)-myriceric acid A.   
To investigate this approach we needed to synthesize the 2.20 E and Z compounds.  This 
was initiated by the reduction of 3,3-dimethylglutaric acid (2.21) with lithium aluminum hydride 
(LiAlH4) in THF to give 3,3-dimethylpentane-1,5-diol (2.22) quantitatively.29   Treatment of diol 
2.22 with DMAP, imidazole, TBSCl in DMF resulted in a mixture of three compounds – diol 
2.22, alcohol 2.23, and di-silylated compound.  To avoid this mixture we used McDougal et 
al.’s30 method by treating diol 2.22 with one equivalent of sodium hydride to deprotonate one 
alcohol and reacted this with TBSCl to obtain monoalcohol 2.23 in 71% yield along with some 
recovered diol 2.22 (Scheme 2.11). 
 
Scheme 2.11: Synthesis of monoalcohol 2.23 
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(a)  LiAlH4, THF quantitative yield;  (b)  NaH, THF 1 h; TBSCl 1 h, 71% yield. 
 
Monoalcohol 2.23 was oxidized to its corresponding aldehyde 2.24 by treatment with 
IBX in dimethyl sulfoxide (DMSO) overnight.   A Knoevenagel condensation, following Tietze 
et al.’s procedure31, of aldehyde 2.24 with ethyl acetoacetate was accomplished by treatment 
with acetic acid and piperidine to give an almost quantitative yield of a 50/50 mixture of the β-
ketoesters 2.20E and 2.20Z which were easily separated by column chromatography (Scheme 
2.12). 
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Scheme 2.12: Synthesis of β-ketoesters 2.20 E and 2.20 Z 
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(a)  IBX, DMSO overnight 81% yield;  (b)  ethyl acetoacetate, piperidine, AcOH, CH2Cl2 0oC, quantitative yield. 
 
These isomers, we believed, would help us to investigate the stereochemical outcome of 
the initial Michael addition of the Robinson annulation to form the D ring. 
Having the conjugated β-ketoesters 2.20E and 2.20Z we attempted the Robinson 
annulation reaction of both phenyl sulfide 2.16 and phenyl selenide 2.17 with either 2.20E or 
2.20Z.  Unexpectedly and unfortunately using various bases under various reaction conditions 
we were unable to accomplish the Robinson annulation reaction. (Scheme 2.13)  
 
Scheme 2.13: Failed Robinson annualation of 2.16 or 2.17 with 2.20E or Z 
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It is suspected that the failure of the Robinson annulation reaction is due to the great 
steric hindrance at the 4-position caused by 3,3-dimethylbutanosilyl ether group.  This prevents 
the initial Michael addition needed for the Robinson annulation reaction.  Another reason may 
be, as discovered later; that the conjugated β-ketoester 2.20E or Z decomposes very easily under 
basic conditions.  Since the Michael addition reaction is carried out under basic conditions, 
2.20E or Z may have decomposed before any reaction occurred.  These results convinced us that 
a different approach for the construction of the D and E rings needed to be investigated. 
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2.3.3 Linear approach for the construction of the D ring 
 
As described in the previous section, it was suspected that the side chain in 2.20E or Z 
created significant steric hindrance that it prevented the initial Michael addition needed to 
accomplish the Robinson annulation reaction.  An obvious solution to this problem would be to 
eliminate the side chain from the Michael acceptor; however, we still needed a way to add the 
side chain so we could construct the E ring.  To fulfill these requirements we expected the 
conjugated triple bond compound 3-butyn-2-one (2.26) to be a good candidate. 
 
Scheme 2.14: Retro-synthesis of the linear approach synthetic plan 
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Robinson annulation of 2.16 or 2.17 with 2.26 was expected to result in the formation of 
the D ring as the dienone 2.25.  In 2.25 the less substituted β-position of the ketone would be 
expected to be more reactive toward a nucleophile.  This would allow for the regio-selective 
Michael addition of the side chain and the resulting enolate may be trapped with ethyl 
cyanoformate to give the desired compound 2.19 (Scheme 2.14). 
Our investigation of this approach was started by treating the α-phenyl sulfide 2.16 with 
sodium hydride in THF to form its enolate that was then reacted with 3-butyn-2-one (2.26).  This 
reaction did not go through the full Robinson annulation reaction sequence; it did the Michael 
addition followed by the intramolecular aldol addition where it stopped and produced ketol 2.27 
(Scheme 2.15).  The elimination reaction did not occur because it was carried out under aprotic 
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conditions so there was no proton available to protonate the tertiary alkoxide formed by the 
intramolecular aldol addition so no β-elimination could occur. 
 
Scheme 2.15 Synthesis of bicyclic compound 2.27 
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(a)  NaH, THF, 2.26, 30% yield. 
 
Ketol 2.27 was still useful; in fact, it improved the regio-selectivity of the Michael 
addition reaction that was planned to add the side chain.  After the addition of the side chain, 
elimination of the β-hydroxyl group would produce the substituted α,β-unsaturation.  To 
determine whether this amendment to the plan was possible, we decided to test the Michael 
addition to enone 2.27 by treating it with the simple methyl cuprate in THF at -78oC.  This 
reaction unexpectedly resulted in the decomposition of ketol 2.27, to unidentifiable materials 
(Scheme 2.16). 
 
Scheme 2.16: Michael addition of methylcuprate to enone 2.27 
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This may be because of the phenyl sulfide in the γ-position possibly causing steric 
hindrance for the Michael addition.  It may also be that the phenyl sulfide was eliminated since it 
can be a leaving group.  It was decided that the phenyl sulfide group would be removed by 
oxidation to the sulfoxide 2.29.  Heating of the sulfoxide would result in a syn-β-elimination to 
form the conjugated dienone 2.30 (Scheme 2.17). 
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Scheme 2.17: Plan for the synthesis of conjugated dienone 2.30 
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(a) oxone, 4:1 dioxane:H2O, 39% yield. 
 
Formation of the conjugated dienone 2.30 would raise the question whether the Michael 
addition would occur at the 4-position or the 6-position.  From Marshall et al.’s32 studies it has 
been determined that the regioselectivity of the Michael addition to conjugated dienones is 
primarily directed by sterics.32   In his first example, which best resembles our model compound 
2.30, there is a slight preference for addition to the 4-position.32   Because of this, along with the 
fact that in our proposed compound 2.34 the 4-position is less hindered than the 6-position we 
expect that the organocuprate addition would result in the desired 1,4-addion (Scheme 2.18). 
 
Scheme 2.18: Marshall’s study of regioselective Michael addition to conjugated dienones32 
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Oxidation of the phenyl sulfide 2.27 was accomplished by treating it with oxone in a 
solution of 4:1 dioxane:water to give the phenyl sulfoxide 2.29.  The syn-β-elimination to 
produce 2.30 was attempted by refluxing 2.29 in toluene.   
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Scheme 2.19: Aromatization of the model D ring 
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(a)  Toluene, reflux, 28% yield. 
 
Refluxing 2.29 in toluene produced a new product.  After isolation it was determined that 
it was not the desired conjugated dienone 2.30, instead the model D ring had aromatized to form 
the phenol 2.35 (Scheme 2.19).  It was suspected that this resulted from the high temperature 
required to accomplish the syn-β-elimination reaction of the sulfoxide.  To avoid the high 
temperature reaction, we believed that we could use the phenyl selenide analogue 2.36.  Its 
oxidation to the selenoxide would result in syn-β-elimination even at very low temperatures to 
produce the dienone 2.30 directly.     
 
Scheme 2.20: Aromatization of the model D ring at low temperature 
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(a)  NaH, THF, 2.26, 10% yield;  (b)  oxidation, 0oC. 
 
Following the same procedure as with the α-phenyl sulfide 2.16, α-phenyl selenide 2.17 
was treated with sodium hydride in THF.  The resulting enolate was reacted with 3-butyn-2-one 
to form the phenyl selenide ketol analogue 2.36.  Unfortunately, the oxidation of selenide 2.36 
using different oxidants and conditions at low temperatures still resulted in the aromatization of 
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the model D ring to form phenol 2.35 (Scheme 2.20).  These results forced us to rethink our 
approach and try to design a new one. 
From analysis of intermediates 2.27 and 2.36 it can be seen that the model D ring is 
highly functionalized.  It has a phenyl sulfide or phenyl selenide group, a tertiary hydroxyl 
group, which are reasonable leaving groups and an α,β-unsturated ketone group (Figure 2.5). 
 
O
XPh
OH
2.27, X=S
2.36, X=Se  
Figure 2.5: Highly functionalized model D ring 
 
The high substitution on the model D ring may be contributing to its facile aromatization.  
To see whether aromatization could be prevented we decided to reduce the amount of functional 
groups on the model D ring.  The unsaturation of the α,β-unsaturated ketone was removed 
because it seems to be the simplest functionality to remove and also to regenerate. 
Synthesis of the new compound was accomplished by treating the α-phenyl sulfide 2.16 
with sodium methoxide in methanol to form the enolate.  This was then reacted with methyl 
vinyl ketone 2.37 to undergo a Robinson annulation reaction to give the new model CD rings as 
enone 2.38 in high yield and no aromatization (Scheme 2.21). 
 
Scheme 2.21: Robinson annulation reaction to form the D ring without aromatization 
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(a)  NaOMe, MeOH, reflux, 92 % yield. 
 
After obtaining this high yielding Robinson annulation reaction we believed this was a 
promising route for the synthesis of the D and E rings of (+)-myriceric Acid A [(+)-1.1].  So, it 
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was decided that the study of this linear approach would be continued with the actual ABC ring 
compound (-)-2.1. 
2.4 Conclusion 
 
The ABC rings (-)-2.1 of (+)-myriceric acid A were successfully synthesized.  The first 
asymmetric center was formed using an asymmetric aldol condensation reaction employing the 
unnatural amino acid D-phenylalanine as the organo-catalyst to control the enantioselectivity.  
This new center having an axial angular methyl group helped to control the formation of the 
other stereocenters in the molecule.  A major problem encountered was that some of the 
enantiomeric purity was lost in the second Robinson annulation reaction from (-)-2.9 to (+)-2.2 
as a result of a competing retro-aldol reaction in the started material.  The enantiomeric purity 
was improved at a later stage by ketalization and purification of the ketal (+)-2.13 by column 
chromatography and recrystallization. 
Model studies were done to study the construction of the DE rings using cyclohexanone 
(2.15) as a simple model of the C ring.  The initial convergent synthesis plan was unable to be 
accomplished because the β-position of the enone 2.20E or Z was hindered and the enone easily 
decomposed under basic conditions.  After this discovery, two linear approaches were 
investigated: the first was using 3-butyn-2-one (2.26) as the Michael acceptor and D ring 
precursor; and the second using methyl vinyl ketone (2.37) as the Michael acceptor and D ring 
precursor.  The initial approach resulted in aromatization of the D ring to phenol 2.35 because of 
the high functionalization on the D ring.  The second approach provided the D ring compound 
2.38 through a high yielding Robinson annulation.  The model D ring 2.38 had two of the 
essential functional groups that could be used to further functionalize the D ring and the final 
product.  Having these results we decided to continue our studies of this approach with our ABC 
ring compound (-)-2.1. 
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CHAPTER 3 - Synthesis of the D ring of (+)-myriceric acid A 
3.1 Robinson annulation of α-phenyl sulfide approach 
 
In the previous chapter the synthesis of tricyclic ketone (-)-2.1 was described.  This 
compound contains the ABC rings with four of the stereocenters of our target compound (+)-
myriceric acid A [(+)-1.1].  Our original plan, as described in Chapter 1, was a convergent 
synthesis.  However, after several model studies we determined that our best approach would be 
a linear synthesis in which we first build the D ring, functionalize it and then add the E ring.   
 
Scheme 3.1: Linear retro-synthetic plan toward (+)-myriceric acid A 
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From the model studies described in Chapter 2 it was determined that the α-phenyl 
sulfide on compound 2.16 would be used as a model for the C ring.  Its α-phenyl sulfide serves 
two purposes; 1.) It stabilizes the anion formed from removal of the α-hydrogen and 2.) It can be 
oxidized and eliminated to form the double bond between C13-C14 in the target compound.  The 
linear synthetic plan summarized in the retro-synthesis above (Scheme 3.1) was based on the 
results obtained in the model study.  In the model studies we accomplished a Robinson 
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Annulation reaction with compound 2.16 and methyl vinyl ketone (2.37) to give the model D 
ring compound 2.38 (Scheme 3.2).   
 
Scheme 3.2: Robinson annulation reaction accomplished in the model studies 
O
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a.)  NaOMe, MeOH, rt overnight, 92% yield. 
 
Continuing our total synthesis using this approach, our first task was to synthesize the 
tricyclic form of 2.16 from our tricylcic ketone (-)-2.1.  It was expected that the phenyl sulfide 
addition would be regio- and stereo-selective because only one α-position of the ketone is 
available for deprotonation and the other α-position had a quaternary center with and axial 
methyl group that blocks the top face.  
 
Scheme 3.3: Synthesis of tricyclic β-ketosulfide (+)-3.2 
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a.)  LDA, THF rt, PhSSPh (phenyl disulfide), 71% yield. 
 
As expected, the enolate of (-)-2.1 was easily formed using LDA and it was then reacted 
with phenyl disulfide to give the expected regio- and stereo-selective α-phenyl sulfide compound 
(+)-3.2.   The phenyl sulfide group was on the opposite face from the axial methyl group, which 
was confirmed by NOE observed between the axial methyl group and the α-hydrogen (Scheme 
3.3). 
Following the model, our next step was to do a Robinson annulation reaction with (+)-3.2 
and methyl vinyl ketone (MVK) (2.37).  Using the same conditions as in the model, compound 
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(+)-3.2 was treated with sodium methoxide followed by addition of the methyl vinyl ketone at 
room temperature, but this resulted in no reaction.  Because (+)-3.2 was a more complex 
molecule with more steric hindrance than the model compound 2.16 we believed that the 
reaction could occur at elevated temperatures. Upon increasing the temperature to 55-60oC the 
reaction resulted in the formation of two products as observed by TLC.  Unexpectedly, after 
isolation it was determined that these products were not Robinson Annulation products.  Instead 
they were the two diastereomers of the intermediate Michael addition reaction that produced (-)-
3.3a and (-)-3.3b in quantitative yield (Scheme 3.4). 
 
Scheme 3.4: Michael addition of tricyclic β-ketosulfide (+)-3.2 with MVK 
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a.)  NaOMe, MeOH/THF, 55-60oC 2h, 100% yield, 3:1 3.3a:3.3b. 
 
The mixture of diastereomers was easily separated to give a 3:1 product mixture with 
diastereomer (-)-3.3a, which has the phenyl sulfide equatorial as the major product, and 
diastereomer (-)-3.3b, which has the phenyl sulfide axial as the minor product, respectively.  
Based on steric hindrance the opposite ratio was expected, however, this product ratio can be 
rationalized based on transition state energy of the enolate in the carbanion resonance structure.  
The carbanion, just before attack, would start approximating sp3 hybridization before forming the 
Michael addition product.  If the carbanion attacks from the top then the phenyl sulfide is in a 
more stable equatorial position and lower energy of transition state giving (-)-3.3a as the major 
product.  Attack from the bottom face places the phenyl sulfide in an axial position leading to 
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steric interaction with the adjacent axial methyl group thereby increasing the energy of that 
transition state and giving (-)-3.3b as the minor product.  This stereochemical outcome was not a 
problem because in the later stages of the synthesis it would be destroyed. 
At first glance the Michael addition products (-)-3.3a and (-)-3.3b were expected to 
undergo the intramolecular aldol condensation very easily to give 3.1a or 3.1b, respectively.  To 
investigate this, the intramolecular aldol condensation was attempted with the major 
diastereomer (-)-3.3a.   
 
Scheme 3.5: Failed intramolecular aldol condensation of (-)-3.3a 
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a.) several basic conditions 
 
The aldol condensation of (-)-3.3a was attempted with many different bases, in different 
solvents and at different temperatures (Scheme 3.5).  Most of the conditions resulted in no 
reaction.  Some, however, resulted in reverse Michael addition in which (+)-3.2 was isolated 
(Scheme 3.6). 
Scheme 3.6: Reverse Michael addition reaction in (-)-3.3a 
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The stability of the anion of the α-phenyl sulfide compound (+)-3.2 makes it a reasonable 
leaving group.  The axial methyl group α to the ketone blocks the top face of the carbonyl in (-)-
3.3a and makes the retro Michael reaction more favorable than the intramolecular aldol in (-)-
3.3a.  De Groot et al.33 report a similar behavior in their study of the synthesis of “functionalized 
decalones by Robinson annulation of substituted cyclohexanones”33 using the sterically 
congested cyano ketone 3.4.   The initial Michael addition of 3.4 with methyl vinyl ketone occurs 
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smoothly to give a mixture of diastereomers 3.5 and 3.6.  They reported that under basic 
conditions cyclization was not achieved, instead a retro Michael addition reaction was observed.  
However, under Knoevenagel conditions they were able to accomplish the cyclization.  For the 
cyclization reaction of the two diastereomers 3.5 and 3.6 only one product 3.7 was obtained33 
(Scheme 3.7). 
Scheme 3.7: De Groot’s Robinson annulation of substituted cyclohexanones33 
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a.)  NaOMe, MVK, benzene.  b.)  Pyrrolidine, AcOH, toluene. 
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Figure 3.1: Transition States for aldol condensation of compound 3.5 and 3.6. 33 
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The outcome of the intramolecular aldol condensation was rationalized based on the 
transition states of the cyclization of 3.5 and 3.6.33   Transition states 3.5A and 3.5B show that 
the cyclization of 3.5 can go smoothly to 3.7.  On the other hand, all the transition states of 3.6 
(3.6A, 3.6B, or 3.6C) were both conformationally and geometrically unfavorable for the 
cyclization (Figure 3.1).  Molecule 3.6 instead underwent a retro Michael addition followed by 
re-addition of the MVK to 3.5 and in that way cyclization to 3.7 occurred.33 
Comparing the C-ring of (-)-3.3a with 3.5 and 3.6 it can be seen that it would have a 
transition state similar to 3.5C and 3.6C in which both the enolate group and methyl group are 
axial and on the same face which are the most unfavorable transition states for the cyclization.  
De Groot et al could accomplish the cyclization using Knoevenagel conditions because the one 
ring system in 3.5 can flip to adapt the more favorable conformations, 3.5A and 3.5B.  We 
attempted these conditions without any success.  This is because in our case, the tricyclic ring 
system is very rigid and the transition state is locked as the unfavorable conformation.  The retro 
Michael addition is therefore more favorable in (-)-3.3a.  
Based on these results, we decided to investigate whether our minor isomer (-)-3.3b, 
which has the favorable conformation as in 3.5A and 3.5B in which the enolate group is 
equatorial and on the opposite face of the axial methyl group, would result in cyclized product.   
 
Scheme 3.8: Aromatization of the Robinson annulation product of (-)-3.3b 
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a.)  NaOMe, MeOH reflux, 31% yield. 
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As suspected, treating (-)-3.3b with sodium methoxide in methanol and refluxing resulted 
in cyclization, however the cyclized product turned out to be the aromatized D ring compound 
3.11.  From this result it can be speculated that the intramolecular aldol reaction took place, 
forming enone 3.9.  However, under the thermodynamic conditions the enol 3.10 was formed 
from 3.9 and finally under the basic conditions the phenyl sulfide acted as a leaving group and 
was eliminated to give the phenol 3.11 (Scheme 3.8). 
The studies of de Groot et al.33 and our results indicated that for the intramolecular aldol 
condensation reaction to occur, to form our D ring, the enolate group must be in an equatorial 
position or a conformation that would allow the enolate to react with the ketone from the 
opposite face of the axial methyl group.  It was also indicated that the gamma phenyl sulfide 
group needed to be removed or replaced to prevent aromatization of the D ring. This however 
posed the problem on how to reform the necessary double bond at that position. 
 
3.2   Dienone Approach 
 
To overcome the steric limitations and elimination of the phenyl sulfide encountered in 
the previous section with compounds (-)-3.3a and (-)-3.3b, respectively, we decided to modify 
our approach.  By oxidizing the mixture of sulfide diastereomers to their corresponding sulfoxide 
3.12, followed by heating to accomplish a β-syn-elimination, the C12-C13 double bond in (-)-
3.13 and in the final product would be formed.  This double bond alleviates three problems; 1.) It 
eliminates the steric limitations by making the C13 sp2 hybridized, and therefore flat, allowing 
for the enolate on the side chain to react from the opposite face of the axial methyl group.  2.) 
Because the phenyl sulfide leaving group is no longer at C13, no elimination is possible for 
aromatization of the D ring.  3.) In this route both diastereomers are useful because the diastereo-
center has been destroyed so the overall yield of the synthesis is increased.   
The diastereomeric mixture of (-)-3.3 was oxidized by treatment with m-
chloroperbenzoic acid in methylene chloride at 0oC for 15 minutes.  Interestingly, the isolated 
product was not the sulfoxide 3.12; instead the deprotected (-)-3.13 was obtained.  Removal of 
the ketal protecting group is believed to be caused by the sulfinic acid that is produced by the β-
syn-elimination of the sulfoxide in 3.12.  To prevent the deprotection, the acid was neutralized 
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by the addition of sodium bicarbonate to the reaction, which then resulted in quantitative yield of 
enone (-)-3.13.  The sulfoxide 3.12 was not isolated because of the rigidity in compound 3.12 
facilitated the β-syn-elimination reaction so no high temperature was needed to form (-)-3.13 
(Scheme 3.9). 
 
Scheme 3.9: Removal of the phenyl sulfide group by oxidation 
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a.)  CH2Cl2, mCPBA, NaHCO3, 0oC 15 min, 100% yield. 
 
Precedence for the formation of conjugated dienones by aldol condensation of a similar 
β-enone-ketone 3.14 was shown by El Gaied et al.34.  They showed that when 3.14 was treated 
with potassium carbonate in ethanol it produced the conjugated dienone 3.15 in 67% yield34 
(Scheme 3.10). 
 
Scheme 3.10: Intramolecular aldol condensation of β-enone-ketone 3.1434 
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a.) K2CO3, EtOH, 67% yield. 
 
Although El Gaied et al.34 report their reaction gives 3.15 as the major product, it is 
obvious that there are two possible reactions that can occur in both compound 3.14 and 
compound (-)-3.13.  The side chain enolate could either undergo an intra-molecular 1,2-addition 
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reaction (aldol condensation) or an intra-molecular 1,4-addition (Michael addition), each 
resulting in a different product (Scheme 3.11). 
 
Scheme 3.11: Aldol condensation vs. Michael addition 
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Many different bases were tried. 
 
As speculated, treatment of (-)-3.13 under the similar reaction conditions (potassium 
carbonate in ethanol) resulted in both reactions; the aldol addition forming compound 3.16 and 
the Michael addition forming compound 3.17.  To continue our synthesis we required compound 
3.16.  However, the major product in this reaction turned out to be the Michael addition adduct 
3.17 with a trace amount of conjugated dienone 3.16.  In an attempt to change the outcome of the 
reaction, toward preferential formation of the desired conjugated dienone 3.16, different reaction 
conditions (different bases, solvents and temperatures) were investigated.  Unfortunately, most of 
the reaction conditions produced the undesired compound 3.17 as the major product and a trace 
amount < 10% of the desired dienone 3.16.   
This preference for the Michael addition in compound (-)-3.13 is caused by the C8 
quaternary center sterically hindring the ketone resulting in a sluggish aldol condensation.  On 
the other hand the C12 position is less hindered favoring the Michael addition and consequently 
formation of adduct 3.17.   
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While trying to improve the aldol condensation reaction, studies to continue the synthesis 
with conjugated dienone 3.16 were initialized.  Conjugated dienone 3.16 already possessed the 
C12-C13 double bond of the final product.  The next goal was to functionalize the C14 position 
with a hydroxy methyl group.  As discovered in the previous studies, nucleophilic addition to 
C14 would be sluggish because of the adjacent quaternary center.  Also, if another less hindered 
electrophilic position was available the reaction would prefer to occur at that position.   This was 
encounter again with the conjugated dienone 3.16, which has two possible elctrophilic positions.  
Since the C12 is the less hindered electrophilic position, the nucleophile would prefer to add at 
C12 instead of the C14 position.   
To overcome these problems it was decided that the double bond would be masked as an 
alcohol.  This alcohol would be used as an anchor to stereoselectively direct a Stork silyl methyl 
radical cyclization reaction followed by a Fleming-Tamao oxidation to produce the desired C14 
hydroxy methyl group.35   Lallemand et al.35 employed this method to form the cyclic silyl ether 
3.19 and consequently diol 3.20 with a similar angular hydroxy methyl group that we require 
(Scheme 3.12). 
 
Scheme 3.12: Lallemand’s stereoselective formation of an angular hydroxy methyl group35 
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a.)  (n-Bu)3SnH (1.5eq), AIBN (cat.), benzene, reflux 4 h 100% yield; b.) 30% H2O2 (excess), NaHCO3 (1.3eq), 
MeOH/THF (1/1), reflux 18 h 65% yield. 
 
To convert the C12-C13 double bond to an alcohol, it was first oxidized to an epoxide.   
Treament of compound 3.16 with m-CPBA in methylene chloride produced epoxide 3.21 with 
the epoxide in the β-face of the molecule.  This stereochemistry was expected based on steric 
hindrance of the axial methyl group at C8 and it was confirmed by NOE observed between the 
C12-hydrogen and the hydrogens on the axial methyl group on C8 (Scheme 3.13). 
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Scheme 3.13: Epoxidation of conjugated dienone 3.16 
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a.)  m-CPBA, CH2Cl2, rt, 80% yield. 
 
The next step was to selectively open the epoxide to give the alcohol on C12 as in 
compound 3.22.  Since the alcohol would be on the bottom face, it could be used as an anchor to 
direct the functionalization of the β-position with the desired hydroxy methyl group following 
Lallemand et al.’s35 procedure.  The C12 hydroxy group could then be eliminated to reform the 
C12-C13 double bond. Because of the small amount of the product, investigations for the 
conversion of the epoxide 3.21 to the alcohol 3.22 were not possible. 
Although the yield of the aldol condensation reaction of 3.16 could not be improved, the 
studies indicated that the aldol condensation reaction was possible but sluggish compared to the 
Michael addition reaction.  To force the aldol condensation reaction to occur the competing 
electrophilic position at C12 needed to be protected or eliminated.  If this is done, a method for 
reforming the C12-C13 double bond would be necessary. 
 
3.3   Convergent approach:  double Michael addition 
 
From a review of recent literature, a new convergent synthetic approach to synthesize the 
D and E rings was envisioned.  Deslongchamps et al. reported a cascade polycyclization36-39 
approach, which they used to synthesize tetracyclic compounds 3.26 and 3.27.36   Sulfoxide 3.24 
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and activated cyclohexenone 3.23 were treated with cesium carbonate in methylene chloride, 
which resulted in a double Michael addition reaction and during their purification the sulfoxide 
was eliminated to produce enone 3.25.  After refluxing 3.25 with p-toluenesulfonic acid in 
benzene, another Michael additon reaction was accomplished from which they obtained 
tetracyclic enones 3.26 and 3.2736 (Scheme 3.14). 
 
Scheme 3.14: Cascade polyciclization reaction36 
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a.)  Cs2CO3, CH2Cl2; b.) p-TsOH, benzene, reflux, 13% of 3.26 and 13% of 3.27. 
 
The initial double Michael addition and subsequent elimination of sulfoxide to produce 
3.25 was envisioned as a method that could be used for the formation of the D ring.  If an 
appropriate side chain was designed the E ring could also be formed.  There are two important 
results that were key to our synthesis: 1.) Deslongchamps et al.36 discovered that by using β-
ketosulfoxide 3.24 they obtained a configuration at C9 in which the hydrogen was cis to the ester 
as in enone 3.25.  This configuration is key for our synthesis.  2.) The elimination of the 
sulfoxide produced an α,β-unsaturated ketone. As mentioned before the β-position could be 
functionalized using a Michaed addition with an appropriate neucleophile that could be 
converted to the required hydroxymethyl group. 
To use this method for our synthesis, two compounds were needed.  For the equivalent of 
3.23, the C ring of our compound needed to be converted to an activated cyclohexenone like 
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compound 3.28.  To construct the D and E rings an equivalent of sulfoxide 3.24 needed to be 
synthesized with an appropriate side chain that could be used to construct the E ring like 
compound 3.29 (Figure 3.2). 
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Figure 3.2: Analogues for the double Michael addition reaction 
 
Synthesis of 3.28 was started from the previously synthesized ABC ring alcohol 2.14.  
Treatment of alcohol 2.14 with triethylamine and methanesulfonyl chloride in methylene 
chloride produced quantitative yield of mesylate 3.30.  Initially, elimination of the mesylate was 
attempted using DBU as the base, which resulted in no reaction.  Using a method employed by 
Rivera et al.40 to eliminate a tosylate, mesylate 3.30 was treated with lithium bromide and lithium 
carbonate in refluxing DMF to produce alkene 3.31 in high yield (Scheme 3.15). 
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Scheme 3.15: Synthesis of tricyclic alkene 3.31 
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a.)  Et3N, MsCl, CH2Cl2 100% yield.  b.)  LiBr, Li2CO3, DMF reflux 2 h, 76% yield. 
 
Alkene 3.31 has only one allylic position so the allylic oxidation was expected to occur 
without any problems.  Gribble et al.16,17 used chromium trioxide and t-butylhydrogenperoxide in 
methylene chloride to accomplish an allylic oxidation to produce a tricyclic enone similar to 
3.32.  Applying this procedure to alkene 3.31 produced the desired enone 3.32 but, because the 
conditions produce chromic acid this also catalyzed the removal of the ketal protecting group.  A 
mixture of 3.32 and 3.33 in less than 50% yield along with other unidentified side products were 
obtained.  These results prompted the investigation of other allylic oxidation procedures from 
which a mild reaction condition was discovered.   Auhmani et al.41 and Ho et al.42 produced α,β-
unsaturated ketones by allylic oxidation in which they employed t-butylhydrogenperoxide, and 
catalytic copper iodide in acetonitrile at 50oC.  When alkene 3.31 was treated with these 
conditions, enone 3.32 was produced in 75% yield as the only product (Scheme 3.16). 
 
Scheme 3.16: Allylic oxidation to form tricyclic enone 3.32 
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It was decided that the proposed double Michael addition reaction would be investigated 
first using the activated cyclohexenone as the β-ketoaldehyde 3.28a.  To obtain this the 
unsaturation on 3.32 was reduced by treatment with catalytic amount of palladium on carbon, in 
ethanol, and under 1 atmosphere of hydrogen gas to produce saturated ketone 3.34.  Using the 
reaction series employed by Meyer et al.43 and Grieco et al.44, ketone 3.34 was treated with 
sodium hydride in benzene to produce its kinetic enolate, which was reacted with ethyl formate 
to produce α-hydroxymethylene ketone 3.35.  This was then oxidized by treatment with DDQ 
and acetic acid in dioxane to produce the β-ketoaldehyde 3.28a (Scheme 3.17). 
 
Scheme 3.17: Synthesis of β-ketoaldehyde 3.28a 
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a.)  10% Pd-C (cat.), EtOH, 1atm H2, 59% yield;  b.)  NaH, benzene, ethylformate;  c.)  DDQ, AcOH, dioxane, 67% 
yield, 2 steps. 
 
After the synthesis of the activated ketone 3.28a, the synthesis of the β-ketosulfoxide 
3.29 needed to be accomplished before the double Michael addition reaction could be attempted.  
The synthesis of β-ketosulfoxide 3.29 was initiated from the previously synthesized aldehyde 
2.24.  A Wittig reaction, using aldehyde 2.24 and (carbethoxymethylene)triphenylphosphorane in 
methylene chloride produced the α,β-unsaturated ethyl ester 3.36 in high yield (81% yield).36  
Methylphenylsulfoxide was treated with LDA in THF to form its methyl carbanion, which was 
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reacted with ethyl ester 3.36 to produce the desired β-ketosulfoxide 3.29 in 62% yield45 (Scheme 
3.18). 
Scheme 3.18: Synthesis of β-ketosulfoxide 3.29 
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a.)  P(Ph)3CHCO2Et, CH2Cl2, reflux, 81% yield.  b.)  LDA, CH3-S(O)-Ph, THF, 62% yield. 
 
Since the aldehyde at C13 was not necessary for our synthesis, the double Michael 
addition reaction was first attempted with the unactivated α,β-unsaturated ketone 3.32.  When 
enone 3.32 and sulfoxide 3.29 were treated with cesium carbonate in methylene chloride no 
reaction occurred.  This indicated that the activated α,β-unsaturated ketone 3.28a was necessary 
for the reaction to occur.  However, when enone 3.28a and sulfoxide 3.29 were treated under the 
similar reaction conditions, only sulfoxide 3.29 was recovered indicating that the enone 3.28a 
may have decomposed (Scheme 3.19). 
 
Scheme 3.19: Attempt of the double Michael addition reaction for the formation of the D 
ring 
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a.) Cs2CO3, CH2Cl2. 
 
Perhaps changing the electron-withdrawing group at C13 to an ester as in 3.28b, 
proposed earlier, may prevent decomposition and result in the double Michael addition reaction.  
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Because of the lack of material and the prospect of a more feasible alternative rout, we did not 
pursue this approach further.  Instead the investigations were focused on another linear approach. 
3.4   Synthesis of the D ring: aldol condensation of diketone 
 
In section 3.1 it was discovered that the intramolecular aldol condensation reaction 
cannot occur if the enolate group at C13 was in the axial position, in compound (-)-3.3a.  For its 
diastereomer (-)-3.3b with the opposite configuration at C13, the condensation reaction occurred, 
but the phenyl sulfide was eliminated resulting in aromatization of the D ring.  In section 3.2, the 
C13 stereocenter was destroyed by converting it to a double bond between C12-C13, compound 
(-)-3.13.  This also formed a competing reaction position at C12, which turned out to be more 
favorable.  To overcome the problems encountered in section 3.1 and 3.2, it was decided that the 
double bond between C12-C13 would be eliminated completely so only the aldol condensation 
reaction was possible. 
 
Scheme 3.20: H2/Pd-C reduction of enone (-)-3.13 
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a.) Pd-C, EtOH, 1 atm H2, 60% yield 3.39a + b and 25% yield 3.40a + b. 
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 The C12-C13 double bond in diketone enone (-)-3.13 was reduced by treatment with a 
catalytic amount of palladium on activated carbon, in ethanol, and under one atmosphere of 
hydrogen gas to produce a mixture of four compounds. These were easily separated by column 
chromatography to give; diastereomers 3.39a and 3.39b and their deprotected analogs 3.40a and 
3.40b, respectively (Scheme 3.20). 
The diastereomeric mixture of 3.39a and 3.39b was treated with potassium carbonate in 
refluxing ethanol to produce the intramolecular aldol condensation adducts as a diastereomeric 
mixture of 3.41a and 3.41b.  Similarly the mixture of 3.40a and 3.40b was also treated under the 
same conditions to produce the diastereomeric mixture of 3.42a and 3.42b (Scheme 3.21). 
 
Scheme 3.21: Intramolecular aldol condensation reaction, using potassium carbonate in 
ethanol 
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a.)  K2CO3, EtOH, reflux, 100 % yield. 
 
Although reduction of diketoenone (-)-3.13 produced the desired products 3.39a and 
3.39b, it also produced the unwanted deprotected diastereomers 3.40a and 3.40b.  To avoid this 
complicated mixture, a more efficient route to produce the desired products 3.39a and 3.39b was 
necessary.  Treatment of the mixture of phenyl sulfide diastereomers (-)-3.3a and (-)-3.3b with 
catalytic amount of AIBN and tributyltin hydride in refluxing toluene46, proved to be a very 
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clean and efficient method to produce 3.39a and 3.39b directly and in high yield (Scheme 3.22).  
It made the synthesis of 3.39a and 3.39b one step shorter and increased their overall yield.  
 
Scheme 3.22: Radical elimination of phenyl sulfide group to produce diketones 3.39 
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a.)  AIBN (cat.), (n-Bu)3SnH, Toluene, reflux, 89% yield, 1:1 ratio of 3.39a:3.39b 
 
Treating the diastereomers (-)-3.39a and (-)-3.39b separately with sodium methoxide in 
methanol at room temperature, followed by refluxing, showed that diastereomer (-)-3.39a was 
converted cleanly to its corresponding cyclization adduct 3.41a (Scheme 3.23). 
 
Scheme 3.23: Intramolecular aldol condensation using sodium methoxide 
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a.) NaOMe, MeOH rt. 2 h, reflux 2 h, 92% yield.   
 
On the other hand (-)-3.39b produced a mixture of 3.41a and 3.41b.  This indicated that 
the C13 hydrogen of (-)-3.39b was partially epimerized producing its diastereomer (-)-3.39a and 
consequently 3.41a.  However, it was discovered that by treating (-)-3.39b with excess sodium 
methoxide for three days followed by refluxing for two hours, the reaction outcome was 
controlled to produce exclusively 3.41a as the product.  This can be rationalized by an 
equilibration of diastereomer (-)-3.39b to (-)-3.39a under high concentration of sodium 
methoxide and consequent aldol condensation of (-)-3.39a to form its corresponding annulation 
adduct 3.41a (Scheme 3.24). 
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Scheme 3.24: Epimerization of C13 hydrogen and formation of 3.41a as the only 
diastereomer 
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b.)  NaOMe, MeOH rt. 3 days, reflux 2 h, 81% yield. 
 
Compound 3.41a now has the ABCD rings of (+)-myriceric acid A, however the D ring 
needs to be functionalized.  The functionalization will be discussed in the following chapter. 
 
3.5   Conclusion 
 
Many approaches were investigated to construct the D ring of (+)-myriceric acid A from 
which it was discovered that the axial methyl group at C8 plays a significant role in the reactivity 
of the C14 position.  In the first approach, the axial methyl group blocked the enolate, which was 
on the same face in compound (-)-3.3a, preventing the aldol condensation reaction and a retro 
Michael addition occurred instead.  Cyclization did occur with its diastereomer (-)-3.3b in which 
the enolate group was trans and in the equatorial position, but the C13 phenyl sulfide was 
eliminated resulting in aromatization of the D ring.  In the second approach the sulfide was 
oxidized and eliminated to form a C12-C13 double bond in compound (-)-3.13.  This destroyed 
the C13 stereocenter and flattened the position allowing the enolate to come from the opposite 
face of the axial methyl group.  It also formed a less hindered electrophilic position at C12, 
which was more favorable and resulted in the undesired Michael addition adduct as the major 
product.  The third approach was a convergent approach, which was not investigated thoroughly 
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due to the lack of material and discovery of the fourth approach.  Finally in the fourth approach 
the C12-C13 double bond was removed.  This eliminated the possibility of the competing 
Michael addition reaction and resulted in the synthesis of the D ring compound 3.41a of (+)-
myriceric acid A. 
Functionalization of the D ring and construction of the E ring will be discussed in the 
following chapter.  
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CHAPTER 4 - Functionalization of the D ring of (+)-myriceric acid 
A 
4.1   Retro Synthesis 
 
In chapter 2 the ABC rings with all the stereocenters of (+)-myriceric acid A [(+)-1.1] 
were constructed.  In chapter 3, after many approaches, the construction of the D ring was 
accomplished as tetracyclic enone 3.41a.  The D ring of (+)-myriceric acid A has three key 
functional groups: 1) the C12-C13 double bond, 2) the angular hydroxy methyl group at C14 to 
which the caffeic ester side chain is attached, and 3) the carboxylic group on C17. 
 
Scheme 4.1: Retrosynthesis of (+)-myriceric acid A from the ABCD compound 3.41a 
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The ABCD ring compound 3.41a has none of the functional groups required in the D ring 
of (+)-myriceric acid A.  To accomplish the synthesis of (+)-1.1 from 3.41a, it was envisioned 
that 3.41a had to first be converted to 4.1 which has the D ring fully functionalized.  In 
compound 4.1, the hydroxy group at C13 would allow for the formation of C12-C13 double 
bond, the hydroxy methyl group at C14 would allow for the addition of the caffeic ester group, 
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the ethyl ester group at C17 could be hydrolyzed to the carboxylic acid group, and the C17-C18 
double bond would be used to construct the E ring.  This chapter will discuss the approaches 
investigated for the synthesis of 4.1. 
 
4.2    Radical cyclization approach 1 
 
The challenge of using the ABCD ring compound 3.41a, to continue the synthesis of (+)-
myriceric acid A, was the formation of the C12-C13 double bond.  Our fist task was to figure out 
a way to form this double bond.  In their synthesis of (-)-chettaphanin I and II, Marcos et al.47,48, 
used a reaction series that could be useful for the formation of the C12-C13 double bond in 
enone 3.41a.  By ketalizing the ketones in enone 4.2, they moved the C4-C5 double bond to the 
C5-C10 position forming compound 4.3.  Epoxidation of the double bond in 4.3 followed by 
removal of the ketal protecting groups in 4.4 produced the γ-hydroxy enone 4.5. 
 
Scheme 4.2: Marcos’s synthesis of γ-hydroxy enone 4.547,48 
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a.)  1.) Ethylene glycol, p-TsOH, benzene, 8 h; 2.) LAH, Et2O, 1.5 h; 3.) DMM, LiBr, p-TsOH, 12 h, rt.  b.)  m-
CPBA, CH2Cl2, 30 min, rt.  c.)  p-TsOH, acetone, 2 h, rt. 
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The key results from this reaction series were the formation of the γ-hydroxy group 
which, in our case, could be eliminated to form the C12-C13 double bond, and the preservation 
of the α,β-unstaturated ketone, which could be used for functionalization of the C14 position.   
Following Marcos et al.’s procedure47,48, 3.41a was treated with catalytic p-
toluenesulfonic acid (PTSA) and excess ethylene glycol in refluxing toluene under azeotropic 
distillation.  This produced two compounds; the epimerized double bond diketal compound 4.6 
and the undesired aromatic compound 4.7.  It was discovered that by replacing p-toluensulfonic 
acid with pyridinium p-toluenesulfonic acid (PPTS), the reaction produced the desired diketal 
compound 4.6 as the only product. 
 
Scheme 4.3: Synthesis of diketal alkene compound 4.6 
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a.) p-TsOH, ethylene glycol, toluene, 2 h, 41% yield of 4.6 and 12% yield of 4.7.  b.)  PPTS, ethylene glycol, 
toluene, 2 h, 90% yield of 4.6. 
 
Epoxidation of the double bond in 4.6 was accomplished by treatment with mCPBA in 
methylene chloride to produce epoxide 4.8.  Based on the steric effect of the axial methyl group 
on C8, it was postulated that the epoxidation occurred from the opposite face producing epoxide 
compound 4.8 with the epoxide on the bottom face. 
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Scheme 4.4: Epoxidation of compound 4.6 to form epoxide compound 4.8 
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a.) m-CPBA, CH2Cl2, rt, 100% yield. 
  
Treatment of diketal epoxide 4.8 with PTSA in acetone produced γ-hydroxy enone 4.9 
along with a mixture of other compounds.  To avoid the complex mixture, another route to 4.9 
was developed.  Ttreatment of 4.6 with 1:1 THF:1M HCl at 40oC produced dione 4.10.  Dione 
4.10 was then treated with mCPBA in methylene chloride to form dione epoxide 4.11, which was 
treated with potassium carbonate to produce the γ-hydroxy enone 4.9 cleanly. 
 
Scheme 4.5: Synthesis of γ-hydroxy enone 4.9 
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a.) PTSA, acetone, 44% yield of 4.9.  b.)  1:1 THF: 1 M HCl, 40oC, 74% yield; c.) mCPBA, CH2Cl2, rt, 72% yield.  
d.)  K2CO3, ETOH, rt, 100% yield. 
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 Formation of the hydroxy group at C13 in compound 4.9 had two purposes: 1.) it could 
now be used for the formation of the C12-C13 double bond, and 2.) because it is on the bottom 
face, it could be used as an anchor to direct the functionalization of the C14 carbon.  By using 
Lallemand et al.’s reaction sequence35, described in the previous chapter, the hydroxy group 
could be converted to the bromomethyldimethylsilyl ether 4.12.  Since the silyl ether would be 
on the bottom face, the Stork-silyl-methyl radical cyclization would occur forming the cyclic 
silyl ether on the bottom face, as in compound 4.13.  Fleming-Tamao oxidation, using hydrogen 
peroxide and sodium bicarbonate in a mixture of refluxing methanol and THF, would produce 
compound 4.14 having the C13 hydroxy group, the desired hydroxymethyl group at C14, and the 
desired configuration at C14. 
 
Scheme 4.6: Proposed radical cyclization approach for the formation of the C14 
hydroxymethyl group 
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a.)  Imidazole, DMAP, DMF, BrCH2(CH3)2SiCl or NaH, THF, BrCH2(CH3)2SiCl.  b.) cat. AIBN, Bu3SnH, Toluene, 
reflux. c.)  30% H2O2, NaHCO3, MeOH/THF (1/1), reflux. 
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Treatment of 4.9 using two different conditions: imidazole, DMAP, 
bromomethyldimethylsilylchloride in DMF, or; sodium hydride, bromomethyldimethyl 
silylchloride, in THF; did not result in the silyl ether 4.12.  Instead, they formed the phenol 
compound 4.15.  Formation of the silyl ether did not occur because the alcohol is tertiary and 
very hinderd.  The aromatization possibly resulted from first, the enolization of the ketone to 
transition state 4.9b, followed by elimination of the C13 hydroxy group catalyzed by basic 
conditions. 
 
Scheme 4.7: Proposed mechanism for aromatization of compound 4.9 to phenol 4.15 
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a.)  Imidazole, DMAP, DMF, BrCH2(CH3)2SiCl or NaH, THF, BrCH2(CH3)2SiCl. 
 
Because of the low reactivity of the tertiary alcohol at C13 and the aromatization of 4.9 
under strong basic conditions, the approach needed to be modified.  For the radical cyclization to 
be accomplished, two requirements were needed: 1.) the silyl ether had to be formed and 2.) a 
double bond must be present, at the C14 position, for reaction with the radical.  It was decided 
that dione 4.10 would be used to fulfill these requirements.  It had a double bond between C13-
C14 and the ketone at C16 could be reduced to a secondary alcohol, which would serve as the 
anchor for the radical cycization reaction.  
Compound 4.10 has two ketones, so a regio- and stereo selective reduction of the ketone 
on C16 was needed.  The regio-selective reduction could be accomplished by using a bulky 
hydride donor because the C16 ketone is the less hindered of the two ketones.  Similarly, the 
“steric approach control”49 would result in the bulky hydride donor to approach the ketone on its 
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equatorial face and consequently produce the desired axial alcohol, as in compound 4.16.  As 
expected, treatment of dione 4.10 with the bulky hydride, K-selectride, regioselectively reduced 
the alcohol at C16 and only one diastereomer was formed.  This diastereomer was presumed to 
be the axial alcohol 4.16, based on the “steric approach control”49. 
 
Scheme 4.8: Regio- and stereo-selective reduction of the C16 ketone in 4.10 to produce 
alcohol 4.16 
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a.) K-selectride, THF, -78oC, 91% yield. 
 
Secondary alcohol 4.16 was treated with imidazole, DMAP, bromomethyldimethyl 
silylchloride in methylene chloride at room temperature to produce quantitative yield of silyl 
ether 4.17.  This was immediately purified by column chromatography in which the silica was 
neutralized by washing with 1 % triethylamine.  The product was used immediately for the next 
reaction.  Treatment of 4.17 with catalytic AIBN, tributyltin hydride in refluxing benzene 
produced one single product.  After isolation, it was determined that, the product was not the 
desired cyclic silyl ether 4.19, instead quantitative yield of the trimethylsilylether 4.18 was 
produced. 
Scheme 4.9: Failed Stork-silyl-methyl radical cyclization reaction 
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a.)  Imidazole, DMAP, CH2Cl2, BrCH2(CH3)2SiCl, 60% yield.  b.) cat. AIBN, Bu3SnH, benzene, reflux, 50% yield. 
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 Failure of the radical cyclization in 4.17 may be rationalized based on the low reactivity 
of the C13-C14 double bond.  The degree of substitution at the C14 is high compared to 
Lallemand et al.’s compound35.  Additionally, the quaternary center adjacent to C14 adds steric 
hindrance that reduces the reactivity of this position.  The C14 position could possibly be 
activated if it were the β-position of an α,β-unstaturated ketone.    
From the investigation of this approach it was determined that the C12-C13 double bond 
may be formed by formation of a hydroxyl group at the C13 position.  This however may cause 
aromatization so functionalization of the C14 position needs to be done before the formation of 
the C12-C13 double bond. 
 
4.3   Michael addition of vinyl cuprate or anionic oxy-Cope rearrangement 
 
In the previous section it was determined that functionalization of the C14 position was 
necessary to prevent aromatization of the D ring.  The functional group required at the C14 
position is a hydroxymethyl group to which the caffeic ester side chain is attached in (+)-
myriceric acid A.  The initial ABCD ring compound 3.41a is an α,β-unsaturated ketone.  This 
should allow for a conjugate addition at the C14 position.  Unfortunately, no nucleophile exists 
that would form the angular hydroxymethyl functional group directly.  To overcome this, a 
nucleophile that can be converted to the hydroxymethyl functionality needs to be used for the 
Michael addition reaction. 
 
Scheme 4.10: Proposed hydroxy methyl intermediate 4.20 
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Vinyl Grignard reagents mixed with catalytic copper iodide have been used as Michael 
addition nucleophiles to α,β-unsaturated ketones50-53.  The axial methyl group at C8 should block 
the top face and control the Michael addition of the vinyl nucleophile to come from the bottom 
face to give 4.21.  Ozonolysis of the vinyl group50,51 should produce an aldehyde 4.22.  This 
could then be reduced to the desired hydroxymethyl group at C14 in compound 4.20. 
 
Scheme 4.11: Proposed formation of the hydroxymethyl group by conjugate addition of a 
vinyl nucleophile 
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a.) Michael addition of vinyl nucleophile  b.) ozonolysis  c.)  hydride reduction. 
 
α,β-Unstaturated ketone 3.41a was treated with a mixture of vinylmagnesium bromide   
and catalytic copper iodide dimethylsulfide complex in THF at –78oC.  Consumption of the 
starting enone 3.41a occurred very quickly to produce a new compound.  After isolation it was 
determined that the new compound was not the desired β-vinylketone 4.21; instead a 1,2-
addition occurred producing compound 4.23.   
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Scheme 4.12: 1,2-addition reaction of vinyl cuprate 
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a.) vinylmagnesium bromide, cat. CuI.MeSMe, THF –78oC. 
 
Failure of the Michael addition may be caused by the high substitution of the C14 
position and the steric hindrance of the adjacent quaternary center, which result in the preference 
for the competing 1,2-addition reaction, to produce 4.23. 
The preference for the 1,2-addition over the 1,4-addition resulted in the investigation of a 
different approach.  In the new approach, an allyl Grignard would be used to accomplish a 1,2-
addition to produce an adduct with the C16 configuration as in 4.24.  The 3-hydroxyl-1,5-diene 
4.24 would be used for an oxy-Cope rearrangement reaction to stereoselectively functionalize the 
C14 position.   
 
Scheme 4.13: Proposed oxy-Cope rearrangement of compound 4.24 
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The oxy-Cope product 4.25 would have an allyl group at the C14 position.  To convert 
this to the desired hydroxymethyl functionality, the double bond of the allyl group would be 
isomerized to an internal double bond.  This would be accomplished by using the procedure 
employed by Sakurai et al56, as shown in the transformation of 4.26 to 4.27. Ozonolysis followed 
by hydride reduction should result in the formation of the β-hydroxymethyl compound 4.20. 
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Scheme 4.14: Isomerization of terminal double bond to an internal double bond56 
O O
4.26 4.27
H H
a
 
a.)  (PhCN)2PdCl2, benzene, reflux. 
urnell et al.54 conducted a study, of 1,2-additions of allyl magnesium reagents to 
cyclohe
cheme 4.15: 1,2-addition of allyl magnesium chloride to enone 3.41a 
 
B
xenones, from which they determined that allyl magnesium reagents preferentially add 
axial to cyclohexenones.  Treatment of α,β-unsaturated ketone 3.41a with allyl magnesium 
chloride at -78oC produced two 1,2-addition products, diastereomers 4.24 and 4.28.  After 
isolation and 13C NMR analysis, it was determined that the major product was the desired 
diasteriomer 4.24.  The stereo-chemistry of the carbinol centers were assigned based their 
chemical shifts in the 13C NMR spectra, in which the signal further downfield belongs to the 
axial-addition product54.  The C16 chemical shift of 4.24 was more downfield relative to the C16 
chemical shift in 4.28, confirming our expectations of the reaction. 
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a.) allylmagnesiumchloride, THF, -78oC, 4.24 (60 % yield), 4.28 (20 % yield) 
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Unexpectedly, attempts at a thermal oxy-Cope-rearrangement resulted in no product 
formati
cheme 4.16: Failed anionic oxy-Cope rearrangement 
on only recovery of the starting compound 4.24.  Formation of the anion of the hydroxyl 
group (anionic oxy-Cope) may result in the oxy-cope-rearrangement proceeding at lower 
temperatures49.  As explained by Carey and Sunberg49, the best results are obtained when a large 
cation is used as the counter ion, the normal choice being the potassium cation.49   
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a.) KH, THF, rt – 50oC. 
 was decided that potassium hydride was to be used as the base to deprotonate the 
hydrox
 the highly substituted C14 
position
 
It
yl group, resulting in the K+ as the counter ion.  Initially, treatment of 4.24 with KH in 
THF at room temperature resulted in no product formation.   The reaction temperature was then 
increased to 50oC, which resulted in complete consumption of the starting compound 4.24.   This 
produced an unexpected UV active product based on TLC.  After isolation it was determined that 
the product was not the desired oxy-Cope-rearrangement product 4.25, instead it was the 
elimination product 4.29, which explained the UV activity on TLC. 
Failure of the oxy-Cope-rearrangement may be because of
 and the rigidity of the tetracylcic compound preventing conformational change for 
favorable orbital overlap. 
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4.4 Conjugate addition of a nitrile group. 
 
Fuchs et al.55 demonstrated that an angular hydroxymethyl group can be accomplished 
from the conjugate addition of a nitrile group.  They initially performed a Negata hydrocyanation 
reaction of the α,β-unsaturated ketone 4.30 by treatment with diethylaluminumcyanide to 
produce the axial nitrile compound 4.31.  The ketone in 4.31 was protected as the t-
butyldimethylsilyl (TBS) enol ether 4.32 by treatment with triethylamine and t-
butyldimethylsilyl triflate.  Treatment of the nitrile 4.32 with DIBAl-H in hexane with ether as 
the solvent and subsequent hydrolysis of the imine with buffered acetic acid resulted in the 
formation of an aldehyde.  Further reduction with DIBAl-H produced the hydroxymethyl 
compound that was protected as its benzyl ether with benzyl bromide.   Treatment of the 
enolsilyl ether with hydrochloric acid produced the benzyl protected hydroxymethyl compound 
4.33.55 
 
Scheme 4.17: Fuchs’s synthesis of benzyl protected hydroxymethyl compound 4.3355 
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a.)  Et2AlCN, 60%.  b.)  TBS-Tf, Et3N, CH2Cl2 100%.  c.)  i. DIBAL(hexane), ether ii. AcOH 95%.  d.)  DIBAL 
(hexane), ether 90%  e.)BnBr  f.)  HCl. 
 
It was decided that this reaction series would be employed on enone 3.41a to 
functionalize the C14 position with the desired hydroxymethyl group.  Because of unavailability 
of diethylaluminum cyanide, a different cyanation approach was investigated.  The α,β-
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unsaturated ketone 3.41a was treated with ammonium chloride, potassium cyanide, in a 2:1 
mixture of DMF and water4 at 90oC to produce our desired β-cyanoketone 4.34. 
 
Scheme 4.18: Cyanation of compound 3.41a to produce β-cyanoketone 4.34 
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a.) NH4Cl, KCN, 2:1 DMF:H2O, 91% yield. 
 
Based on the steric effect of the axial methyl group adjacent to C14, it was presumed that 
the nitrile addition occurred from the opposite face giving the C14 configuration illustrated 
compound 4.34.  In an effort to shorten the synthetic steps, reduction of the nitrile was attempted 
without protection of the ketone, which should produce aldehyde 4.36.  When nitrile 4.34 was 
treated with excess DIBAl-H in THF, with THF as the solvent, the reaction resulted in reduction 
of only the ketone to form alcohol 4.35 - the nitrile remained intact. 
 
Scheme 4.19: Attempted reduction of nitrile group without protection of the ketone 
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a.) 1.0 M DIBAL in THF, THF; AcOH, 73% yield of 4.35 
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After isolation of alcohol 4.35, it was retreated under the same conditions, which resulted 
in no formation of 4.36 only recovery of the starting alcohol 4.35.  Since the direct reduction 
approach was unsuccessful, the C16 ketone was protected as its TBS enol ether.  β-ketonitrile 
4.34 was treated with triethylamine and TBS-triflate in methylene chloride at 0oC to produce 
enol silyl ether 4.37 quantitatively.   
Scheme 4.20: Synthesis of TBS-enol ether 4.37 
H
H
O
O
O
4.34
H
14
CN
a
H
H
OTBS
O
O
4.37
H
14
CN
16 16
 
a.) Et3N, TBS-Tf, CH2Cl2 0oC 1 h, 100% yield. 
 
After purification of enol silyl ether 4.37, by column chromatography, a colorless oil was 
obtained.  Storage of the oil at 0oC overnight formed crystals from which the crystal structure 
was obtained by single-crystal X-ray analysis.  This crystal structure confirmed the presence of 
all the functional groups (enolsilylether at C16, nitrile group at C14) and stereochemistry of all 
the stereocenters (C14 and C13 centers) of compound 4.37. 
H
H
OTBS
O
O
4.37
H
14
CN
16
13
 
   
Figure 4.1: Crystal structure obtaind from single-crystal X-ray analysis of enol silyl ether 
4.37 
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Treatment of 4.37, under similar conditions as Fuchs et al.55, with DIBAl-H in THF with 
THF as the solvent did not result in the reduction of the nitrile, instead compound 4.37 was 
recovered.  We then tried treating 4.37 with lithium aluminum hydride in THF.  This gave the 
same result, of no reduction, even after increasing the temperature of the reaction.  Interestingly, 
by changing the DIBAl-H reagent from DIBAl-H in THF to DIBAl-H in toluene and using 
toluene as the solvent, the nitrile was consumed after 15 minutes at room temperature to form a 
very polar compound.  After isolation it was determined that the product was not the desired 
aldehyde 4.38, instead the intermediate imine 4.39 was isolated as the product. 
Normally imines are hydrolyzed to their corresponding aldehydes during aqueous work 
up of the reactions.  In the reaction described above the reaction was quenched with a buffered 
solution of 6% acetic acid that was saturated with potassium acetate.  This neutral solution for 
hydrolysis of the imine is similar to what Fuchs et al.55 used in their work up and is used to 
prevent the removal of the acid sensitive enol silyl ether protecting group.   
 
Scheme 4.21: Reduction of nitrile 4.37 to imine 4.39 
H
H
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O
O
4.37
H
14
CN
H
H
OTBS
O
O
4.38
H
14
O
a. or b.
H
H
OTBS
O
O
H
NH
c
14
4.39  
a.) 1 M DIBAL in THF, THF, KOAc/AcOH; b.)  LAH, THF rt – 50oC, KOAc/AcOH; c.) 1 M DIBAL in toluene, 
toluene, rt 15 minutes, KOAc/AcOH, NaHCO3, 58% yield               
 
Because of the steric hindrance of the imine, it was believed that the hydrolysis might be 
slow so the imine 4.39 was retreated with the buffered solution of acetic acid and potassium 
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acetate and left to proceed for a longer time.  After 2 days it was determined that imine 4.39 was 
still intact.  In their partial synthesis of myriceric acid A from the natural product oleanolic acid, 
Konoike et al.2 report a similar problem.  They had an imine on the same C14 position that was 
stable under usual hydrolysis conditions.2   They accomplished the hydrolysis of their imine by 
treating it with sodium nitrite in aqueous dioxane-acetic acid to produce its corresponding 
aldehyde.2 
 
Scheme 4.22: Failed hydrolysis of imine 
H
H
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O
O
H
NH
14
4.39
H
H
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O
O
4.38
H
14
O
a. or b.
 
a.) KOAc/AcOH, THF, rt 2 days; b.) KOAc/AcOH, NaNO2, rt 2 days 
 
To prevent removal of the enol silyl ether, Konoike et al.’s2 procedure was modified.  
Instead of treating with acetic acid, imine 4.39 was treated with the buffered solution of acetic 
acid/potassium acetate and sodium nitrite for 2 days.  Unfortunately, these conditions also failed 
to provide the aldehyde 4.38.  Since the neutral hydrolysis conditions failed, it was decided that 
the usual acid hydrolysis condition would be attempted.  Imine 4.39 was treated with aqueous 
acetic acid in THF, which produced a new compound.  After isolation it was determined that the 
product was not the aldehyde 4.38, instead an interesting cyclic imine compound 4.40 was 
formed with the TBS group still on the C16 oxygen. 
 
Scheme 4.23: Synthesis of cyclic imine 4.40 
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a.) AcOH, THF rt, 60% yield. 
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It was believed that removal of the TBS protecting group followed by re-treatment with 
acid should produce keto aldehyde 4.22.  However, in an effort to make the synthesis shorter, it 
was decided that deprotection and acid hydrolysis would be attempted in one step starting with 
imine 4.39.  It was expected that treatment of imine 4.39 with HF would result in removal of the 
silicon protecting group and acid hydrolysis of the imine.  This condition resulted in complete 
decomposition of the compound, probably because of the harshness of the hydrofluoric acid, HF. 
 
Scheme 4.24: Decomposition of imine by HF 
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a.) HF, THF, 0oC, 30 minutes, decomposition. 
 
Interestingly, when imine 4.39 was treated with TBAF in THF at room temperature a new 
product formed within 30 minutes.  This product was determined to be the cyclic imine alcohol 
4.41.  Treatment of 4.41 with acetic acid in a 1:1 solution of THF and water under reflux 
produced the desired keto aldehyde 4.22 in high yield (80%). 
 
Scheme 4.25: Synthesis of aldehyde 4.22 through hemiiminal 4.41 
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14 16
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b
 
a.) TBAF, THF, rt, 69% yield after 2 steps from 4.39; b.) AcOH, 1:1 THF:H2O, reflux 4 h, 80% yield. 
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To complete the formation of the hydroxymethyl functionality at C14, the aldehyde in 
4.22 needs to be reduced.  Because of the steric hindrance around the aldehyde the C16 ketone 
may need to be protected before reduction of the aldehyde is attempted. 
 
4.5 Conclusion 
 
In section 4.2 it was discovered that forming a hydroxy group at C13 could form the C12-
C13 double bond.  It was also discovered that this C13 hydroxy group facilitated the 
aromatization of the D ring.  To prevent aromatization, functionalization of the C14 position was 
necessary.  In section 4.2 and 4.3, attempts were made to add the C14 hydroxymethyl group: the 
intramolecular radical cylcization in section 4.2, the Michael addition of the vinyl cuprate 
approach, and the oxy-Cope-rearrangement approach in section 4.3, failed because of the high 
substitution at the C14 position and the steric hindrance caused by the quaternary center on C8 
adjacent to the C14 position. 
In section 4.4 the Michael addition to the C14 position was finally accomplished using a 
nitrile group as the nucleophile.  Reduction of the nitrile turned out to be dependent on the 
solvent used for the DIBAl-H reaction, in which it only occurred when toluene was used as the 
solvent.  The reduction of the nitrile resulted in the formation of the imine 4.39 which proved to 
be difficult to hydrolyze under normal hydrolysis conditions because of high steric hindrance in 
its surroundings.  Removal of the protecting group of 4.39 resulted in a new cyclic imine alcohol 
compound 4.41, which was cleanly hydrolyzed to aldehyde 4.22 when treated with acid. 
From these results it is believed that functionalization of the C14 position was possibly 
the major hurdle in the functionalization of the D ring of (+)-myriceric acid A.  Other reactions, 
not shown here, have been accomplished in which the other functionalities were constructed.  So, 
a fully functionalized ABCD ring compound should be completed in the near future and this will 
facilitate the total synthesis of (+)-myriceric acid A. 
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CHAPTER 5 - Activity studies of tetracyclic synthetic intermediates 
of (+)-myriceric acid A 
5.1 Fujimoto’s structure-activity relationship studies of myriceric acid and its 
derivatives 
 
In their structure-activity relationship (SAR) studies of the myriceric acids and their 
derivatives, Fujimoto et al.1, suggested that four functional groups were important for the 
endothelin-A receptor antagonist activity.1   These important functionalities are the carbonyl 
group at C3, the carboxylic acid group at C17, the trans-caffeoyloxy group at C27, and the 
dimethyl groups at C20 (Figure 5.1).  Reduction of the carbonyl group at C3 or migration of one 
of the methyl groups at C20 resulted in reduction of the receptor antagonist activity.  Removal of 
the carbonyl group at C3 or the trans-caffeoyloxy group at C27 or replacement of the C17 
carboxylic acid group by a methyl ester group, resulted in complete loss of the binding affinity.1    
 
H
CO2H
H
H
O O
O
OR1
OR2
3
20
17
27
(+)-1.1: R1, R2 = H
1.22: R1 = SO3H, R2 = OH
1.23: R1 = OH, R2 = SO3H
1.24: R1 = SO3H, R2 = SO3H  
Figure 5.1: Myriceric acid A and sulfated derivatives 
 
When the hydroxy groups on the trans-caffeoyloxy group were sulfated, as in compounds 
1.22, 1.23, and 1.24, the binding affinities increased to 15 nM, 3.4 nM, and 41 nM, respectively.1 
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5.2 Synthetic intermediates of myriceric acid A which were tested as ETA 
receptor antagonists using SMA bioassay 
 
In the course of our synthesis several interesting tetracyclic compounds were obtained 
(Figure 5.2).  Many of these contained functionalities that were not present in the myriceric acid 
derivatives tested by Fujimoto et al.1   To elaborate the SAR done by Fujimoto et al.1, we 
decided to test these tetracyclic compounds using the SMA bioassay described in chapter 1. 
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4.15 5.3 (-)-2.9
5.4 (+)-1.1
 
Figure 5.2: Synthetic intermediates that were tested 
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All the compounds listed were tested first for their antagonistic activity then for their 
ability to reverse the vasospasm.  In these experiments, only the changes in the blood vessel 
diameter were recorded and the experiments were performed in the apparatus illustrated below. 
 
1 mM
Ca2+
10 mM
Ca2+
10 uM
drug
10 nM
ET-1
reservoirs
water jacket
superfusion
chamber
00:00:01:00
VCR
microscope
video
camera
video monitor
chart recorder
computer
vacuum
SMA
Holder
time code generator
valves
video edge detector
SMA image
Edge detection
window
recorded
constriction
 
Figure 5.3: Schematic of apparatus used for testing antagonistic activity of the compounds 
 
Four solutions were made for these experiments: 1.0 mM Ca2+ physiological salt solution 
(PSS); 10 mM physiological salt solution; 10 μM drug solution, in which the drug is dissolved in 
the 1.0 mM Ca2+ PSS; and 10 nM ET-1 solution, in which the ET-1 is dissolved in the 1.0 mM 
Ca2+ PSS.  All the solutions were at pH 7.4 and a full description on how to make them is 
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described in the experimental section.  Each solution was poured into a separate reservoir as 
shown in the diagram above and kept at 37oC with a water jacket maintained at 37oC.   
After the SMA has been isolated and cut into segments, one segment was transferred into 
the superfusion chamber, filled with 1 mM Ca2+ solution, and held in place by two blunted glass 
needles mounted on micromanipulators.  After the segment was secure, it was superfused with 1 
mM Ca2+ solution for 1 minute.  To induce a constriction, the 1 mM Ca2+ valve is closed and the 
10 mM Ca2+ valve is open and the SMA is superfused for 1 minute with 10 Ca2+ solution, which 
caused a constriction.  This constriction was set to 100 %, and used as a control to compare to 
the constriction caused by ET-1.  After the 1 minute of 10 mM Ca2+ was over, the valve was 
closed and the 1 mM Ca2+ valve was opened and the SMA was superfused for 1 minute with this 
solution.  At 1.0 mM Ca2+ solution, the SMA diameter quickly returned to its normal diameter.  
This process was repeated once more. 
 To determine whether the drug is an antagonist, the 1 mM Ca2+ valve was closed and the 
drug valve was open and the SMA was superfused for 1 minute with the 10 μM solution of the 
drug.  This step is done to determine whether the drug alone has any effect on the SMA.  After 
the SMA has been superfused for 1 minute with the drug alone, the ET-1 valve is also open and 
the SMA is superfused for 1 minute with both the drug solution and the 10 nM ET-1 solution.  If 
the drug is an antagonist, no constriction should be observed when the SMA is superfused with 
both the drug solution and the ET-1 solution.  If the drug in not an antagonist, then the ET-1 
should induce the vasospasm even when the SMA is being superfused with both the drug and the 
ET-1 solutions.  This was the case with all the compounds tested as is seen in the representative 
experiment illustrated in the figure below (Figure 5.4). 
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Figure 5.4: Representative experiment – testing antagonistic activity of compounds and 
reversal of vasospasm 
 
 After the SMA is superfused with the drug and ET-1 solutions for 1 minute, both valves 
are closed and the 1 mM Ca2+ valve is open and the SMA is superfused for 2 minutes with 1 mM 
Ca2+ solution.  This is done to wash away the drug and the ET-1.  For the drugs that were tested, 
they were unable to prevent the vasospasm, and even after washing away the ET-1 the 
constriction still remained while the SMA was superfused with the 1 mM Ca2+ solution.  To test 
whether the drug can reverse the vasospasm, after the 2 minute washing of the SMA with 1 mM 
Ca2+ solution, the constricted SMA was superfused with 10 μM drug solution for 1 minute.  If it 
was unable to reverse the vasospasm, no effect would be seen during this time, as seen in figure 
5.4.  If it can reverse it, then an increase of the SMA diameter should be observed. 
 After the SMA is superfused for 1 minute with the drug solution, it is superfused once 
more with 1 mM Ca2+ solution to wash away the drug and the effect was observed.  After this 
wash the experiment was ended, the SMA was washed away with 1 mM Ca2+ solution and the 
chamber was washed for 3 minutes with 1 mM Ca2+ solution before another experiment was 
started. 
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5.3 Results and discussion 
 
After testing all the compounds listed, entry 1 to 11, none showed any antagonistic 
activity (Figure 5.4).  All showed a constriction greater than 100 % when compared to the 
constriction induced by the 10 mM Ca2+ solution (Table 5.1). 
 
Table 5-1: Compounds tested and % constriction 
Entry Compound 
Control 
constriction: 
Average of 10 
mM Ca 
Constriction (μm)
Constriction
caused by 10 nM 
ET-1 in the 
presence of 10 
μM Compound 
(μm) 
% Constriction 
caused by 10 nM 
ET-1 in the 
presence of 10 
μM Compound 
Relaxation of 
constriction by 
addition of 
compound 
(μm) 
% relaxation 
Of 
constriction 
by addition of 
compound 
1 4.11 11.21 17.91 160 NA NA 
2 4.16 4.51 8.09 179 NA NA 
3 4.10 16.19 21.21 131 NA NA 
4 4.9 13.18 20.9 159 NA NA 
5 5.1 18.6 24.08 129 NA NA 
6 5.1 7.73 11.11 144 5.77 52 
7 5.2 12.16 23.62 194 NA NA 
8 4.15 4.7 5.5 117 NA NA 
9 5.3 5.35 7.91 148 NA NA 
10 (-)-2.9 10.61 18.36 173 NA NA 
11 5.4 15.9 17.46 110 NA NA 
 
 
(+)-Myriceric acid A was also tested using similar conditions.  First, its antagonistic 
activity was tested by superfusing the SMA with 10 μM myriceric acid A solution and 10 nM 
ET-1 solution.  At these concentrations, constriction was still induced by the ET-1 in the 
presence of myriceric acid A.  As seen in Figure 5.5-A, the constriction is not as significant as 
with the other drugs tested, so some prevention was observed.  The antagonistic activity was 
seen more clearly when the test was repeated using lower concentrations.  Myriceric acid A 
showed antagonistic activity by preventing the constriction of the SMA when the SMA was 
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superfused with both, a 1 μM solution of (+)-myriceric acid A and 1 nM solution of ET-1 
(Figure 5.5-B). 
H
CO2H
H
H
O O
O
OH
OH  
   A 
 
   B 
 
Figure 5.5: A - failed antagonistic activity of (+)-myriceric acid A at higher concentrations; 
B – antagonistic activity of (+)-myriceric acid A at lower concentrations 
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 To determine whether myriceric acid A could reverse the vasospasm, the constriction of 
the SMA was induced with 1 nM ET-1 for 1 minute.  After the vasospasm was induced with ET-
1, the SMA was superfused for 2 minutes with 1.0 mM Ca2+ solution to wash away the ET-1.  As 
expected, this did not reverse the vasospasm.  After the SMA was superfused for 2 minutes with 
1 mM Ca2+ solution, the constricted SMA was superfused with 1 μM solution of myriceric acid 
A for 1 minute.  As seen in Figure 5.5, (+)-myriceric acid A failed to reverse the 
vasoconstriction. 
All the compounds were tested 3-7 times each, and the results obtained for each 
compound were normally consistent for the same compound, showing no atagonistic activity.  
When nitrile 5.1 was tested, two results were obtained as illustrated in Figure 5.6-A and 5.6-B, 
entry 5 and 6 respectively.  In both experiments, nitrile 5.1 showed no antagonistic activity, by 
failing to prevent the ET-1 induced vasoconstriction.  In the experiment summarized in entry 6 
(Figure 5.6-B) and others (not shown), when the SMA was superfused with the nitrile 5.1 a slight 
increase in vessel diameter occurred, but it still failed to prevent the vasoconstriction when ET-1 
was added.  After the irreversible vasoconstriction was induced by ET-1, the nitrile was tested to 
see whether it could reverse it.  When the constricted SMA was superfused for 1 minute with the 
nitrile, there was a 52% relaxation of the constriction (Figure 5.6-B).  When the addition of 
nitrile 5.1 was terminated the constriction returned to the normal constriction. 
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Figure 5.6: A-antagonistic activity of nitrile 5.1; B – antagonistic acitivity and reversal of 
vasospasm by nitrile 5.1 
 
These results indicate that nitrile 5.1 is not an endothelin receptor antagonist.  The results 
illustrated in Figure 5.6-B (entry 6) indicate that nitrile 5.1 may be able to reverse the vasospasm.  
However, because of the inconsistency between the results illustrated in Figure 5.6-A and 5.6-B, 
it cannot be concluded that nitrile 5.1 can reverse the vasospasm.  Repetition of this experiment 
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and further investigations are necessary to determine whether nitrile 5.1 can reverse the 
vasospasm.     
 
5.4 Conclusion 
 
Although none of the compounds tested showed any antagonistic activity, they contribute 
to the structure-activity relationship by confirming the necessity of other functional groups like 
the trans-caffeoyloxy ester group and the carboxylic acid group.  It is possible that addition of 
these functional groups may result in an active tetracyclic compound.  Further more the nitrile 
compound 5.1, needs to be investigated further to determine if it can reverse the 
vasoconstriction. 
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 CHAPTER 6 - Experimental 
General Procedures.  Unless other wise stated, Nuclear Magnetic Resonance (NMR) spectra 
were recorded on a varian 400 MHz and varian 200 MHz instrument, for proton NMR; Varian 
100 MHz and Varian 50 MHz instrument, for carbon NMR.  The NMR spectra were obtained in 
chloroform-d (CDCl3), for proton NMR, the chemical shifts are given in parts per million (ppm) 
downfield from tetramethylsilane (TMS) as an internal standard, unless other wise stated.  
Coupling constants (J) are given in hertz.  Solvents were dried by distillation under argon from 
CaH2 (CH2Cl2, pyridine, Et3N, DMF, diisopropylamine), Na-Ph2CO (THF, Et2O), Mg (EtOH, 
MeOH), and LAH (toluene, benzene).  All other reagents were obtained from commercial 
suppliers and used without further purification.  All reactions were performed under argon 
atmosphere, unless otherwise stated.  Thin layer chromatography (TLC) was performed on plates 
obtained from Aldrich and column chromatography was performed on silica gel (200-400 mesh) 
from Natland corporation. 
Chapter 2, Experimental Section 
2-Methyl-2-(3-oxopentyl)cyclohexane-1,3-dione (2.4) 
 
O
O
O
2.4  
 
(AA-6-70) To a refluxing solution of 5 g (39.6 mmol) of 2-methyl-1,3-cyclohexanedione and 
0.089 g (1.6 mmol) of potassium hydroxide dissolved in 30 mL of dry methanol was added 
dropwise, over five minutes, 5 g (59.4 mmol) of ethyl vinyl ketone.  After refluxing overnight 
the reaction was quenched with saturated aqueous ammonium chloride and 1 M hydrochloric 
acid then extracted three times with ethyl acetate.  The combined ethyl acetate layers was washed 
with brine, dried over magnesium sulfate, and concentrated to give 8.32 g (quantitative yield) of 
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triketone 2.4 as a yellow oil, which was used directly for the next reaction.  1H-NMR (CDCl3) δ 
ppm 2.78-2.59 (m, 4 H), 2.39 (q, J = 7.3 Hz, 2 H), 2.32 (t, J = 7.3 Hz, 2 H), 2.07 (t, J = 7.9 Hz, 2 
H), 2.10-1.84 (m, 2 H), 1.24 (s, 3 H), 1.02 (t, J = 7.3 Hz, 3 H); 13C-NMR ( CDCl3) δ ppm 210.5, 
210.3 (2 C), 64.6, 38.0 (2 C), 37.2, 36.2, 30.0, 20.0, 17.8, 7.9.  
 
(R)-5,8a-Dimethyl-3,4,8,8a-tetrahydronaphthalene-1,6(2H,7H)-dione [(-)-2.5]20  
 
 
 
(AA-6-72) To a solution of 8.32 g (39.6 mmol) of triketone 2.4 in 200 mL of dry DMF was 
added 6.54 g (39.6 mmol) of D-phenylalanine and 4.6 g (19.8 mmol) of d-CSA.  After 2 hours at 
room temperature, the reaction temperature was increased by 15oC every 2 hours until it got to 
85oC and stirred overnight. After cooling to room temperature, cold saturated aqueous sodium 
bicarbonate was added to the reaction and it was extracted three times with diethyl ether.  The 
combined diethyl ether layers was washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
hexane and diethyl ether in which the product comes out at a solvent ratio of 6:1 – 4:1 
hexane:ether to give 4.6 g (61% yield, after 2 steps) of the product (-)-2.5 as a yellow oil.  
Rotation: [α]25D = -124o (c = 0.495, CHCl3) (lit.21 -125o c = 0.54 after column, and -140o c = 
0.200 after recrystallization)   1H-NMR (CDCl3) δ ppm 2.88 (dt, J = 15.6, 5.8 Hz, 1 H), 2.73-
2.64 (m, 1 H), 2.66 – 2.40 (m, 4 H), 2.20 - 2.04 (m, 3 H), 1.81 (s, 3 H), 1.80 – 1.71 (m, 1 H), 
1.42 (s, 3 H); 13C-NMR (50 MHz NMR (CDCl3) δ ppm 211.7, 197.2, 158.1, 130.4, 50.4, 37.1, 
33.1, 29.4, 27.0, 23.1, 21.3, 11.0.   
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(4aR,5R)-5-Hydroxy-1,4a-dimethyl-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one [(-)-
2.9]20  
 
O
OH
(-)-2.9  
(AA-7-15) To a solution of 4.62 g (24.1 mmol) of ketone (-)-2.5 dissolved in 60 mL of dry 
ethanol at 0oC was added 227 mg (6.01 mmol) of sodium borohydride.  After stirring for 1 hour 
the reaction was quenched by adding saturated ammonium chloride and 1 M hydrochloric acid.  
The solution was diluted and extracted three times with diethyl ether and the combined diethyl 
ether layers was washed with brine, dried over magnesium sulfate, concentrated and purified by 
silica gel column chromatography using a solvent gradient of hexane and diethyl ether in which 
the compound came out at a solvent ratio of 1:1 hexane:ether to give 4.1 g (87% yield) of (-)-2.9 
as a yellow oil.  Rotation: [α]25D = -144o (c = 0.25, CHCl3) (lit.,20 after crystallization [α]25D = -
164.6o (c = 2.16, CHCl3))  1H NMR (400 MHz, CDCl3) δ ppm 3.42 ( dt, J = 11.4, 4.7 Hz, 1 H), 
2.69 (dm, J = 14.9 Hz, 1 H), 2.46-2.43 (m, 2 H), 2.14 (dt, J = 13.2, 4.4 Hz, 1 H), 2.10-2.02 (m, 1 
H), 1.95-1.81 (m, 3 H), 1.78 (d, J = 1.5 Hz, 3 H), 1.70 (ddd, J = 24.6, 12.9, 4.1 Hz, 1 H), 1.52 
(bd, J = 5.6, 1 H), 1.37 (qt, J = 13.5, 4.4 Hz, 1 H), 1.18 (s, 3 H); 13C-NMR (CDCl3) δ ppm 200.1, 
162.5, 130.2, 78.6, 42.6, 34.0 (2 C), 30.5, 27.7, 23.5, 16.4, 11.9.  
(4aS,8R,8aR)-8-Hydroxy-1,4a,8a-trimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-
2(3H)-one [(+)-2.2]17   
OH
O
(+)-2.2
 
(AA-10-23) To a stirring solution of 4.18 g (21.5 mmol) of ketone (-)-2.9 dissolved in 60 mL of 
dry methanol was added 3.5 g (65 mmol) of sodium methoxide.  After 3 hours at room 
temperature 6.47 mL (65 mmol) of ethyl vinyl ketone was added dropwise over 5 minutes and 
the solution was stirred at room temperature overnight then refluxed for six hours.  After cooling, 
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saturated aqueous ammonium chloride and 1 M hydrochloric acid were added to the reaction, 
which was diluted and extracted three times with diethyl ether.  The combined diethyl ether 
layers were washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography using a solvent gradient of hexane and diethyl ether in which the 
compound came out at a 2:1 solvent ratio of hexane: diethyl ether to give 3.83 g (69% yield) of 
the enone (+)-2.2 as an off white solid. Rotation: [α]25D = +21o (c = 0.145, CHCl3), (lit.17 after 
crystallization, [α]27D = +50o (c = 2.0, CHCl3))   1H NMR (400 MHz, CDCl3) δ ppm 5.50 (t, J = 
3.8 Hz, 1 H) 3.48 (dd, J = 8.8, 7.7 Hz, 1 H) 2.67 - 2.42 (m, 4 H) 2.28 - 2.20 (m, 2 H) 2.10 – 1.96 
(m, 3 H) 1.81 - 1.73 (m, 2 H) 1.78 (s, 3H) 1.53 - 1.44 (m, 2 H) 1.42 (s, 3 H) 1.27 (s, 3 H); 13C-
NMR (CDCl3) δ ppm 198.7, 163.4, 148.3, 128.3, 120.2, 76.1, 41.4, 39.1, 35.1, 34.5, 34.1, 28.1, 
26.1, 24.8, 24.6, 20.6, 11.36.  
 
(4aS,8R,8aR)-8-Hydroxy-1,1,4a,8a-tetramethyl-4,4a,7,8,8a,9,10,10a-
octahydrophenanthren-2(1H,3H,6H)-one [(+)-2.12]15   
 
OH
O
(+)-2.12  
 
(AA-6-16) At -78oC, 83 mL of liquid ammonia was condensed into a three neck round bottom 
flask equipped with a Birch condenser filled with dry ice and acetone. Addition of lithium wire 
324 mg (47 mmol) in small pieces turned the solution dark blue.  After stirring for 10 minutes at 
-78oC, 3.3 g (12.3 mmol) of the enone (+)-2.2 dissolved in 40 mL of dry THF was cannulaed 
into the reaction flask and the reaction was stirred at -35oC.  After 2 hours, the reaction was put 
at -78oC and 6.6 mL (106 mmol) of dry methyl iodide was added and the reaction was put to -
35oC.   After 2 hours the liquid ammonia was left to evaporate overnight.  The solution was made 
acidic by the addition of 2 M HCl and it was extracted four times with methylene chloride.  The 
combined methylene chloride layers were washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
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methylene chloride, hexane, and diethyl ether in which the compound came out at 4:4:0.3 ratio of 
hexane : methylene chloride : diethyl ether to give 1.66 g (49% yield) of the compound (+)-2.12 
as a white solid.  Rotation: lit.,17 [α]24D = +38o (c = 0.45, CHCl3). 1H NMR (400 MHz, CDCl3) δ 
ppm 5.35 (t, J = 4.1 Hz, 1 H), 3.45 – 3.40 (m, 1 H), 2.74 – 2.65 (m, 1 H), 2.41 (ddd, J = 15.9, 
6.0, 3.2 Hz, 1 H), 2.21 – 2.01 (m, 4 H), 1.81 – 1.65 (m, 4 H), 1.62 – 1.56 (m, 2 H), 1.87 (dd, J = 
12.2, 2.6 Hz, 1 H), 1.29 (d, J = 0.9 Hz, 3 H), 1.23 (dd, J = 13.0, 4.0 Hz, 1 H), 1.18 (s, 3 H), 1.09 
(s, 3 H), 1.08 (s, 3 H);  13C-NMR (CDCl3) δ ppm 217.27, 151.42, 117.70, 78.54, 53.82, 47.91, 
39.44, 39.03, 38.87, 38.16, 34.90, 26.28, 25.87, 24.99, 23.33, 21.80, 20.54, 19.49.   
 
(4a'S,8'R,8a'R)-1',1',4a',8a'-Tetramethyl-3',4',4a',6',7',8',8a',9',10',10a'-decahydro-
1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'-ol [(+)-2.13]17   
 
 
 
(AA-7-52) In a round-bottom flask equipped with a Dean-Stark apparatus, 1.1 g (4 mmol) of 
ketone (+)-2.12 was dissolved in 125 mL of toluene.  322 mg (1.2 mmol) of pyridinium para-
toluenesulfonate (PPTS) and 2.5 g (40 mmol) of ethylene glycol were added and the reaction was 
put to reflux.  After 2 hours the reaction was determined to be complete by TLC.  Saturated 
sodium bicarbonate was added to the reaction, which was extracted three times with diethyl 
ether.  The combined ether layers were washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
hexane and diethyl ether in which the compound came out at a 4:1 ratio of hexane:diethyl ether 
to give 1.1 g (85% yield) of the kcetal (+)-2.13 as a white solid. Rotation: [α]24D = +18o (c = 
0.40, CHCl3) lit.17 after recrystallization, [α]27D = +22o (c = 0.26, CHCl3)  1H NMR (400 MHz, 
CDCl3) δ ppm  5.30 (t, J = 4.1 Hz, 1 H), 4.00-3.87 (m, 4 H), 3.41 (dt, J = 10.8, 5.0 Hz, 1 H), 
2.19-2.10 (m, 2 H), 1.95 (dt, J = 12.6, 3.2 Hz, 1 H), 1.92-1.83 (m, 1 H), 1.70-1.55 (m, 7 H), 1.30-
1.20 (m, 3 H), 1.16 (s, 3 H), 1.13 (s, 3 H), 0.97 (s, 3 H), 0.86 (s, 3 H); 13C-NMR (CDCl3) δ ppm 
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152.27, 116.36, 113.28, 78.80, 65.07, 65.00, 51.48, 42.60, 39.50, 39.42, 39.18, 36.12, 27.43, 
26.35, 25.04, 23.78, 23.13, 20.66, 20.11, 18.53.  
 
(4a'R,4b'R,8'R,8a'R)-1',1',4a',8a'-Tetramethyldodecahydro-1'H-spiro[[1,3]dioxolane-
2,2'-phenanthren]-8'-ol [(-)-2.14]18,19   
 
 
 
(AA-8-72) Alkene (+)-2.13, 720 mg (2.2 mmol), was dissolved in 40 mL of ethanol that was 
deoxygenated by bubbling argon through it for 10 minutes; heating was necessary for the alkene 
to dissolve.  After cooling to room temperature 300 mg of 10% palladium on activated carbon 
was added then the reaction was put under hydrogen gas atmosphere by adapting a balloon full 
of hydrogen gas to the reaction flask.  After stirring overnight under hydrogen the reaction was 
determined to be complete by TLC.  The reaction was diluted with ethanol and diethyl ether, 
filtered through celite, concentrated and purified by flash silica gel column chromatography a 1:1 
ratio of hexane:diethyl ether to give a mixture of the desired product and a little of the 
deprotected product which was subjected to the previously described protection procedure, from 
which the compound was obtained and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the compound came out at a 4:1 ratio of 
hexane:diethyl ether to give 700 mg (97% yield) of the alcohol (-)-2.14 as a white solid.  
Rotation: [α]24D = -9.4o (c = 0.100, CHCl3)  (lit.,19 after enzymatic resolution [α]26D = -44o (c = 
0.10, CHCl3).  1H NMR (400 MHz, CDCl3) δ ppm 3.99 – 3.86 (m, 4 H), 3.13 (dd, J = 11.4, 4.1 
Hz, 1 H), 1.90 – 1.74 (m, 3 H), 1.64 – 1.33 (m, 10 H), 1.30 -1.05 (m, 7 H), 0.93 (s, 3 H), 0.88 (s, 
6 H), 0.85 (s, 3 H) ; 13C-NMR (CDCl3) δ ppm 113.50, 81.40, 65.09 (2 C), 56.86, 53.87, 42.46, 
39.86, 39.43, 37.22, 37.07, 30.43, 27.11, 24.79, 23.15, 20.23, 20.13, 18.28, 16.48, 13.31. 
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(4a'S,4b'R,8a'R)-1',1',4a',8a'-Tetramethyldecahydro-1'H-spiro[[1,3]dioxolane-2,2'-
phenanthren]-8'(3'H)-one [(-)-2.1]18,19   
 
 
 
(AA-8-34) Alcohol (-)-2.14, 510 mg (1.6 mmol), was dissolved in 30 mL of DMSO then  487 
mg (1.7 mmol) of IBX was added to the reaction.  After stirring overnight the reaction was 
determined to be complete by TLC.  It was diluted with water and extracted three times with 
diethyl ether.  The combined ether layers where washed with brine, dried over magnesium 
sulfate, concentrated and purified by silica gel column chromatography using a solvent gradient 
of hexane and diethyl ether in which the compound came out between 5:1 and 4:1 ratio of 
hexane:diethyl ether to give 400 mg (78% yield) of the ketone (-)-2.1 as a white solid. Rotation: 
[α]24D = -8o (c = 0.150, CHCl3)   (lit.,19 after enzymatic resolution [α]26D = -26o (c = 0.14, CHCl3) 
1H NMR (400 MHz, CDCl3) δ ppm 3.98 – 3.86 (m, 4 H), 2.54 (td, J = 14.0, 6.9 Hz, 1 H), 2.18 
(dm, 1 H), 2.08 – 2.01 (m, 1 H), 1.82 (td, J = 13.9, 4.0 Hz, 1 H), 1.75 – 1.35 (m, 10 H), 1.26 (dd, 
J = 12.3, 2.1 Hz, 1 H), 1.18 (dd, J = 11.8, 3.0 Hz, 1 H), 1.14 (s, 3 H), 0.98 (s, 3 H), 0.94 (s, 3 H), 
0.84 (s, 3 H) ; 13C-NMR (CDCl3) δ ppm 215.93, 113.17, 65.12, 65.10, 57.62, 53.21, 49.36, 
42.43, 38.25, 37.88, 37.11, 34.65, 27.03, 26.41, 23.09, 20.26, 20.07, 20.04, 18.02, 16.75.  
2-(Phenylthio)cyclohexanone (2.16)   
 
O
SPh
2.16  
 
(AA-3-60) At -20oC, 31.8 mL (50.9 mmol) of 1.6 M n-butyllithium was added to 7.2 mL (50.9 
mmol) of dry diisopropyl amine dissolved in 200 mL of dry THF and stirred for 30 minutes to 
make fresh lithium diisopropyl amine (LDA).  At -78oC, the fresh LDA (50.9 mmol) was added 
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to 5 g (50.9 mmol) of cyclohexanone dissolved in 200 mL of dry THF.  After 1.5 hours 13.3g 
(61.1 mmol) of phenyl disulfide was quickly added to the reaction.  After 5.5 hours the reaction 
was quenched with saturated ammonium chloride and extracted three times with diethyl ether.  
The combined diethyl ether layers was washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
hexane and diethyl ether in which the product came out at 9:1 ratio of hexane to diethyl ether to 
give 6.64 g (62 % yield ) of the product 2.16 as a lightly green oil. 1H NMR (400 MHz, CDCl3) δ 
ppm 7.42 – 7.38 (m, 2 H), 7.31 – 7.22 (m, 3 H), 3.83 (t, J = 6.6 Hz, 1 H), 2.95 – 2.88 (m, 1 H), 
2.82 – 2.19 (m, 2 H), 2.12 -2.04 (m, 1 H), 2.00 – 1.91 (m, 2 H), 1.88 – 1.81 (m, 1 H), 1.74 – 1.65  
(m, 1 H). 
 
2-(Phenylselanyl)cyclohexanone (2.17)  
 
O
SePh
2.17  
 
(AA-4-63) At -20oC, 6.4 mL (10.2 mmol) of 1.6 M n-butyllithium was added to 1.43 mL (10.2 
mmol) of dry diisopropyl amine dissolved in 50 mL of dry THF and stirred for 30 minutes to 
make fresh lithium diisopropyl amine (LDA).  At -78oC, the fresh LDA (10.2 mmol) was added 
to 1 g (10.2 mmol) of cyclohexanone dissolved in 50 mL of dry THF.  After 1.5 hours 2.64 g 
(11.2 mmol) of phenylselenylbromide was quickly added to the reaction.  After 5.5 hours the 
reaction was quenched with saturated aqueous ammonium chloride and extracted three times 
with diethyl ether.  The combined diethyl ether layers was washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the product came out at 19:1 ratio of 
hexane to diethyl ether to give 2.21 g (86 % yield ) of the product 2.17. 1H NMR (400 MHz, 
CDCl3) δ ppm 7.56 – 7.52 (m, 2 H), 7.32 – 7.25 (m, 3 H), 3.93 (td, J = 3.9, 1.7 Hz, 1 H), 3.03 – 
2.95 (m, 1 H), 2.36 – 2.27 (m, 1 H), 2.25 – 2.17 (m, 2 H), 2.02 – 1.93 (m, 1 H), 1.91 – 1.67 (m, 3 
H). 
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3,3-Dimethylpentane-1,5-diol (2.22)29  
 
 
 
(AA-1-61) To a stirring suspension, at 0oC, of 1.42 g (37.4 mmol) of lithium aluminium hyrdride 
in 100 mL of dry THF was added, dropwise over 20 minutes, a solution of 3 g (18.7 mmol) of 
3,3-dimethylglutaric acid in 30 mL of THF.   After stirring overnight at room temperature the 
reaction was quenched slowly with 1 mL of water and stirred for 10 minutes, then 1 mL of 10% 
sodium hydroxide was added slowly and stirred for another 10 minutes.  Another 3 mL of water 
was added and stirred for 10 minutes after which the reaction turned into a cloudy white mixture 
which was filtered and washed with ethyl acetate to give 2.5 g (quantitative yield) of the diol 
2.22 which was used without further purification in the next step.  1H NMR (400 MHz, CDCl3) δ 
ppm 3.73 (t, J = 7.1 Hz, 4 H), 1.58 (t, J = 7.1 Hz, 4 H), 0.95 (s, 6 H). 
 
5-(tert-Butyldimethylsilyloxy)-3,3-dimethylpentan-1-ol (2.23)30  
 
 
 
(AA-5-109) Sodium hydride (60% by weight in oil), 60.8 mg (1.52 mmol), was quickly added to 
a solution of 200 mg (1.52 mmol) of diol 2.22 in 3 mL of dry THF.  After stirring at room 
temperature for 50 minutes, 229 mg (1.52 mmol) of tert-butyldimethylsilylchloride (TBSCl) was 
quickly added under argon.  After 1 hour, the reaction was quenched with saturated aqueous 
ammonium chloride and extracted three times with diethyl ether.  The combined diethyl ether 
layers was washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography using a solvent gradient of hexane and diethyl ether in which the 
product came out at 5:1 ratio of hexane to diethyl ether to give  266 mg (71 % yield ) of the 
 96
product 2.23.  1H NMR (400 MHz, CDCl3) δ ppm 3.71 (dt, J = 13.0, 7.0 Hz, 4 H), 1.55 (dt, J = 
14.7, 7.3 Hz, 4 H), 0.94 (s, 6 H), 0.90 (s, 9 H), 0.07 (s, 6 H). 
 
5-(tert-Butyldimethylsilyloxy)-3,3-dimethylpentanal (2.24)  
 
 
 
(AA-2-111) Alcohol 2.23, 1 g (4.06 mmol), and 1.3 g (4.47 mmol) of IBX were dissolved in 5 
mL of dimethyl sulfoxide.  After stirring overnight the reaction was diluted with water at which 
time a white solid formed which was filter and washed several times with water and diethyl 
ether.  The filtrate was then extracted three times with diethyl ether.  The combined diethyl ether 
layers was washed with brine, dried over magnesium sulfate, and concentrated to give 0.8024 g 
(81 % yield ) of the aldehyde 2.24 which was used without further purification for the next step.  
1H NMR (400 MHz, CDCl3) δ ppm 9.85 (t, J = 3.1 Hz, 1 H), 3.72 (t, J = 6.8 Hz, 2 H), 2.33 (d, J 
= 3.1 Hz, 2 H), 1.62 (t, J = 6.8 Hz, 2 H), 1.08 (s, 6 H), 0.89 (s, 9 H), 0.05 (s, 6 H). 
 
(Z)-Ethyl 2-acetyl-7-(tert-butyldimethylsilyloxy)-5,5-dimethylhept-2-enoate (2.20 Z) , & 
(E)-ethyl 2-acetyl-7-(tert-butyldimethylsilyloxy)-5,5-dimethylhept-2-enoate (2.20 E)   
 
 
 
(AA-2-114) To a solution, at 0oC, of 802 mg (3.3 mmol) of aldehyde 2.24 and 473 mg (3.63 
mmol) of ethyl acetoacetate in 1.8 mL of dry methylene chloride was added 28 mg (0.33 mmol) 
of piperidine and 20 mg (0.33 mmol) of acetic acid.  After stirring for 30 minutes the reaction 
was warmed up to room temperature and stirred for another 30 minutes at which time it was 
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diluted with diethyl ether and water and extracted three times with diethyl ether.  The combined 
diethyl ether layer was washed with saturated aqueous sodium bicarbonate, water, brine, dried 
over sodium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which one isomer came out at 19:1 hexane to 
diethyl ether to give 388 mg (33 % yield) of the E isomer 2.20E, and the other came out at 9:1 
hexane to diethyl ether to give 539 mg (46 % yield) of the Z isomer 2.20Z. (E isomer, 2.20E) 1H 
NMR (400 MHz, CDCl3) δ ppm 7.02 (t, J = 7.9 Hz, 1 H), 4.25 (q, J = 7.2 Hz, 2 H), 3.67 (t, J = 
7.0 Hz, 2 H), 2.36 (s, 3 H), 2.20 (d, J = 7.9 Hz, 2 H), 1.51 (t, J = 7.0 Hz, 2 H), 1.31 (t, J = 7.0 Hz, 
3 H), 0.95 (s, 6 H), 0.88 (s, 9 H), 0.05 (s, 6 H); (Z isomer, 2.20Z) 1H NMR (400 MHz, CDCl3) δ 
ppm 6.96 (t, J = 7.9 Hz, 1 H), 4.31 (q, J = 7.2 Hz, 2 H),  3.69 (t, J = 7.0 Hz, 2 H), 2.32 (s, 3 H), 
2.27 (d, J = 7.9 Hz, 2 H), 1.53 (t, J = 7.0 Hz, 2 H), 1.34 (t, J = 6.7 Hz, 3 H), 0.97 (s, 6 H), 0.89 (s, 
9 H), 0.05 (s, 6 H). 
 
8a-Hydroxy-4a-(phenylthio)-4a,5,6,7,8,8a-hexahydronaphthalen-2(1H)-one (2.27)  
 
SPh
OH
O
2.27  
 
(AA-3-83) A solution of ketosulfide 2.16, 1 g (4.8 mmol), in 10 mL of THF was added to a 
suspension of 139 mg (5.8mmol) of pre-washed NaH in 20 mL of THF at –78oC, then put to RT.  
After 1.5 hours the reaction was put at –78oC, and 326 mg (4.8 mmol) of 3-butyn-2-one was 
added then it was left to slowly warm up to RT.  After 2 hours, the reaction was diluted with 
ethyl acetate, quenched slowly with saturated ammonium chloride, and extracted three times 
with ethyl acetate.   The combined ethyl acetate layer was washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography to give 400 
mg (30% yield) of the enone 2.27. 1H NMR (400 MHz, CDCl3) δ ppm 7.53 – 7.49 (m, 2 H), 7.41 
– 7.28 (m, 3 H), 6.63 (d, J = 9.9 Hz, 1 H), 5.95 (d, J = 9.5 Hz, 1 H), 3.04 (s, 1 H), 2.77 (d, J = 
16.6 Hz, 1 H), 2.35 (d, J = 16.8 Hz, 1 H), 2.06 – 1.98 (m, 1 H), 1.77 – 1.60 (m, 5 H), 1.51 – 1.43 
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(m, 1 H), 1.34 – 1.24 (m, 1 H);  13C-NMR (CDCl3) δ ppm 198.56, 152.57, 138.13 (2 C), 130.06, 
129.30 (2 C), 128.72, 125.76, 73.50, 61.27, 35.36, 35.14, 30.60, 23.91, 20.97. 
 
8a-Hydroxy-4a-(phenylsulfinyl)-4a,5,6,7,8,8a-hexahydronaphthalen-2(1H)-one (2.29)  
 
 
 
(AA-3-105)  To a solution of 170 mg (0.62 mmol) of enone 2.27 in 5mL of 4:1 dioxane:water, at 
0oC, was added 381 mg (0.62 mmol) of OXONE and left to warm up to RT.  After 30 minutes 
the reaction was diluted with ethyl acetate, water and extracted three times with ethyl acetate.   
The combined ethyl acetate layer was washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography to give 71 mg (39% yield) of the 
enone sulfoxide 2.29.  1H NMR (400 MHz, CDCl3) δ ppm 7.61 – 7.51 (m, 5 H), 6.30 (d, J = 9.9 
Hz, 1 H), 5.92 (d, J = 10.1 Hz, 1 H), 5.08 (s, 1 H), 3.45 (d, J = 17.7 Hz, 1 H), 2.78 (d, J = 17.6 
Hz, 1 H), 2.49 (td, J = 13.1, 3.5 Hz, 1 H), 1.86 – 1.76 (m, 3 H), 1.64 – 1.59 (m, 2 H), 1.49 – 1.45 
(m, 1 H), 1.26 -1.14 (m, 1 H). 
5,6,7,8-Tetrahydronaphthalen-2-ol from enone sulfoxide (2.35)  
 
 
 
(AA-4-15) Enone sulfoxide 2.29, 74.7 mg (0.26 mmol), was dissolved in 7 mL of toluene and 
refluxed.  After 5 hours the reaction was cooled to RT, diluted with diethyl ether, water and 
extracted three times with diethyl ether.  The combined diethyl ether layer was washed with 
brine, dried over magnesium sulfate, concentrated and purified by silica gel column 
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chromatography to give 11 mg (28 % yield) of the phenol 2.35. 1H NMR (400 MHz, CDCl3) δ 
ppm 6.92 (d, J = 8.1 Hz, 1 H), 6.58 (dd, J = 8.1, 2.6 Hz, 1 H), 6.54 (d, J = 2.6 Hz, 1 H), 4.53 (d, J 
= 4.1 Hz, 1 H), 2.71 – 2.68 (m, 4 H), 1.76 (p, J = 3.2 Hz, 4 H). 
8a-Hydroxy-4a-(phenylselanyl)-4a,5,6,7,8,8a-hexahydronaphthalen-2(1H)-one (2.36)  
 
SePh
OH
O
2.36  
 
(AA-4-56) Freshly prepared 0.1M LDA, 8.7 mL (0.87 mmol), was added to a solution of 200 mg 
(0.79 mmol) of phenyl selenide 2.17 in 5 mL of THF at –78oC.  After one hour, 93 μL (1.19 
mmol) of 3-butyn-2-one was added at –78oC.  After 2 hours, the reaction was diluted with ethyl 
acetate, quenched slowly with saturated aqueous ammonium chloride, and extracted three times 
with ethyl acetate.   The combined ethyl acetate layer was washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography to give 25 
mg (10 % yield) of enone 2.36. 1H NMR (400 MHz, CDCl3) δ ppm 7.61- 7.58 (m, 2 H), 7.40 – 
7.36 (m, 1 H), 7.31 – 7.27 (m, 2 H), 6.74 (d, J = 9.8 Hz, 1 H), 5.85 (d, J = 9.9 Hz, 1 H), 2.66 (d, J 
= 16.6 Hz, 1 H), 2.29 (d, J = 16.5 Hz, 1 H), 2.12 (td, J = 13.4, 3.7 Hz, 1 H), 1.93 – 1.87 (m, 1 H), 
1.76 – 1.65 (m, 5 H), 1.52 – 1.45 (m, 1 H), 1.36 – 1.27 (m, 1 H). 
4a-(Phenylthio)-4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one (2.38)  
SPh
O
2.38  
 
(AA-4-118) Sodium methoxide, 108 mg (2 mmol), was added to a solution of 200 mg (1 mmol) 
of phenyl sulfide 2.16 in 5 mL methanol at RT.  After one hour, 170 μL (2 mmol) of methyl 
vinyl ketone was added at RT.  After 24 hours the reaction was diluted with diethyl ether, slowly 
quenched with saturated aqueous ammonium chloride, and extracted three times with diethyl 
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ether.  The combined ether layer was washed with brine, died over magnesium sulfate, 
concentrated and purified by silica gel column chromatography to produce 260 mg (100% yield) 
enone 2.38.  1H NMR (400 MHz, CDCl3) δ ppm 7.61- 7.58 (m, 2 H), 7.40 – 7.36 (m, 1 H), 7.31 
– 7.27 (m, 2 H), 6.74 (d, J = 9.8 Hz, 1 H), 5.85 (d, J = 9.9 Hz, 1 H), 2.66 (d, J = 16.6 Hz, 1 H), 
2.29 (d, J = 16.5 Hz, 1 H), 2.12 (td, J = 13.4, 3.7 Hz, 1 H), 1.93 – 1.87 (m, 1 H), 1.76 – 1.65 (m, 
5 H), 1.52 – 1.45 (m, 1 H), 1.36 – 1.27 (m, 1 H). 
 
Chapter 3, Experimental Section 
 
4a'S,4b'R,7'S,8a'R)-1',1',4a',8a'-Tetramethyl-7'-(phenylthio)decahydro-1'H-
spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(+)-3.2] 
O
O
O
H
SPh
(+)-3.2
 
(AA-10-62) To a solution of 460 mg (1.44 mmol) of ketone (-)-2.1 in 10 mL of THF at -20oC 
was added 43 mL (4.31 mmol) of freshly made 0.1 M lithium diisopropyl amine (LDA).  
Immediately after the addition of the LDA the reaction was put to room temperature.  After 
stirring at room temperature for one hour a solution of 472 mg (2.16 mmol) of phenyl disulfide 
dissolved in 10 mL of THF was cannulaed into the reaction and left to stir overnight at room 
temperature.  After stirring overnight the reaction was quenched with saturated aqueous 
ammounium chloride and extracted three times with diethyl ether.  The combined diethyl ether 
layers were washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography using a solvent gradient of hexane, methylene chloride and diethyl 
ether in which the product came out at a 4:4:0.1 solvent ratio of hexane:methylene 
chloride:diethyl ether to give 440 mg (71 % yield) of the α-phenyl sulfide (+)-3.2 as a white 
solid. Rotation: [α]25D = +10.8o (c = 0.130, CHCl3)(AA-8-57). 1H NMR (400 MHz, CDCl3) δ 
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ppm 7.41 – 7.37 (m, 2 H), 7.30 – 7.21 (m, 3 H), 4.21 (dd, J = 13.1, 6.4 Hz, 1 H), 3.97 – 3.86 (m, 
4 H), 2.35 – 2.28 (m, 1 H), 1.84 – 1.36 (m, 10 H), 1.29 – 1.21 (m, 3 H), 1.19 (s, 3 H), 0.96 (s, 3 
H), 0.93 (s, 3 H), 0.84 (s, 3 H);  13C-NMR (CDCl3) δ ppm 209.91, 134.38, 132.62 (2 C), 129.09 
(2 C), 127.32, 112.98, 65.09 (2 C), 57.93, 54.91, 53.03, 50.04, 42.36, 38.28, 36.95, 34.87, 34.74, 
26.95, 23.06, 20.96, 20.03, 19.91, 17.93, 16.67;  HRMS calcd. for C26H36O3S (M+H+) 429.2463, 
found 429.2444. 
 
(4a'S,4b'R,7'R,8a'R)-1',1',4a',8a'-Tetramethyl-7'-(3-oxobutyl)-7'-
(phenylthio)decahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-
3.3a] and (4a'S,4b'R,7'S,8a'R)-1',1',4a',8a'-tetramethyl-7'-(3-oxobutyl)-7'-
(phenylthio)decahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-
3.3b]  
 
(AA-10-29)   The α-ketosulfide (+)-3.2, 500 mg (1.17 mmol), and 126 mg (2.33 mmol) of 
sodium methoxide were dissolved in 8 mL of methanol and 16 mL of THF.  After stirring for 
one hour at room temperature 292 μL (3.51 mmol) of methyl vinyl ketone was syringed into the 
reaction and stirred for 15 minutes at room temperature then the reaction was heated to 55oC and 
stirred for an additional one hour.  After cooling to room temperature the reaction was quenched 
by adding saturated aqueous ammonium chloride and the solution was extracted three times with 
diethyl ether.  The combined diethyl ether layer was washed with brine, dried over magnesium 
sulfate, concentrated and purified by silica gel column chromatography using a solvent gradient 
of hexane and diethyl ether in which the first diastereomer comes out between 4:1 and 3:1 
hexane to diethyl ether solvent ratio and the second diastereomer comes out between 2:1 and 1:1 
hexane to diethyl ether solvent ratio to give 272 mg of (-)-3.3a (70 % yield) and (-)-3.3b 116 mg 
(30 % yield) (97% total yield) respectively, of the two diastereomers as white solids. Less polar 
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[(-)-3.3a] Rotation: [α]25D = -32.3o (c = 0.235, CHCl3) 1H NMR (400 MHz, CDCl3) δ ppm 7.40 
(m, 5 H), 3.99 – 3.90 (m, 4 H), 2.55 – 2.35 (m, 2 H), 2.27 (dd, J = 11.8, 6.9 Hz, 1 H), 2.90 (s, 3 
H), 2.06 -1.78 (m, 7 H), 1.68 – 1.24 (m, 8 H), 1.06 (s, 3 H), 098 (s, 3 H), 0.95 (s, 3 H), 0.87 (s, 3 
H); 13C-NMR (CDCl3) δ ppm 211.52, 208.18, 137.59 (2 C), 130.36, 129.66, 128.88 (2 C), 
113.17, 65.06 (2 C), 58.01, 53.31, 49.07, 47.86, 42.35, 39.23, 38.11, 36.87, 36.19, 30.91, 30.56, 
30.17, 26.87, 23.11, 20.70, 20.18, 18.27, 16.46, 16.10: HRMS calcd. for C30H42O4S (M+H+) 
499.2882, found 499.2884. More polar [(-)-3.3b]  Rotation: [α]25D = -50.4o (c = 0.115, CHCl3); 
1H NMR (400 MHz, CDCl3) δ ppm 7.23 -7.28 (m, 5 H), 3.99 – 3.87 (m, 4 H), 2.50 – 2.30 (m, 2 
H), 2.09 (s, 3 H), 2.02 – 1.66 (m, 9 H), 1.50 (s, 3 H), 1.47 -1.12 (m, 7 H), 1.01 (s, 3 H), 0.94 (s, 3 
H), 0.84 (s, 3 H); 13C-NMR (CDCl3) δ ppm 211.23, 208.24, 136.62 (2 C), 130.73, 129.58, 128.97 
(2 C), 113.25, 65.14 (2 C), 58.21, 56.74, 53.17, 49.41, 42.42, 39.05, 38.01, 36.93, 36.84, 36.44, 
31.07, 30.21, 27.01, 23.96, 23.03, 19.94, 18.09, 17.37, 17.06; HRMS calcd. for C30H42O4S 
(M+H+) 499.2882, found 499.2886. 
 
(4aR,4bR,10bR)-1,1,4a,10b-Tetramethyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolan]-9-ol (3.11)   
 
 
 
(AA-5-31) To a solution of 20 mg (0.04 mmol) of diketosulfide (-)-3.3b in 1.5 mL of methanol 
was added 4.3 mg (0.08 mmol) of sodium methoxide and the whole was put to reflux.  After 
refluxing overnight, the reaction was cooled and then quenched with saturated aqueous 
ammonium chloride and extracted three times with diethyl ether.  The combined diethyl ether 
layer was washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography using a gradient of hexane and diethyl ether to give 4.6 mg (31 % 
yield) of the compound 3.11 as a white solid. 1H NMR (200 MHz, CDCl3) δ ppm 6.87 (d, J = 8.1 
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Hz, 1 H), 6.71 (d, J = 2.6 Hz, 1 H), 6.55 (dd, J = 8.1, 2.6 Hz, 1 H), 4.50 (bs, 1 H), 3.98 – 3.85 (m, 
4 H), 2.90 – 2.61 (m, 2 H), 2.82 – 2.24 (m, 1 H), 1.95 – 1.25 (m, 11 H), 1.18 (s, 3 H), 0.96 (d, J = 
1.5 Hz, 6 H), 0.85 (s, 3 H). 
 
(4a'S,4b'R,8a'R)-1',1',4a',8a'-Tetramethyl-7'-(3-oxobutyl)-4',4a',4b',5',8a',9',10',10a'-
octahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-3.13]  
 
 
 
(AA-10-31) (NMR-aa-5-58)  To a stirring solution, at 0oC, of 576 mg (1.16 mmol) of 
diketosulfide (-)-3.3a+b in 17 mL of methylene chloride was added 273 mg (1.16 mmol) of  73 
% m-chloroperbenzoic acid and 195 mg (2.32 mmol) of sodium bicarbonate.  After stirring for 
30 minutes the reaction was quenched with 10 % aqueous sodium sulfite and saturated aqueous 
sodium bicarbonate and extracted three times with diethyl ether.  The combined diethyl ether 
layers were washed with brined, dried with magnesium sulfate, concentrated and purified by 
silica gel column chromatography using a solvent gradient of hexane and diethyl ether in which 
the compound came out at solvent ratio of 1:1 hexane to diethyl ether to give 388 mg (97 % 
yield) of the compound (-)-3.13 as a white solid. Rotation: [α]25D = -26.8o (c = 0.340, 
CHCl3)(AA-8-57). 1H NMR (400 MHz, CDCl3) δ ppm 6.69 (t, J = 4.1 Hz, 1 H), 3.98 – 3.85 (m, 
4 H), 2.54 – 2.32 (m, 4 H), 2.28 – 2.25 (m, 2 H), 2.11 (s, 3 H), 1.95 – 1.91 (m, 1 H), 1.82 (td, J = 
13.4, 4.1 Hz, 1 H), 1.63 – 1.39 (m, 6 H), 1.30 – 1.22 (m, 2 H), 1.02 (s, 3 H), 1.00 (s, 3 H), 0.94 
(s, 3 H), 0.85 (s, 3 H); 13C-NMR (CDCl3) δ ppm 208.61, 205.51, 144.63, 135.83, 113.17, 65.17, 
65.13, 53.57, 53.14, 45.32, 42.89, 42.41, 37.60, 36.40, 34.82, 30.14, 26.87, 25.21, 23.75, 23.12, 
20.19, 18.66, 18.30, 16.57; HRMS calcd. for C24H36O4 (M+H+) 389.2692, found 389.2677.  
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(4aR,4bR,10bR)-1,1,4a,10b-Tetramethyl-4,4a,4b,5,7,8,10b,11,12,12a-decahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolan]-9(3H)-one (3.16) and (6a'R,12a'R,12b'S)-
4',4',6a',12b'-tetramethyldodecahydro-1'H-spiro[[1,3]dioxolane-2,3'-tetraphene]-
7',10'(2'H,4'H)-dione (3.17)  
 
 
 
(AA-5-88) Diketoenone (-)-3.13, 11.1 mg (0.029 mmol), and 5.8 mg (0.145 mmol) of sodium 
hydride (60 % in oil) were dissolved in 1 mL of THF then put to reflux.  After two hours the 
reaction was cooled then quenched with saturated aqueous ammonium chloride and extracted 
three times with diethyl ether.  The combined diethyl ether layers were washed with brine, dried 
over magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether to give 2.3 mg of the 1,2 addition adduct  3.16 (21 % 
yield) as a white solid and 3.3 mg of the 1,4 addition adduct 3.17 ( 31 % yield) as a white solid.  
(MINOR PRODUCT, 3.16)  1H NMR (400 MHz, CDCl3) δ ppm 6.02 – 5.99 (m, 1 H), 5.77 (s, 
1 H), 3.98 – 3.85 (m, 4 H), 2.64 – 2.56 (m, 2 H), 2.46 – 2.34 (m, 2 H), 2.27 – 2.10 (m, 2 H), 1.97 
– 1.91 (m, 1 H), 1.81 (td, J = 13.6, 4.0 Hz, 1 H), 1.67 – 1.60 (m, 2 H), 1.55 – 1.44 (m, 4 H), 1.33 
– 1.21 (m, 4 H), 1.03 (s, 3 H), 1.00 (s, 3 H), 0.95 (s, 3 H), 0.86 (s, 3 H) (MAJOR PRODUCT, 
3.17) 1H NMR (400 MHz, CDCl3) δ ppm 3.98 – 3.86 (m, 4 H), 3.01 (t, J = 5.7 Hz, 1 H), 2.76 – 
2.67 (m, 1 H), 2.62 (td, J = 14.3, 7.2 Hz, 1 H), 2.45 (dt, J = 6.6, 2.1 Hz, 1 H), 2.28 (t, J = 13.9 
Hz, 1 H), 2.23 – 2.01 (m, 3 H), 1.86 – 1.38 (m, 10 H), 1.30 (dd, J = 12.2, 3.0 Hz, 1 H), 1.20 (s, 3 
H), 1.15 (td, J = 13.6, 4.3 Hz, 1 H), 1.01 (s, 3 H), 0.94 (s, 3 H), 0.85 (s, 3 H);  13C-NMR (CDCl3) 
δ ppm 214.80, 211.84, 113.04, 65.17, 65.14, 53.49, 51.54, 49.58, 44.56, 42.81, 42.52, 40.11, 
38.16, 38.11, 37.16, 34.53, 27.01, 25.78, 25.44, 23.14, 20.46, 20.07, 18.04, 16.72. 
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(41R,5aS,6aR,6bR,12aR)-6b,10,10,12a-Tetramethyl-3,4,6,6a,6b,7,8,10,10a,11,12,12a-
dodecahydrospiro[chryseno[6-b]oxirene-9,2'-[1,3]dioxolan]-2(5aH)-one (3.21)  
 
 
 
(AA-5-92)  To a solution, at 0oC, of 3.2 mg (0.0086 mmol) of dienone 3.16 in 0.5 mL of 
methylene chloride was added 1.9 mg (0.0086 mmol) of m-chloroperbenzoic acid (77 % by 
weight).  After one hour the reaction was put to room temperature and stirred for an additional 
six hour.  The reaction was quenched with 10 % aqueous sodium sulfite and saturated aqueous 
sodium bicarbonate and extracted three times with diethyl ether.  The combined diethyl ether 
layers were washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography using a solvent gradient of hexane and diethyl ether in which the 
compound came out at a 3:1 – 2:1 solvent ratio of hexane to diethyl ether to give 2.5 mg (78 % 
yield) of the epoxide 3.21 as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 6.03 (s, 1 H), 
3.97 – 3.84 (m, 4 H), 3.43 (s, 1 H), 2.86 – 2.77 (m, 1 H), 2.54 -2.33 (m, 3 H), 2.22 – 2.15 (m, 1 
H), 2.04 – 1.97 (m, 1 H), 1.82 (q, J = 14.3 Hz, 3 H), 1.51 – 1.40 (m, 7 H), 1.07 (s, 3 H), 0.97 (s, 3 
H), 0.93 (s, 3 H), 0.84 (s, 3 H). 
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(4a'R,4b'R,8'R,8a'R,10a'R)-1',1',4a',8a'-Tetramethyldodecahydro-1'H-
spiro[[1,3]dioxolane-2,2'-phenanthrene]-8'-yl methanesulfonate (3.30)  
 
H
HO
O
OMs
3.30  
 
(AA-7-48) triethylamine, 109 μL (0.78 mmol), was added to a solution of 84 mg (0.26 mmol) of 
alcohol (-)-2.14 in 2.5 mL of methylene chloride.  After 15 minutes at room temperature it was 
put to 0oC, 30.2 μL (0.39 mmol) of methane sulfonyl chloride was added and the reaction was 
left to warm-up to RT.  After 2 hours, some methanol and saturated aqueous sodium bicarbonate 
were added and stirred briefly.  After extracting three times with diethyl ether, the combined 
layers were washed with brine, dried over magnesium sulfate, and concentrated to produce 104 
mg (100 % yield) of the mesylate 3.30.  No further purification was done.  1H NMR (200 MHz, 
CDCl3) δ ppm 4.20 (dd, J = 11.4, 4.8 Hz, 1 H), 3.99 – 3.86 (m, 4 H), 2.98 (s, 3 H), 2.09 – 1.62 
(m, 6 H), 1.50 – 1.11 (m, 10 H), 0.96 (s, 3 H), 0.92 (s, 3 H), 0.89 (s, 3 H), 0.84 (s, 3 H). 
 
(4a'R,4b'S,8a'S,10a'R)-1',1',4a',8a'-Tetramethyl-3',4',4a',4b',5',6',8a',9',10',10a'-
decahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthrene] (3.31)  
 
H
HO
O
3.31  
 
(AA-7-49) To a solution of 104 mg (0.26 mmol) of mesylate 3.30 in 10 mL of DMF was added 
96 mg (1.3 mmol) of lithium carbonate, 113 mg (1.3 mmol) of lithium bromide and put to reflux.  
After 5 hours the reaction was stopped, cooled to room temperature, diluted with diethyl ether 
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and 1 M HCl was added slowly and stirred briefly.  After extracting three times with diethyl 
ether, the combined layers were washed with brine, dried over magnesium sulfate, concentrated 
and purified by silica gel column chromatography to produce 60 mg (76 % yield after 2 steps) of 
tricylcic alkene 3.31.  1H NMR (200 MHz, CDCl3) δ ppm 5.44-5.25 (m, 2 H), 4.01-3.39 (m, 4 
H), 2.09-1.60 (m, 7 H), 1.45-1.07 (m, 7 H), 0.95 (s, 3 H), 0.94 (s, 3 H), 0.88 (s, 3 H), 0.84 (s, 3 
H). 
 
(4a'R,4b'S,8a'S,10a'R)-1',1',4a',8a'-Tetramethyl-4',4a',4b',5',8a',9',10',10a'-
octahydro-1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-6'(3'H)-one (3.32)  
 
H
HO
O
O
3.32  
 
(AA-7-89)  To a solution of 21 mg (0.07 mmol) of alkene 3.31 in 0.6 mL of acetonitrile was 
added 0.15 mg (cat.) CuI and 74 mg (0.58 mmol) tert-butylhydrogenperoxide (90 %) then heated 
to 50oC.  After running overnight the reaction was cooled to room temperature and a solution of 
10 % aqueous sodium sulfite was added and stirred for 5 minutes.  The mixture was diluted with 
sodium bicarbonate, diethyl ether and extracted three times with diethyl ether.  The combined 
diethyl ether layers were washed with brine, dried over magnesium sulfate, concentrated and 
purified by silica gel column chromatography using a solvent gradient of hexane and diethyl 
ether to give 17 mg (77 % yield) of the enone 3.32.  1H NMR (200 MHz, CDCl3) δ ppm 6.61 (d, 
J = 9.9 Hz, 1 H), 5.75 (d, J = 9.5 Hz, 1 H), 3.99 – 3.86 (m, 4 H), 2.44 – 2.23 (m, 2 H), 1.86 – 
1.61 (m, 3 H), 1.51 – 1.45 (m, 3 H), 1.41 – 1.33 (m, 2 H), 1.31 -1.27 (m, 1 H), 1.24 – 1.20 (m, 1 
H), 1.09 (s, 3 H), 0.96 (s, 3 H), 0.95 (s, 3 H), 0.86 (s, 3 H). 
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(4a'R,4b'S,8a'S,10a'R)-1',1',4a',8a'-Tetramethyldecahydro-1'H-spiro[[1,3]dioxolane-
2,2'-phenanthren]-6'(3'H)-one (3.34)  
 
H
HO
O
O
3.34  
 
(AA-7-92) To a solution of 37 mg (0.116 mmol) of enone 3.32 in 3 mL of ethanol was added 6 
mg (cat.) Pd-C(10%) then put under 30 psi of hydrogen gas.  After 1 hour the reaction was 
diluted with ethanol and diethyl ether then filtered through celite.  The resulting solution was 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
hexane and diethyl ether to give 22 mg (59 % yield) of the ketone 3.34.  1H NMR (400 MHz, 
CDCl3) δ ppm 3.99-3.86 (m, 4 H), 2.46-2.20 (m, 4 H), 1.84-1.14 (m, 12 H) 1.11 (s, 3 H), 0.95 (s, 
3 H), 0.89 (s, 3 H), 0.86 (s, 3 H). 
 
(4a'R,4b'S,8a'S,10a'R,Z)-7'-(Hydroxymethylene)-1',1',4a',8a'-tetramethyldecahydro-
1'H-spiro[[1,3]dioxolane-2,2'-phenanthren]-6'(3'H)-one (3.35)   
 
H
HO
O
O OH
3.35  
 
To a dispersion of 10 mg (0.24 mmol) of NaH in 0.2 mL of benzene was added a solution of 22 
mg (0.08 mmol) of ketone 3.34 in 0.5 mL of benzene and 13 μL (0.16 mmol) of ethyl formate.  
After 24 hours the reaction was diluted with diethyl ether and water then extracted with 1 % 
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NaOH solution.  The aqueous layer was acidified with 1 M HCl and extracted three times with 
diethyl ether.  The combined ether layers were washed with brine, dried over magnesium sulfate 
and concentrated to produce 24 mg of the enol 3.35 without any further purification.  1H NMR 
(400 MHz, CDCl3) δ ppm 8.43 (bd, 1 H), 4.00-3.86 (m, 4 H), 2.38-2.25 (m, 3 H), 2.09 (d, J = 
14.5 Hz, 1 H), 1.94 (d, J = 14.3 Hz, 1 H), 1.85-1.67 (m, 4 H), 0.96 (s, 3 H), 0.91 (s, 3 H) 0.87 (s, 
3 H), 0.87 (s, 3 H). 
 
(4a'R,4b'S,8a'S,10a'R)-1',1',4a',8a'-Tetramethyl-6'-oxo-
3',4',4a',4b',5',6',8a',9',10',10a'-decahydro-1'H-spiro[[1,3]dioxolane-2,2'-
phenanthrene]-7'-carbaldehyde (3.28a)   
 
H
HO
O
O O
H
3.28a
 
 
(AA-7-96)  To a solution of 24 mg (0.08 mmol) of crude enol 3.35 in 0.5 mL of dioxane was 
added a solution of 18.2 mg (0.08 mmol) of DDQ and 1drop of acetic acid in 0.5 mL of dioxane.  
After 1 hour the reaction was diluted with diethyl ether and washed with saturated aqueous 
sodium bicarbonate until the wash was colorless.  The ether layer was washed with brine, dried 
over magnesium sulfate, and concentrated to give 16 mg (67 % yield, after 2 steps) of crude 
product 3.28a without any further purification.  1H NMR (400 MHz, CDCl3) δ ppm 10.05 (s, 1 
H), 4.00-3.86 (m, 4 H), 2.56-2.34 (m, 2 H), 1.91-1.47 (m, 11 H), 1.15 (s, 3 H), 0.98 (s, 3 H), 0.96 
(s, 3 H), 0.86 (s, 3 H). 
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 (E)-Ethyl 7-(tert-butyldimethylsilyloxy)-5,5-dimethylhept-2-enoate (3.36)  
 
OTBSEtO
O
3.36  
 
(AA-7-62) To a solution of 353 mg (1.45 mmol) of aldehyde 2.24 in 7 mL of methylene chloride 
was added 756 mg (2.2 mmol) of (carbethoxymethylene)-triphenylphosphorane then put to 
reflux.  After 6 hours the reaction was cooled to room temperature, diluted with diethyl ether and 
water and extracted three times with diethyl ether.  The combined ether layers were washed with 
brine, dried over magnesium sulfate, concentrated and purified by silica gel column 
chromatography using a solvent gradient of hexane and diethyl ether.  The compound came out 
using a solvent ratio of 19:1 hexane to diethyl ether to give 368 mg (81 % yield) of the 
conjugated ethyl ester 3.36. 1H NMR (200 MHz, CDCl3) δ ppm 6.99 (dt, J = 15.8, 8.1 Hz, 1 H), 
5.81 (d, J = 15.8 Hz, 1 H), 4.19 (q, J = 7.3 Hz, 2 H), 3.68 (t, J = 7.0 Hz, 2 H), 2.13 (dd, J = 7.7, 
1.5 Hz, 2 H), 1.50 (t, J = 7.3 Hz, 2 H), 1.29 (t, J = 7.0 Hz, 3 H), 0.94 (s, 6 H), 0.89 (s, 9 H), 0.05 
(s, 6 H).  
 
(E)-8-(tert-Butyldimethylsilyloxy)-6,6-dimethyl-1-(phenylsulfinyl)oct-3-en-2-one (3.29)  
 
OTBS
O
S
Ph
O
3.29
 
 
(AA-7-67) To a solution of 54 mg (0.38 mmol) of methylphenyl sulfoxide 3.36 in 1 mL of THF 
at –20oC was added 3.8 mL (0.38 mmol) of freshly prepared LDA. After 1 hour at –20oC, a 
solution of 100 mg (0.32 mmol) of conjugated ester in 4 mL of THF was added and the reaction 
was left to slowly warm up to room temperature.  After 2 hours, the reaction was diluted with 
diethyl ether, quenched with saturated aqueous ammonium chloride, and extracted three times 
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with diethyl ether.  The combined ether layers were washed with brine, dried over magnesium 
sulfate, concentrated and purified by silica gel column chromatography using a solvent gradient 
of hexane and diethyl ether.  The compound came out using a solvent ratio of 1:1 hexane to 
diethyl ether to give 80 mg (62 % yield) of the sulfoxide 3.29.  1H NMR (200 MHz, CDCl3) δ 
ppm 7.70-7.63 (m, 2 H), 7.66-7.50 (m, 3 H), 6.90 (dt, J = 15.8, 7.7 Hz, 1 H), 6.11 (dt, J = 15.8, 
1.1 Hz, 1 H), 4.00 (dd, J = 41.0, 13.6 Hz, 2 H), 3.67 (t, J = 7.0 Hz, 2 H), 2.15 (dd, J = 7.7, 1.1 
Hz, 2 H), 1.47 (t, J = 7.3 Hz, 2 H), 0.92 (s, 6 H), 0.88 (s, 9 H), 0.04 (s, 6 H). 
 
(4a'S,4b'R,7'R,8a'R)-1',1',4a',8a'-Tetramethyl-7'-(3-oxobutyl)decahydro-1'H-
spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-3.39a] and 
(4a'S,4b'R,7'S,8a'R)-1',1',4a',8a'-tetramethyl-7'-(3-oxobutyl)decahydro-1'H-
spiro[[1,3]dioxolane-2,2'-phenanthren]-8'(3'H)-one [(-)-3.39b] from sulfides (-)-3.3a 
and (-)-3.3b 
 
H
HO
O
O O
H
H
O O
+
H H
(-)-3.39a (-)-3.39b
O
O
 
 
(AA-10-71)  A mixture of diketosulfides (-)-3.3a+b, 425 mg (0.85 mmol), was dissolved in 17 
mL of dry toluene.  To this solution, 14 mg (0.085 mmol) of AIBN was added and the mixture 
was put to reflux.  At reflux, 0.460 mL of tributyltinhydride was added and refluxed overnight.  
After determining that the reaction was complete, by TLC, the reaction was stopped, cooled and 
the solvent was removed by vacuum and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether to give two diastereomers (-)-3.39a+b with a 
combined yield of 89% in which the first diastereomer came out at a 2:1 solvent ratio of hexane 
to diethyl ether to give 150 mg (45 % yield) of (-)-3.39a as a white solid.  The other diastereomer 
came out between a 2:1 – 1:1 solvent ratio of hexane to diethyl ether to give 146 mg (44 % yield) 
of (-)-3.39b as a white solid.  (less polar (-)-3.39a) Rotation: [α]25D = -25o (c = 0.160, CHCl3); 
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1H NMR (400 MHz, CDCl3) δ ppm 3.97 – 3.85 (m, 4 H), 2.58 – 2.51 (m, 2 H), 2.41 – 2.33 (m, 1 
H), 2.12 (s, 3 H), 2.10 – 2.04 (m, 1 H), 1.92 – 1.55 (m, 7 H), 1.51 – 1.12 (m, 8 H), 1.11 (s, 3 H), 
0.97 (s, 3 H), 0.93 (s, 3 H), 0.84 (s, 3 H); 13C-NMR (CDCl3) δ ppm 215.93, 209.40, 113.16, 
65.14, 65.11, 58.47, 53.19, 49.26, 44.73, 42.43, 41.65, 38.32, 37.04, 34.58, 33.99, 30.10, 27.02, 
24.18, 23.12, 20.58, 20.11, 20.07, 18.05, 16.68; HRMS calcd. for C24H38O4 (M+H+) 391.2848, 
found 391.2838. (more polar (-)-3.39b) Rotation: [α]25D = -72o (c = 0.05, CHCl3) 1H NMR (200 
MHz, CDCl3) δ ppm 3.99 – 3.86 (m, 4 H), 2.47 (t, J = 7.3 Hz, 2 H), 2.63 – 2.30 (m, 1 H), 2.13 (s, 
3 H), 1.96 – 1.74 (m, 5 H), 1.70 – 1.40 (m, 7 H), 1.38 -1.15 (m, 4 H), 1.07 (s, 3 H), 0.95 (s, 3 H), 
0.93 (s, 3 H), 0.84 (s, 3 H); 13C-NMR (CDCl3) δ ppm 219.81, 209.06, 113.24, 65.13 (2 C), 53.61, 
51.58, 48.04, 44.42, 42.36, 41.70, 37.66, 36.62, 36.33, 30.16, 26.92, 25.41, 25.02, 23.10, 20.30, 
20.09, 16.24, 17.22, 16.14; HRMS calcd. for C24H38O4 (M+H+) 391.2848, found 391.2856. 
 
(4aR,4bR,6aR,10bR)-1,1,4a,10b-Tetramethyl-4,4a,4b,5,6,6a,7,8,10b,11,12,12a-
dodecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolan]-9(3H)-one [(-)-3.41a] from [(-)-
3.39a]  
 
H
HO
O
O O
H
(-)-3.39a
H
HO
O
H
O
(-)-3.41a
 
 
(AA-10-72)  Diketone (-)-3.39a, 9.7 mg (0.025 mmol), and 4.5 mg (0.084 mmol) of sodium 
methoxide were dissolved in 0.5 mL of methanol and 0.25 mL of THF and stirred overnight at 
room temperature.  The reaction was then refluxed for and additional 4 hours after which it was 
cooled down and quenched with saturated aqueous ammonium chloride and extracted three times 
with diethyl ether.  The combined diethyl ether layers were washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the compound came out at a 3:1 solvent 
ratio of hexane to diethyl ether to give 8.5 mg (92 % yield) of the enone (-)-3.41a as a white 
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solid.  Rotation: [α]25D = -30o (c = 0.06, CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 5.82 (d, J = 
1.8 Hz, 1 H), 3.98 – 3.86 (m, 4 H), 2.58 – 2.47 (m, 1 H), 2.37 (dt, J = 16.4, 5.0 Hz, 1 H), 2.28 – 
2.19 (m, 1 H), 2.11 – 1.97 (m, 2 H), 1.88 – 1.75 (m, 2 H), 1.72 -1.45 (m, 8 H), 1.30 -1.16 (m, 4 
H), 1.12 (s, 3 H), 0.94 (s, 6 H), 0.86 (s, 3 H); 13C-NMR (CDCl3) δ ppm 201.65, 176.89, 119.98, 
113.21, 65.14, 65.09, 57.30, 53.37, 42.39, 41.39, 38.53, 38.06, 37.17, 36.23, 35.39, 34.65, 29.62, 
27.09, 23.12, 22.81, 20.62, 20.14, 18.63, 16.66; HRMS calcd. for C24H36O3 (M+H+) 373.2743, 
found 373.2729. 
 
(4aR,4bR,6aR,10bR)-1,1,4a,10b-Tetramethyl-4,4a,4b,5,6,6a,7,8,10b,11,12,12a-
dodecahydro-1H-spiro[chrysene-2,2'-[1,3]dioxolan]-9(3H)-one [(-)-3.41a] from [(-)-
3.39b]  
 
H
HO
O
O O
H
(-)-3.39b
H
HO
O
H
O
(-)-3.41a  
 
(AA-10-73)  Diketone (-)-3.39b, 9.1 mg (0.023 mmol), and 4.5 mg (0.084 mmol) of sodium 
methoxide were dissolved in 0.5 mL of methanol and 0.25 mL of THF and stirred for three days 
at room temperature.  The reaction was then refluxed for and additional 4 hours after which it 
was cooled down and quenched with saturated ammonium chloride and extracted three times 
with diethyl ether.  The combined diethyl ether layers were washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the compound came out at a 3:1 solvent 
ratio of hexane to diethyl ether to give 7 mg (81 % yield) of the enone (-)-3.41a as a white solid. 
Rotation: [α]25D = -30o (c = 0.06, CHCl3)  1H NMR (400 MHz, CDCl3) δ ppm 5.82 (d, J = 1.8 
Hz, 1 H), 3.98 – 3.86 (m, 4 H), 2.58 – 2.47 (m, 1 H), 2.37 (dt, J = 16.4, 5.0 Hz, 1 H), 2.28 – 2.19 
(m, 1 H), 2.11 – 1.97 (m, 2 H), 1.88 – 1.75 (m, 2 H), 1.72 -1.45 (m, 8 H), 1.30 -1.16 (m, 4 H), 
1.12 (s, 3 H), 0.94 (s, 6 H), 0.86 (s, 3 H); 13C-NMR (CDCl3) δ ppm 201.65, 176.89, 119.98, 
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113.21, 65.14, 65.09, 57.30, 53.37, 42.39, 41.39, 38.53, 38.06, 37.17, 36.23, 35.39, 34.65, 29.62, 
27.09, 23.12, 22.81, 20.62, 20.14, 18.63, 16.66; HRMS calcd. for C24H36O3 (M+H+) 373.2743, 
found 373.2729. 
Chapter 4, Experimental Section 
 
Diketal (4.6)  
 
O
O
H O
O
4.6  
 
(AA-8-93) In a round bottom flask equipped with a Dean-Stark apparatus, 208.3 mg (0.56 mmol) 
of enone (-)-3.41a was dissolved in 27 mL of toluene.  Pyridinium para-toluenesulfonate 
(PPTS), 45 mg (0.17 mmol), and 347 mg (5.6 mmol) of ethylene glycol were added and the 
reaction was put to reflux.  After 2 hours the reaction was determined to be complete by TLC.  
Saturated aqueous sodium bicarbonate was added to the reaction, which was extracted three 
times with diethyl ether.  The combined ether layers were washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the compound came out between a 4:1 to 
2:1 ratio of hexane:diethyl ether to give 210 mg (90 % yield) of the diketal 4.6 as a white solid.  
1H NMR (200 MHz, CDCl3) δ ppm 4.02-3.81 (m, 8 H), 2.25-1.10 (m, 20 H), 0.96 (s, 3 H), 0.92 
(s, 3 H), 0.88 (s, 3 H), 0.82 (s, 3 H); 13C-NMR (CDCl3) δ ppm 135.67, 125.40, 113.47, 109.30, 
65.09, 65.00, 64.58, 64.39, 55.94, 53.37, 42.37, 38.21, 37.81, 37.16, 36.87, 33.80, 32.14, 30.86, 
29.74, 27.09, 23.06, 20.21, 19.96, 18.64, 17.99, 16.54. 
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Diketal epoxide (4.8)  
 
O
O
H O
OO
4.8  
 
(AA-8-54) To a stirring solution, at 0oC, of 11.8 mg (0.028 mmol) of diketal 4.6 in 2 mL of 
methylene chloride was added 9 mg (0.037 mmol) of 73 % m-chloroperbenzoic acid and 3.5 mg 
(0.042 mmol) of sodium bicarbonate.  After stirring for 1 hour the reaction was quenched with 
10 % aqueous sodium sulfite and saturated sodium bicarbonate and extracted three times with 
diethyl ether.  The combined diethyl ether layers were washed with brine, dried with magnesium 
sulfate, concentrated and purified by silica gel column chromatography using a solvent gradient 
of hexane and diethyl ether in which the compound came out at a solvent ratio of 4:1 to 2:1 
hexane to diethyl ether to give 12 mg (100 % yield) of the epoxide 4.8.  1H NMR (200 MHz, 
CDCl3) δ ppm 4.02-3.81 (m, 8 H), 2.11-1.13 (m, 20 H), 1.01 (s, 3 H), 0.90 (s, 3 H), 0.85 (s, 3 H), 
0.82 (s, 3 H);  13C-NMR (CDCl3) δ ppm 113.30, 107.88, 69.73, 65.04, 64.98, 64.52, 64.17, 
62.37, 52.79, 46.48, 42.31, 37.58, 36.90, 36.78, 35.17, 35.05, 29.39, 28.23, 28.14, 27.01, 23.11, 
20.07, 18.05, 17.76, 16.13, 15.97. 
 
(4aR,4bR,6aR,10bR)-6a-Hydroxy-1,1,4a,10b-tetramethyl-
4,4a,4b,5,6,6a,7,8,10b,11,12,12a-dodecahydrochrysene-2,9(1H,3H)-dione (4.9)  
O
O
H O
O
H
O
OH
O
O
4.8 4.9
 
 
(AA-8-56) Epoxy diketal 4.8, 12.5 mg (0.028 mmol), and 0.5 mg (0.003 mmol) of p-
toluenesulfonic acid were dissolved in 0.5 mL of dry acetone and left to stir at room temperature.  
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After 5 hours the reaction was diluted with diethyl ether, quenched with saturated aqueous 
sodium bicarbonate and extracted three times with diethyl ether.  The combined ether layers 
were washed with brine, dried over magnesium sulfate, concentrated and purified by silica gel 
column chromatography using a solvent gradient of hexane and diethyl ether to produce 4.2 mg 
(44 % yield) of the β-hydroxy enone 4.9.  1H NMR (200 MHz, CDCl3) δ ppm 5.90 (s, 1 H), 
2.90-2.30 (m, 4 H), 2.18-1.66 (m, 10 H), 1.55-1.34 (m, 5 H), 1.18 (s, 3 H), 1.09 (s, 6 H), 1.07 (s, 
3 H) 
 
(4aR,4bR,10bR)-1,1,4a,10b-Tetramethyl-4,4a,4b,5,6,7,8,10,10b,11,12,12a-
dodecahydrochrysene-2,9(1H,3H)-dione (4.10)   
 
H
O
O
4.10  
 
(AA-8-102) To a solution of 32 mg (0.77 mmol) of diketal 4.6 dissolved in 2.5 mL of THF was 
added 2.5 mL of 1 M HCl and the reaction heated to 40oC.  After 1 hour the reaction was 
complete, as determined by TLC, so it was diluted with diethyl ether, quenched with saturated 
aqueous sodium bicarbonate and extracted three times with diethyl ether.  The combined ether 
layers were washed with brine, dried over magnesium sulfate, concentrated and purified by silica 
gel column chromatography.  Using a solvent gradient of hexane and diethyl ether, 18.8 mg (74 
% yield) of the dione 4.10 was isolated.  1H NMR (400 MHz, CDCl3) δ ppm 2.81 (q, J = 20.2 
Hz, 2 H), 2.59-2.34 (m, 4 H), 2.32-2.25 (m, 2 H), 2.12-2.04 (m, 2 H), 2.03-1.97 (m, 1 H), 1.80 
(dt, J = 12.6, 2.3 Hz, 1 H), 1.72-1.62 (m, 2 H), 1.59-1.52 (m, 2 H), 1.51-1.42 (m, 3 H), 1.27-1.18 
(m, 2 H), 1.09 (s, 3 H), 1.05 (s, 3 H), 1.01 (s, 3 H), 0.96 (s, 3 H);  13C-NMR (CDCl3) δ ppm 
218.01, 212.36, 135.63, 127.57, 97.04, 55.35, 54.84, 47.49, 39.15, 38.54, 38.43, 37.78, 37.58, 
34.16, 32.16, 30.55, 26.85, 21.05, 20.15, 19.76, 18.37, 16.42. 
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Diketone epoxide (4.11)  
 
H
O
O
O
4.11  
 
(AA-10-115) To a stirring solution, at 0oC, of 6.7 mg (0.02 mmol) of diketone 4.10 in 0.5 mL of 
methylene chloride was added 6 mg (0.026 mmol) of 73 % m-chloroperbenzoic and stirred for 2 
hours then warmed up to room temperature.  After 2 more hours, the reaction was quenched with 
10 % aqueous sodium sulfite and saturated aqueous sodium bicarbonate and extracted three 
times with diethyl ether.  The combined diethyl ether layers were washed with brine, dried with 
magnesium sulfate, concentrated and purified by silica gel column chromatography using a 
solvent gradient of hexane and diethyl ether in which the compound came out at a solvent ratio 
of 2:1 hexane to diethyl ether to give 5 mg (72 % yield) of the epoxide 4.11.  1H NMR (400 
MHz, CDCl3) δ ppm 2.69 (q, J = 18.5 Hz, 2 H), 2.47 (dd, J = 8.5, 6.1 Hz, 2 H), 2.44-2.36 (m, 1 
H), 2.20-1.96 (m, 4 H), 1.93-1.84 (m, 2 H), 1.77-1.73 (m, 1 H), 1.62-1.56 (m, 2 H), 1.50-1.33 (m, 
6 H), 1.09 (s, 3 H), 1.08 (s, 3 H), 1.03 (s, 3 H), 0.91 (s, 3 H). 
 
(4aR,4bR,6aR,10bR)-6a-Hydroxy-1,1,4a,10b-tetramethyl-
4,4a,4b,5,6,6a,7,8,10b,11,12,12a-dodecahydrochrysene-2,9(1H,3H)-dione (4.9)   
 
H
O
O
O
H
OH
O
O
4.11 4.9
 
 
(AA-8-84) Epoxide 4.11, 17 mg (0.05 mmol), and 14 mg (0.1 mmol) of potassium carbonate 
were dissolved in 1 mL of ethanol.  After 4 hours the reaction was diluted with diethyl ether, 
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quenched with saturated aqueous ammonium chloride and extracted three times with diethyl 
ether.  The combined ether layers were washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography.  Using a solvent gradient of 
hexane and diethyl ether, 17 mg (100 % yield) of β-hydroxyenone 4.9 was obtained.  1H NMR 
(200 MHz, CDCl3) δ ppm 5.90 (s, 1 H), 2.90-2.30 (m, 4 H), 2.18-1.66 (m, 10 H), 1.55-1.34 (m, 5 
H), 1.18 (s, 3 H), 1.09 (s, 6 H), 1.07 (s, 3 H). 
 
(4aR,4bR,10bR)-9-Hydroxy-1,1,4a,10b-tetramethyl-3,4,4a,4b,5,6,10b,11,12,12a-
decahydrochrysen-2(1H)-one (4.15)  
 
H
OH
O
4.15
 
 
(AA-8-86) To a suspension of 4 mg (0.1 mmol) of 60% NaH in 0.1 mL of THF was added a 
solution of 8.7 mg (0.025 mmol) of β-hydroxy enone 4.9 in 0.5 mL of THF.  After 10 minutes, 
100 μL (0.54 mmol) of bromomethyldimethylsilylchloride was added.  After 30 minutes the 
reaction was determined to be complete by TLC, so it was diluted with diethyl ether, quenched 
with saturated aqueous ammonium chloride and extracted three times with diethyl ether.  The 
combined ether layers were washed with brine, dried over magnesium sulfate, and concentrated.  
After crude NMR it was determined to be the phenol 4.15, no further purification was done.  1H 
NMR (400 MHz, CDCl3) δ ppm 6.90 (d, J = 8.2 Hz, 1 H), 6.73 (d, J = 2.3 Hz, 1 H), 6.58 (dd, J = 
8.2, 2.7 Hz, 1 H), 4.55 (s, 1 H), 2.92-2.84 (m, 1 H), 2.80-2.71 (m, 1 H), 2.60-2.44 (m, 2 H), 2.86 
(dt, J = 12.5, 3.1 Hz, 1 H), 2.09-2.03 (m 1 H), 1.83-1.66 (m, 6 H), 1.52-1.46 (m, 4 H), 1.35-1.32 
(m, 2 H), 1.22 (s, 3 H), 1.11 (s, 3 H), 1.09 (s, 3 H), 1.02 (s, 3 H). 
 119
(4aR,4bR,9S,10bR)-9-Hydroxy-1,1,4a,10b-tetramethyl-
3,4,4a,4b,5,6,7,8,9,10,10b,11,12,12a-tetradecahydrochrysen-2(1H)-one (4.16)   
 
H
OH
O
4.16
 
 
(AA-8-103) K-selectride, 57 μL (0.057 mmol), was added to a solution of 18.8 mg (0.057 mmol) 
of diketone 4.10 in 1.4 mL of THF at –78oC.  After 30 minutes the reaction was diluted with 
diethyl ether, quenched with suaturated aqueous ammonium chloride and extracted three times 
with diethyl ether.  The combined ether layers were washed with brine, dried over magnesium 
sulfate, concentrated and purified by silica gel column chromatography.  Using a solvent 
gradient of hexane and diethyl ether the compound came out between a 4:1 to 2:1 solvent ratio of 
hexane to diethyl producing, 17.3 mg (91 % yield) of keto alcohol 4.16.  1H NMR (400 MHz, 
CDCl3) δ ppm 4.07 (bs, 1 H), 2.57-2.41 (m, 2 H), 2.22 (bd, J = 16.7 Hz, 1 H), 2.07-1.90 (m, 6 
H), 1.85 (dt, J = 12.6, 3.2 Hz, 2 H), 1.75-1.40 (m, 8 H), 1.19 (dd, J = 12.0, 2.1 Hz, 2 H), 1.08 (s, 
3 H), 1.05 (s, 3 H), 1.00 (s, 3 H), 0.95 (s, 3 H). 
 
(4aR,4bR,9S,10bR)-9-((Bromomethyl)dimethylsilyloxy)-1,1,4a,10b-tetramethyl-
3,4,4a,4b,5,6,7,8,9,10,10b,11,12,12a-tetradecahydrochrysen-2(1H)-one (4.17)  
 
H
O
O
Si
Br
4.17  
 
(AA-8-104) Alcohol 4.16 17 mg (0.052 mmol), 14.3 mg (0.21 mmol) of imidazole, and 3.2 mg 
(0.026 mmol) of DMAP were dissolved in 0.5 mL of methylene chloride.  After 5 minutes, 15 
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μL (0.1 mmol) of bromomethyldimethylsilylchloride was added to the solution at room 
temperature.  After 1 hour the reaction was diluted with diethyl ether and water and extracted 
three times with diethyl ether.  The ether layers were washed with brine, dried over magnesium 
sulfate, concentrated and immediately purified by silica gel column chromatography.  The silica 
was neutralized by washing with 1 % triethyl amine in hexane then a solvent gradient of hexane 
and ethyl ether was used and the compound came out between a solvent ratio of 19:1 to 9:1 
hexane to diethyl ether to produce 15 mg (60 % yield) of the bromomethyldimethylsilylether 
4.17. 1H NMR (400 MHz, CDCl3) δ ppm 4.02-3.97 (m, 1 H), 2.57-2.40 (m, 4 H), 2.22 (bd, J = 
16.1 Hz, 1 H), 2.04-1.82 (m, 7 H), 1.73-1.65 (m, 1 H), 1.62-1.51 (m, 4 H), 1.49-1.39 (m, 3 H), 
1.21-1.13 (m, 2 H), 1.08 (s, 3 H), 1.05 (s, 3 H), 0.99 (s, 3 H), 0.95 (s, 3 H), 0.27 (s, 6 H). 
 
(4aR,4bR,9S,10bR)-1,1,4a,10b-Tetramethyl-9-(trimethylsilyloxy)-
3,4,4a,4b,5,6,7,8,9,10,10b,11,12,12a-tetradecahydrochrysen-2(1H)-one (4.18)  
 
H
O
O
Si
4.18
 
 
(AA-8-105) Tributyltin hydride, 17 μL ( 0.062 mmol), was added to a refluxing solution of 0.5 
mg (0.0031 mmol) of AIBN, and 15 mg ( 0.031 mmol) of  bromo-methyldimethylsilylether 
compound 4.17 in 4 mL of benzene.  After 5 hours the reaction was diluted with diethyl ether 
and water and extracted three times with diethyl ether.  The ether layers were washed with brine, 
dried over magnesium sulfate, concentrated and immediately purified by silica gel column 
chromatography.  Using a solvent gradient of hexane and diethyl ether the compound came out 
between a solvent ratio of 19:1 to 9:1 of hexane to diethyl ether to produce 6 mg (50 % yield) of 
the trimethyl silylether 4.18. 1H NMR (400 MHz, CDCl3) δ ppm 3.90-3.82 (m, 1 H), 2.57-2.39 
(m, 2 H), 2.22 (bd, J = 14.6 Hz, 1 H), 2.01-1.80 (m, 7 H), 1.73-1.59 (m, 2 H), 1.55-1.37 (m, 6 H), 
1.21-1.13 (m, 2 H), 1.08 (s, 3 H), 1.05 (s, 3 H), 1.00 (s, 3 H), 0.95 (s, 3 H), 0.12 (s, 9 H).  
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(4aR,4bR,9S,10bR)-9-Allyl-1,1,4a,10b-tetramethyl-
3,4,4a,4b,5,6,6a,7,8,9,10b,11,12,12a-tetradecahydro-1H-spiro[chrysene-2,2'-
[1,3]dioxolan]-9-ol (4.24) and (4aR,4bR,9R,10bR)-9-allyl-1,1,4a,10b-tetramethyl-
3,4,4a,4b,5,6,6a,7,8,9,10b,11,12,12a-tetradecahydro-1H-spiro[chrysene-2,2'-
[1,3]dioxolan]-9-ol (4.28)   
 
HO
O
OH
HO
O
OH
4.24
Major
4.28
minor
+
 
 
(AA-10-55) A 1.7 M allyl magnesium chloride, 110 μL (0.185 mmol), solution was added to a 
solution of 46 mg (0.123 mmol) of enone (-)-3.41a in 2 mL of THF at –78oC.  After 30 minutes 
the reaction was diluted with diethyl ether, quenched with saturated aqueous ammonium chloride 
and extracted three times with diethyl ether.  The combined ether layers were washed with brine, 
dried over magnesium sulfate, concentrated and purified by silica gel column chromatography.  
Using a solvent gradient of hexane and diethyl ether, 30 mg (59% yield) of the Major product 
4.24 (less polar), and 10 mg (20% yield) of the minor product 4.28 (more polar) were obtained.  
Major product (4.24):  1H NMR (400 MHz, CDCl3) δ ppm 5.95-5.84 (m, 1 H), 5.22 (s, 1 H), 
5.18-5.11 (m, 2 H), 3.99-3.87 (m, 4 H), 2.36-2.19 (m, 3 H), 1.90-1.74 (m, 3 H), 1.69-1.40 (m, 12 
H), 1.29-1.12 (m, 4 H), 1.04 (s, 3 H), 0.94 (s, 3 H), 0.90 (s, 3 H), 0.86 (s, 3 H); 13C-NMR 
(CDCl3) δ ppm 153.61, 134.25, 120.70, 118.81, 113.45, 70.75, 65.06 (2 C), 58.27, 53.89, 46.82, 
42.35, 39.93, 38.98, 37.80, 37.14, 35.56, 33.53, 33.26, 27.38, 27.07, 23.11, 22.13, 21.18, 20.16, 
18.76, 16.36; minor product (4.28): 1H NMR (400 MHz, CDCl3) δ ppm 5.88-5.77 (m, 1 H), 5.30 
(s, 1 H), 5.10 (s, 1 H), 5.08-5.05 (m, 1 H), 3.98-3.85 (m, 4 H), 2.27 (d, J = 7.3 Hz, 2 H), 2.15-
2.07 (m, 1 H), 1.94-1.87 (m, 1 H), 1.84-1.68 (m, 3 H), 1.64-1.10 (m, 15 H), 1.00 (s, 3 H), 0.93 (s, 
3 H), 0.90 (s, 3 H), 0.84 (s, 3 H); 13C-NMR (CDCl3) δ ppm 155.45, 134.45, 120.45, 118.24, 
113.34, 70.14, 65.09, 65.04, 57.58, 53.56, 47.65, 42.35, 39.89, 39.18, 37.72, 37.12, 35.98, 34.04, 
33.97, 27.51, 27.08, 23.10, 23.07, 20.86, 20.13, 18.71, 16.46.  
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(4aR,4bR,6aR,10aS,10bR,12aR)-1,1,4a,10b-Tetramethyl-9-oxohexadecahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbonitrile (4.34)  
 
H
H
O
O
O
4.34
H
CN
 
 
(AA-10-92) Enone (-)-3.41a, 45 mg (0.12 mmol), was dissolved in 0.6 mL of THF and 5 mL of 
2:1 DMF:H2O.  To this solution was added 39 mg (0.72 mmol) of ammonium chloride, 117 mg 
(1.8 mmol) potassium cyanide and the reaction was heated to 85 – 90oC overnight.  After 
determining, by TLC, that the starting material was completely consumed the reaction was 
cooled to room temperature, diluted with water and extracted three times with diethyl ether.  The 
combined diethyl ether layers were washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography using a solvent gradient of 
hexane and diethyl ether in which the compound came out at a 2:1 solvent ratio of hexane to 
diethyl ether to give 40 mg (83 % yield) of the β-nitrile compound 4.34 as a white solid.  
Rotation: [α]25D = -27o (c = 0.045, CHCl3) 1H NMR (400 MHz, CDCl3) δ ppm 3.97 – 3.86 (m, 4 
H), 2.54 (d, J = 14.1 Hz, 1 H), 2.46 (dm, J = 14.6 Hz, 1 H), 2.40 (d, J = 14.1 Hz, 1 H), 2.29 (td, J 
= 14.1, 6.4 Hz, 1 H), 2.00 – 1.94 (m, 2 H), 1.87 – 1.74 (m, 3 H), 1.68 – 1.57 (m, 6 H), 1.52 – 
1.26 (m, 9 H), 1.05 (s, 3 H), 0.91 (s, 3 H), 0.83 (s, 3 H); 13C-NMR (CDCl3) δ ppm 207.55, 
120.50, 112.88, 65.15, 65.00, 55.39, 53.79, 52.43, 43.95, 42.36, 40.64, 40.49, 37.27, 37.15, 36.92 
(2 C), 30.71 (2 C), 27.07, 23.02, 20.12, 20.10, 18.28, 16.52, 15.41. HRMS calcd. for C25H37NO3 
(M+H+) 400.2852, found 400.2851. 
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(4aR,4bR,6aR,9S,10aS,10bR,12aR)-9-Hydroxy-1,1,4a,10b-tetramethylhexadecahydro-
1H-spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbonitrile (4.35)  
 
HO
O H
CN
H
OH
4.35  
 
(AA-10-84) Sodium borohydride, 0.2 mg (0.0042 mmol), was added to a solution of 6.8 mg 
(0.017 mmol) of β-cyanoketone 4.34 in 0.5 mL of ethanol at 0oC.  After 30 minutes the reaction 
was diluted with diethyl ether, quenched with saturated aqueous ammonium chloride and 
extracted three times with diethyl ether.  The combined ether layers were washed with brine, 
dried over magnesium sulfate, concentrated and purified by silica gel column chromatography.  
Using a solvent gradient of hexane and diethyl ether the compound came out at a 2:1 solvent 
ratio of hexane to diethyl producing, 5 mg (73 % yield) of cyano alcohol 4.35.  1H NMR (400 
MHz, CDCl3) δ ppm 4.22-4.17 (m, 1 H), 3.96-3.85 (m, 4 H), 2.10-2.05 (m, 2 H), 1.93-1.87 (m, 1 
H), 1.82-1.24 (m, 19 H), 0.96 (s, 3 H), 0.91 (s, 3 H), 0.88 (s, 3 H), 0.83 (s, 3 H). 
 
(4aR,4bR,6aR,10aS,10bR,12aR)-9-(tert-Butyldimethylsilyloxy)-1,1,4a,10b-
tetramethyl-3,4,4a,4b,5,6,6a,7,10,10a,10b,11,12,12a-tetradecahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbonitrile (4.37)  
 
H
H
OTBS
O
O
4.37
H
CN
 
(AA-11-20) β-Cyanoketone 4.34, 25 mg (0.063 mmol), was dissolved in 2.5 mL of methylene 
chloride followed by the addition of 0.070 ml of triethylamine and stirred at room temperature 
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for 15 minutes.  The solution was put to 0oC, and then 0.050 ml of tert-butyldimethylsilyltriflate 
(TBSOTf) was added.  After 2 hours the reaction was diluted with saturated aqueous sodium 
bicarbonate and extracted three times with diethyl ether.  The combined diethyl ether layers were 
washed with brine, dried over magnesium sulfate, concentrated and immediately purified by 
silica gel column chromatography in which the silica was deactivated by washing with 1 % 
triethylamine.  Using a solvent gradient of hexane and diethyl ether the compound came out at a 
9:1 solvent ratio of hexane to diethyl ether to give 32 mg (100 % yield) of the silyl enol ether 
4.37 as colorless crystals.  Rotation: [α]25D = -16o (c = 0.055, CHCl3) 1H NMR (400 MHz, 
CDCl3) δ ppm 4.87 – 4.84 (m, 1 H), 3.97 – 3.85 (m, 4 H), 2.82 (dm, J = 17.3 Hz, 1 H), 2.12 – 
1.93 (m, 3 H), 1.83 – 1.22 (m, 15 H), 0.99 (s, 3 H), 0.91 (s, 12 H), 0.90 (s, 3 H), 0.83 (s, 3 H), 
0.15 (s, 3 H), 0.14 (s, 3 H);  13C-NMR (CDCl3) δ ppm 147.11, 122.14, 113.01, 102.75, 65.13, 
65.00, 54.14, 52.43, 51.27, 42.35, 40.03, 37.47, 37.27, 36.84, 33.09, 33.01, 31.06, 30.01, 27.07, 
25.92 (3 C), 23.07, 20.16 (2 C), 18.22, 18.17, 16.62, 15.55, -4.10, -4.18; HRMS calcd. for 
C31H51NO3Si (M+H+) 514.3716, found 514.3718. 
 
((4aR,4bR,6aR,10aS,10bR,12aR)-9-(tert-Butyldimethylsilyloxy)-1,1,4a,10b-
tetramethyl-3,4,4a,4b,5,6,6a,7,10,10a,10b,11,12,12a-tetradecahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolane]-10a-yl)methanimine (4.39)  
 
H
H
HO
O
OTBS
NH
4.39  
 
(AA-10-101) Silylenolether 4.37, 10mg (0.0195 mmol), was dissolved in 1ml of dry toluene at 
room temperature.  To this solution was added 100 μl (0.100mmol) of 1.0 M diisobutylaluminum 
hydride in toluene.  After 30 minutes the reaction was determined to be complete, by TLC (15:1 
CH2Cl2:MeOH), and it was diluted with saturated aqueous sodium bicarbonate and extracted 
three times with diethyl ether.  The combined diethyl ether layers were washed with brine, dried 
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over magnesium sulfate, concentrated and purified by silica gel column chromatography in 
which the silica was deactivated by washing with 1 % triethylamine.  Using a solvent gradient of 
hexane and diethyl ether the compound came out at a 3:1 solvent ratio of hexane to diethyl ether 
to give 5.8 mg (58 % yield) of the imine 4.39.  1H NMR (400 MHz, CDCl3) δ ppm 8.38 (bs, 1 
H), 4.69 – 4.68 (m, 1 H), 3.98 – 3.87 (m, 4 H), 2.19 – 2.03 (m, 2 H), 1.96 – 1.88 (m, 1 H), 1.85 – 
1.77 (m, 2 H), 1.72 – 1.64 (m, 4 H), 1.51 – 1.46 (m, 5 H), 1.41 – 1.30 (m, 4 H), 1.23 – 1.14 (m, 2 
H), 1.07 (s, 3 H), 0.93 (s, 3 H), 0.92 (s, 9 H), 0.90 (s, 3 H), 0.80 (s, 3 H), 0.14 (s, 3 H), 0.12 (s, 3 
H); HRMS calcd. for C31H53NO3Si (M+H+) 516.3828, found 516.3865. 
 
Iiminal (4.40)  
 
HO
O H
H
N
OTBS
4.40  
 
(AA-11-25) Imine 4.39, 4 mg (0.0078 mmol), was dissolved in a 9:1:0.05 solution of dioxane to 
water to glacial acetic acid and left to stir at room temperature.  After 24 hour, the reaction was 
diluted with diethyl ether, quenched slowly with saturated aqueous sodium bicarbonate and 
extracted three times with diethyl ether.  The combined ether layers were washed with brine, 
dried over magnesium sulfate, concentrated and purified by silica gel column chromatography.  
Using a solvent gradient of hexane and diethyl ether the compound came out at a 3:1 solvent 
ratio of hexane to diethyl producing, 2.4 mg (60 % yield) of cyclic siloxy iminal 4.40.  1H NMR 
(400 MHz, CDCl3) δ ppm 7.70 (s, 1 H), 4.05-3.85 (m, 4 H), 2.03-1.64 (m, 6 H), 1.38-1.19 (m, 9 
H), 0.93 (s, 3 H), 0.89 (bs, 15 H), 0.85 (s, 3 H), 0.14 (s, 3 H), 0.09 (s, 3 H).   
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Hemiiminal (4.41)  
 
H
H
HO
O
N
OH
4.41  
 
(Aibin’s notebook – AS-4-62) Crude imine 4.39, 46 mg (0.089 mmol), was dissolved in 3 mL of 
dry THF at room temperature followed by the addition of 178 μL of 1.0M tetrabutylammonium 
flouride (TBAF) in THF.   After 1 hour the reaction was determined to be complete, by TLC 
(15:1 CH2Cl2:MeOH), and it was diluted with water and extracted three times with diethyl ether.  
The combined diethyl ether layers were washed with brine, dried over magnesium sulfate, 
concentrated and purified by silica gel column chromatography which produced 25 mg (69 % 
yield after 2 steps from the nitrile) of iminal 4.41 Rotation: [α]25D = -43o (c = 0.05, CHCl3).  1H 
NMR (400 MHz, CDCl3) δ ppm 7.76 (bs, 1 H), 4.00-3.84 (m, 4 H), 1.97 (bd, J = 10.5 Hz, 1 H), 
1.83 (td, J = 14.1, 3.5 Hz, 1 H), 1.73-1.47 (m, 11 H), 1.41-1.15 (m, 9 H), 0.95 (s, 3 H), 0.93 (s, 3 
H), 0.90 (s, 3 H), 0.85 (s, 3 H);  13C-NMR (CDCl3) δ ppm 169.80, 113.29, 98.75, 65.11, 65.07, 
54.63, 53.65, 47.47, 47.36, 42.41, 37.30, 37.18, 36.32, 33.92, 33.64, 32.08, 30.52, 28.92, 27.11, 
23.07, 20.71, 20.11, 18.32, 18.21, 16.67; HRMS calcd. for C25H39NO3 (M+H+) 402.3008, found 
402.3021. 
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(4aR,4bR,6aR,10aS,10bR,12aR)-1,1,4a,10b-Tetramethyl-9-oxohexadecahydro-1H-
spiro[chrysene-2,2'-[1,3]dioxolane]-10a-carbaldehyde (4.22)   
H
H
HO
O
O
O
4.22  
(Aibin’s notebook – AS-4-65) Hemiiminal 4.41, 10 mg (0.025 mmol), was dissolved in 1.25 mL 
(0.125 mmol) of 0.1 M acetic acid in THF and 1.25 mL of water then put to reflux.  After 
refluxing for 5 hours the reaction was cooled to room temperature, diluted with diethyl ether and 
quenched with saturated aqueous sodium bicarbonate.  The aqueous layer was extracted three 
times with diethyl ether.  The combined ether layers were washed with brine, dried over 
magnesium sulfate, concentrated and purified by silica gel column chromatography to produce 8 
mg (80 % yield) of aldehyde 4.22.  1H NMR (400 MHz, CDCl3) δ ppm 10.31 (s, 1 H), 4.01-3.84 
(m, 4 H), 2.49 (d, J = 14.1 Hz, 1 H), 2.39 (dd, J = 16.0, 5.1 Hz, 1 H), 2.27-2.18 (m, 1 H), 2.15-
2.00 (m, 3 H), 1.92-1.16 (m, 15 H), 1.11 (s, 3 H), 0.98 (s, 3 H), 0.92 (s, 3 H), 0.81 (s, 3 H); 13C-
NMR (CDCl3) δ ppm 209.79,209.07, 113.07, 65.15, 65.09, 60.04, 53.52, 53.13, 42.43, 42.40, 
40.71, 39.89, 37.72, 37.61, 36.25, 31.16, 30.56, 28.99, 27.12, 23.03, 21.28, 20.09, 18.32, 17.28, 
17.05 HRMS calcd. for C25H38O4 (M+H+) 403.2848, found 403.2856. 
 
Chapter 5, Experimental Section 
 
All solutions were at pH 7.4. 
 
1 mM Ca2+ physiological salt solution (PSS)  
The physiological salt solution (PSS) contained (in mmol/L) 150 NaCl, 3.6 KCl, 1.0 MgCl2, 1.0 
CaCl2, 5.0 HEPES, and 5.0 glucose dissolved in purified water 18 Ω.13,14   
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10 mM Ca2+ PSS  
For the normalization of the constriction, a 10 mM Ca2+ solution was made by increasing the 
CaCl2 amount added to the physiological salt solution.13,14   
 
10 μM drug solution  
All the compounds tested were made by first dissolving the compound in no more than 0.1% 
volume of anhydrous DMSO relative to the total volume of solution made.  Then the DMSO 
solution was added to the PSS solution making a 10 μM solution. 
 
10 nM ET-1 solution 
10 μg of ET-1 was dissolved in 400 μL of anhydrous DMSO.  200 μL of the ET-1 solution was 
added to 200 mL of PSS to make a 10 nM solution of ET-1. 
 
SMA preparation: 
The SMA was isolated from a Mongolian gerbil using a protocol approved by the Institutional 
Animal Care and Use Committee at Kansas State University.  The gerbils were anesthetized with 
4 % tribromoethanol (TBE) (10 μL/g) and decapitated.  Temporal bones were removed, opened, 
and placed into a microdissection chamber containing PSS at 4oC.  All the excess tissue and bone 
fragments around the cochlea were carefully removed; care was taken not to break the cochlea.  
Removing the otic capsule opened the cochlea, the bone surrounding the modiolus was carefully 
removed, the cochlear nerve was severed, and the SMA was isolated, carefully untangled and cut 
into 7-10 segments (approximately 200 μm long).13,14 
 
Superfusion of SMA: 
Vessel segments were transferred into a superfusion chamber mounted on the stage of an 
inverted microscope.  The vessel was held in place by two blunted glass needles mounted on 
micromanipulators, and superfused. All experiments were performed at 37oC.  The images of the 
vessel were displayed on a monitor and recorded on videotape.  The outer vascular diameter was 
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measured by video edge detectors and recorded on a chart recorder as illustrated in Figure 
5.3.13,14 
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Appendix A - Chapter 2 1H and 13C NMR spectras 
1H NMR of Compound 2.4 
 
O
O
C H3
O
C H3
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6 1.5 1.4 1.3 1.2 1.1 1.0 0.9
1
4.28 3.19 3.00 2.622.09
0
.
0
0
4.28 3.19 3.00 2.622.091.98 1.12
 
 
1H NMR of Compound (-)-2.5 
aa-4-49-1
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
0
.
0
0
O
O
1
4.06 3.08 3.002.731.06
 
 
 
13C NMR of Compound (-)-2.5 
 
1
 
1H NMR of Compound (-)-2.9 
AA-11-14-1pure
Acquisition Time (sec) 3.4154 Comment Std proton Date Jul  1 2008
Frequency (MHz) 399.76 Nucleus 1H Number of Transients 300 Original Points Count 9827 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 4797.03 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
1
3.43 2.931.99 1.251.121.00 0.85
TMS
0
.
0
0
OH
O
 
 
13C NMR of Compound (-)-2.9 
 
1
 
1H NMR of Compound (+)-2.2 
aa-2-47-fr12-17
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
OH
O
1
5.094.31 3.33 3.291.00 0.97
 
 
 1
AA-11-18-pure-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Aug 27 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 2000 Original Points Count 31375 Points Count 32768
Solvent cdcl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chloroform-d
7
7
.
2
3
OH
O
 
13C NMR of Compound (+)-2.2 
Table 2: Crystal data and structure refinement for compound (+)-2.2  
Table 1.  Crystal data and structure refinement for aa0301m. 
Identification code  aa0301m 
Empirical formula  C17 H24 O2 
Formula weight  260.36 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 7.3026(8) Å α= 90°. 
 b = 19.157(3) Å β= 105.620(6)°. 
 c = 10.5171(12) Å γ = 90°. 
Volume 1416.9(3) Å3 
Z 4 
Density (calculated) 1.220 g/cm3 
Absorption coefficient 0.078 mm-1 
F(000) 568 
Crystal size 0.40 x 0.35 x 0.15 mm3 
Theta range for data collection 2.27 to 28.33°. 
Index ranges -8<=h<=9, -25<=k<=25, -13<=l<=13 
Reflections collected 16238 
Independent reflections 5907 [R(int) = 0.0876] 
Completeness to theta = 28.33° 94.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5907 / 1 / 350 
Goodness-of-fit on F2 0.930 
Final R indices [I>2sigma(I)] R1 = 0.0551, wR2 = 0.1354 
R indices (all data) R1 = 0.0841, wR2 = 0.1548 
Absolute structure parameter -1.9(15) 
Extinction coefficient 0.060(6) 
Largest diff. peak and hole 0.234 and -0.264 e.Å-3 
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1H NMR of Compound (+)-2.12 
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13C NMR of Compound (+)-2.12 
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1H NMR of Compound (+)-2.13 
AA-10-47-fr21-40
Acquisition Time (sec) 3.4152 Comment Std proton Date Dec 20 2007
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 64 Original Points Count 9828 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
8.184.37 3.08 2.912.17 1.301.00 1.00
TMS
H2O
0
.
0
0
OH
H
O
O
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13C NMR of Compound (+)-2.13 
AS-1-27-pure-C13
18 Aug 2008
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date May 30 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20
Chloroform-d
7
7
.
2
7
OH
O
O H
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1H NMR of Compound (-)-2.14 
AA-4-88-1crude
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Nov  1 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.59 6.73 5.964.00 3.281.01
TMS
0
.
0
0
OH
O
O H
H
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13C NMR of Compound (-)-2.14 
AA-4-88-1crude-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Nov  1 2004
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 20000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
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.
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7
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O H
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1H NMR of Compound (-)-2.1 
AA-6-33-fr22
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Oct 27 2005
Frequency (MHz) 399.79 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
11.194.00 1.681.061.010.99
TMS
0
.
0
0
O
O
O H
H
 
 148
13C NMR of Compound (-)-2.1 
AA-4-89-fr1-8-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Nov  3 2004
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 20000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O
O
O H
H
 
 149
1H NMR of Compound 2.16 
AA-4-22-fr4-7
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jun 28 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
2.67 2.401.991.000.81
TMS
0
.
0
0
O
SPh
 
 
 150
1H NMR of Compound 2.17 
BW-2-100-fr28-32
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan  3 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 32 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
TMS
0
.
0
0
O
SePh
3.592.80 2.061.00.781.52 0
 
 
 151
1H NMR of Compound 2.22 
AA-3-59-1crude
Acquisition Time (sec) 5.4616 Comment STANDARD 1H OBSERVE Date Mar 25 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 22205 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5999.70 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
6.264.154.00
TMS
0
.
0
0
OH OH
 
 152
1H NMR of Compound 2.23 
AA-1-79-fr11-14
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Oct 18 2003
Frequency (MHz) 399.82 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.05 5.144.284.03
TMS
0
.
0
0
OH O
Si
 
 
 153
1H NMR of Compound 2.24 
AA-2-58-1crude
Acquisition Time (sec) 5.4616 Comment STANDARD 1H OBSERVE Date Oct 20 2003
Frequency (MHz) 399.82 Nucleus 1H Number of Transients 100 Original Points Count 22205 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5999.70 Temperature (grad C) 29.000
11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.0 5.522.5 082.44 2.430.87
TMS
0
.
0
0
H O
Si
O
 
 
 154
1  H NMR of Compound 2.20 E
AA-2-114-fr27-44
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan 26 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
11.43 6.002.393.302.922.302.171.05
TMS
0
.
0
0
O
EtO2C
O
Si
 
 
 155
1H NMR of Compound 2.20 Z 
AA-2-63-fr25-28
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan  2 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.00 4.532.81 2.782.061.850.96
TMS
0
.
0
0
O
Si
CO2Et
O
 
 
 156
1H NMR of Compound 2.27 
AA-3-80-fr34
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Apr 16 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 200 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
H2O
5.753.00 1.521.171.12 1.091.00 0.89 0.84
TMS
0
.
0
0
O
OH
SPh
 
 
 157
13C NMR of Compound 2.27 
 
 158
1H NMR of Compound 2.29 
AA-3-105-fr40
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date May 18 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 200 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
5.85 3.332.761.381.37 1.351.21 1.011.00 0.75
H2O
TMS
0
.
0
0
O
OH
SPh
O
 
 
 159
1H NMR of Compound 2.35 
AA-4-15-fr5
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jun 16 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
H2O
4.18 4.000.72 0.71 0.67
TMS
0
.
0
0
OH
 
 
 160
1H NMR of Compound 2.36 
AA-4-56-fr51-57
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Sep  6 2004
Frequency (MHz) 399.81 Nucleus 1H Number of Transients 100 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
TMS
0
.
0
0
SePh
OH
O
5.001.901.60 1.36 1.261.160.86 0.72
 
 
 161
1H NMR of Compound 2.38 
AA-4-enonesulfide
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Dec 21 2004
Frequency (MHz) 399.80 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
2.94.28 1.181.140.950.682 1.950.94
TMS
0
.
0
0
SPh
O
 
 
 162
Appendix B - MR spectras 
1H NMR of Compound (+)-3.2 
 Chapter 3 1H and 13C N
AA-4-97-fr19-22
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Nov 27 2004
Frequency (M Hz) 399.81 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
13.504.463.84 3.24 3.171.051.00
TMS
0
.
0
0
O
O
O H
H
SPh
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13C NMR of Compound (+)-3.2 
AA-10-26-fr21-64-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Nov  4 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
7
7
.
2
7
O
O
O H
H
SPh
 
 164
NOESY of compound (+)-3.2 
 
 165
1  H NMR of Compound (-)-3.3a
AA-6-12-fr20-34
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Aug 18 2005
Frequency (MHz) 399.79 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
7.58 7.384.62 4.00 2.812.09 1.64
TMS
0
.
0
0
O O
O
O H
H
SPh
 
 166
13C NMR of Compound (-)-3.3a 
AA-8-60-fr40-46-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Jun 26 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O O
O
O H
H
SPh
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NOESY of compound (-)-3.3a 
 
 168
1H NMR of Compound (-)-3.3b 
AA-10-29-fr31
Acquisition Time (sec) 2.5614 Comment Std proton Date Nov  6 2007 Frequency (MHz) 399.77
Nucleus 1H Number of Transients 32 Original Points Count 13104 Points Count 16384 Solvent cdcl3 Sweep Width (Hz) 6396.42
Temperature (grad C) 30.000
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
8.78 7.584.54 4.00 3.14 3.132.912.31
TMS
0
.
0
0
O O
O
O H
H
SPh
 
 169
13C NMR of Compound (-)-3.3b 
 
 170
NOESY of compound (-)-3.3b 
 
 171
1H NMR of Compound 3.11 
AA-5-31-fr13-20
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Mar 31 2005
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 400 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
0.35 0.130.09 0.070.05 0.020.02 0.01
TMS
0
.
0
0
O
O
OH
H
H
 
 172
1 3 H NMR of Compound (-)-3.1
AA-5-58-fr15-24
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date May 13 2005
Frequency (MHz) 399.79 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
7.74.00 .00 2.722.440.96 14 2.78 1.06
TMS
0
.
0
0
O O
H
HO
O
 
 173
13C NMR of Compound (-)-3.13 
AA-5-58-fr15-24-C13
Acquisition Time (sec) 1.3107 Comment 13C OBSERVE Date May 13 2005
Frequency (MHz) 100.54 Nucleus 13C Number of Transients 20000 Original Points Count 29984 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 25000.00 Temperature (grad C) 29.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
7
7
.
2
7
O O
H
HO
O
 
 174
1H NMR of Compound 3.17 
AA-5-90-undprod
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jun 28 2005
Frequency (MHz) 399.79 Nucleus 1H Number of Transients 32 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
11.084.00 2.82 2.782.641.000.860.85
TMS
0
.
0
0
O
H
HO
O
O
 
 175
13C NMR of Compound 3.17 
AA-5-90-undprodC13
Acquisition Time (sec) 1.3107 Comment 13C OBSERVE Date Jun 28 2005
Frequency (MHz) 100.54 Nucleus 13C Number of Transients 20000 Original Points Count 29984 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 25000.00 Temperature (grad C) 29.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
7
7
.
2
7
O
H
HO
O
O
 
 176
1H NMR of Compound 3.16 
 
 
 
 177
1H NMR of Compound 3.21 
AA-5-92-pure
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jun 27 2005
Frequency (MHz) 399.79 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
H2O
0.5 0.0
TMS
0
.
0
0
O
O
O H
H
O
6.523.98 3.713.502.732.62 1.161.00 0.950.88
 
 
 178
1H NMR of Compound 3.30 
AA-6-116-1crude
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Jul 10 2006
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 300 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
H2O
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
TMS
0
.
0
0
O
H
HO
O
S
O O
10.946.324.00 3.732.730.83
 
 
 179
1H NMR of Compound 3.31 
AA-6-119-f7-13
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Jul 20 2006
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 50 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
H2O
TMS
0
.
0
0
H
HO
O
7.15 7.084.28 6.121.59
 
 180
1H NMR of Compound 3.32 
AA-7-13-fr29-35
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Jul 27 2006
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 300 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
6.264.034.00 3.402.36 1.560.54 0.39
H2O
TMS
0
.
0
0
O
O
O
H
H
 
 
 181
1H NMR of Compound 3.34 
AA-7-92-1crude
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan  4 2007
Frequency (MHz) 399.78 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
TMS
0
.
0
0
H
HO
O
O
4.90 4.84 3.002.84
 
 
 182
1H NMR of Compound 3.35 
AA-7-95-1crude
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan 15 2007
Frequency (MHz) 399.78 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
TMS
0
.
0
0
H
HO
O
O OH
0.57 6.284.00
 
 183
1H NMR of Compound 3.28a 
AA-7-96-1crude
Acquisition Time (sec) 6.5536 Comment STANDARD 1H OBSERVE Date Jan 18 2007
Frequency (MHz) 399.78 Nucleus 1H Number of Transients 300 Original Points Count 18505 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 5000.00 Temperature (grad C) 25.000
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
4.304.00 2.621.920.24
TMS
0
.
0
0
H
HO
O
O O
H
 
 
 184
1H NMR of Compound 3.36 
AA-7-62-fr1-10
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Oct 19 2006
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 300 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.28 5.053.272.562.31 2.241.021.00
TMS
0
.
0
0
OTBSEtO
O
 
 
 185
1H NMR of Compound 3.29 
  
 
 186
1H a  NMR of Compound (-)-3.39
AA-10-69-fr17-21
Acquisition Time (sec) 3.4152 Comment Std proton Date Jan 30 2008 Frequency (MHz) 399.77
Nucleus 1H Number of Transients 100 Original Points Count 9828 Points Count 16384 Solvent cdcl3 Sweep Width (Hz) 4797.31
Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
10.46 7.914.00 3.03 2.512.371.86
TMS
0
.
0
0
O
H
HO
O
O
H
 
 187
13C NMR of Compound (-)-3.39a  
 
 188
1H NMR of Compound (-)-3.39b 
AA-8-46-fr39-48
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date May 23 2007
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
6.615.36 4.474.34 3.30 3.292.66
TMS
0
.
0
0
O
H
HO
O
O
H
 
 189
13C NMR of Compound (-)-3.39b 
AA-8-46+63-fr39-48-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Jul  3 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O
H
HO
O
O
H
 
 190
1H NMR of Compound 3.41a 
AA-10-72+73-fr3-9
Acquisition Time (sec) 3.4152 Comment Std proton Date Feb  4 2008
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 100 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 20.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.38 4.234.00 3.852.312.161.22 1.120.73
TMS
0
.
0
0
O
O
O
H
H
H
 
 191
13C NMR of Compound 3.41a 
AA-8-47-fr6-20-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date May 28 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 10000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O
O
O
H
H
H
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Appendix C R spectras 
1H NMR of Compound 4.6 
 - Chapter 4 1H and 13C NM
AA-8-74-fr1-3
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Aug  3 2007
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
21.258.00 3.09
TMS
0
.
0
0
O
O
H O
O
 
 193
13C NMR of Compound 4.6 
 
 194
1H NMR of Compound 4.8 
AA-8-77-fr3-8
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Aug  7 2007
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
22.208.00 3.43
TMS
0
.
0
0
O
O
H O
OO
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13C NMR of Compound 4.8 
AA-8-77-fr3-8-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Aug  7 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
3
O
O
H O
OO
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1H NMR of Compound 4.9 
AA-11-12-fr19-24
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Jun 18 2008
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 300 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
11.30 5.955.254.401.00
TMS
0
.
0
0
H
OH
O
O
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1H NMR of Compound 4.10 
AA-8-102-fr18-33
Acquisition Time (sec) 3.4152 Comment Std proton Date Sep 10 2007
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 300 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
3.61 3.04 2.531.69 1.64 0.90
TMS
0
.
0
0
H
O
O
 
 
 198
13C NMR of Compound 4.10 
AA-8-102-fr18-33-C13
Acquisition Time (sec) 2.6214 Comment 13C OBSERVE Date Sep 10 2007
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 1000 Original Points Count 18720 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 12500.00 Temperature (grad C) 29.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
3
H
O
O
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1H NMR of Compound 4.11 
AA-10-115-fr20-28
Acquisition Time (sec) 3.4154 Comment Std proton Date Jun  3 2008
Frequency (MHz) 399.76 Nucleus 1H Number of Transients 300 Original Points Count 9827 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 4797.03 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
6.794.22 2.662.00 1.87 0.98
TMS
H2O
0
.
0
0
H
O
O
O
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1H NMR of Compound 4.15 
AA-11-phenol
Acquisition Time (sec) 2.5616 Comment Std proton Date Jul 28 2008 Frequency (MHz) 399.76
Nucleus 1H Number of Transients 100 Original Points Count 13103 Points Count 16384 Solvent cdcl3 Sweep Width (Hz) 6395.91
Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
H2O
TMS
0
.
0
0
H
H
OH
O
1.130.86 0.78 0.57 3.192.43 1.14
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1H NMR of Compound 4.16 
AA-8-103-fr8-14
Acquisition Time (sec) 3.4152 Comment Std proton Date Sep 11 2007
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 200 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
10.695.66 2.692.00 0.870.83
TMS
0
.
0
0
H
OH
O
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1H NMR of Compound 4.17 
AA-8-104-fr2-5
Acquisition Time (sec) 3.4152 Comment Std proton Date Sep 12 2007
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 200 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
7.52 4.434.00 3.02 2.901.030.88
TMS
0
.
0
0
H
O
O
Si
Br
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1H NMR of Compound 4.18 
AA-8-105-fr3-5
Acquisition Time (sec) 3.4152 Comment Std proton Date Sep 13 2007
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 200 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
7.07 6.74 6.072.732.00 0.970.89
TMS
0
.
0
0
H
O
O
Si
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1H NMR of Compound 4.24 
AA-10-55-fr1-12
Acquisition Time (sec) 3.4152 Comment Std proton Date Jan  9 2008
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 32 Original Points Count 9828 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
12.25.00 9 3.23.22 3.14 3.8 832.020.96
TMS
0
.
0
0
HO
O
OH
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13C NMR of Compound 4.24 
AA-10-55-fr1-12-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Jan  9 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 20000 Original Points Count 31375 Points Count 32768
Solvent cdcl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
7
7
.
2
3
HO
O
OH
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1H NMR of Compound 4.28 
AA-10-55-fr19-28
Acquisition Time (sec) 3.4152 Comment Std proton Date Jan 10 2008 Frequency (MHz) 399.77
Nucleus 1H Number of Transients 100 Original Points Count 9828 Points Count 16384 Solvent cdcl3 Sweep Width (Hz) 4797.31
Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
17.084.00 3.123.061.790.880.86 0.75
TMS
0
.
0
0
HO
O
OH
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AA-10-55-fr19-28-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Jan 10 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 20000 Original Points Count 31375 Points Count 32768
Solvent cdcl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chloroform-d
7
7
.
2
3
HO
O
OH
 
13C NMR of Compound 4.28 
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21H NMR of Compound 4.34 
AA-10-83-fr7-28
Acquisition Time (sec) 3.4152 Comment Std proton Date Feb 26 2008 Frequency (M Hz) 399.77
Nucleus 1H Number of Transients 32 Original Points Count 9828 Points Count 16384 Solvent CDCl3 Sweep Width (Hz) 4797.31
Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
8.805.51 5.424.00 2.081.181.00
TMS
0
.
0
0
O
O
O
H
H
H CN
 
 
 
2 
13C NMR of Compound 4.34 
AA-10-83-fr7-28-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Feb 26 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 2000 Original Points Count 31375 Points Count 32768
Solvent CDCl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O
O
O
H
H
H CN
 
 
 1H NMR of Compound 4.35 
AA-10-84-fr7-14
Acquisition Time (sec) 3.4152 Comment Std proton Date Feb 25 2008
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 300 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
9.33 6.054.00 3.061.810.95
TMS
0
.
0
0
HO
O H
CN
H
OH
2
 
 
21H NMR of Compound 4.37 
AA-10-88-fr11-16
Acquisition Time (sec) 3.4152 Comment Std proton Date Mar  5 2008
Frequency (MHz) 399.77 Nucleus 1H Number of Transients 300 Original Points Count 9828 Points Count 16384
Solvent CDCl3 Sweep Width (Hz) 4797.31 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
18.10 11.574.50 3.36 2.571.080.99
TMS
0
.
0
0
O
O
O
H
H
H CN
Si
 
 
 
 2
AA-10-88-fr11-16-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Mar  5 2008
Frequency (MHz) 100.53 Nucleus 13C Original Points Count 31375 Points Count 32768 Solvent CDCl3
Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
7
O
O
O
H
H
H CN
Si
 
13C NMR of Compound 4.37 
 Table 3: Crystal data and structure refinement for compound 4.37 
Table 1.  Crystal data and structure refinement for aa0801m. 
Identification code  aa0801m 
Empirical formula  C31 H51 N O3 Si 
Formula weight  513.82 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.5193(3) Å α= 90°. 
 b = 12.2929(5) Å β= 90°. 
 c = 32.1251(13) Å γ = 90°. 
Volume 2969.5(2) Å3 
Z 4 
Density (calculated) 1.149 g/cm3 
Absorption coefficient 0.110 mm-1 
F(000) 1128 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 2.09 to 30.50°. 
Index ranges -10<=h<=10, -16<=k<=17, -45<=l<=45 
Reflections collected 36941 
Independent reflections 9003 [R(int) = 0.0718] 
Completeness to theta = 30.50° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9837 and 0.9678 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9003 / 0 / 334 
Goodness-of-fit on F2 1.151 
Final R indices [I>2sigma(I)] R1 = 0.0888, wR2 = 0.2123 
R indices (all data) R1 = 0.1140, wR2 = 0.2246 
Absolute structure parameter 0.1(2) 
Largest diff. peak and hole 1.002 and -0.572 e.Å-3 
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 2
1H NMR of Compound 4.39 
 
 
 
 2
 
1H NMR of Compound 4.40 
AA-11-25-fr7-12
Acquisition Time (sec) 2.7307 Comment STANDARD 1H OBSERVE Date Jul 21 2008
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 300 Original Points Count 5984 Points Count 8192
Solvent CDCl3 Sweep Width (Hz) 3000.00 Temperature (grad C) 29.000
H2O
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
TMS
0
.
0
0
HO
O H
H
N
OTBS
21.00 4.894.461.38
 
 
  
1H NMR of Compound 4.41 
AS-4-62-pure
Acquisition Time (sec) 2.5616 Comment Std proton Date Oct 29 2008
Frequency (MHz) 399.76 Nucleus 1H Number of Transients 300 Original Points Count 13103 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 6395.91 Temperature (grad C) 25.000
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
10.99 8.81
2
4.0 3.270.84 0 0.87
TMS
Et2O
CH2Cl2
0
.
0
0
H
HO
O
H
N
OH
 
 
  
13C NMR of Compound 4.41 
AS-4-62-pure-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Oct 29 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 3000 Original Points Count 31375 Points Count 32768
Solvent cdcl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
3
H
HO
O
H
N
OH
2
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1H NMR of Compound 4.22 
AA-11-purealdehyde
Acquisition Time (sec) 2.5616 Comment Std 
proton
Date Nov 11 
2008Frequency (MHz) 399.76 Nucleus 1H Number of Transients 300 Original Points Count 13103 Points Count 16384
Solvent cdcl3 Sweep Width (Hz) 6395.91 Temperature (grad C) 25.000
11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
7.75 6.644.00 3.09 2.611.280.86
TMS
acetone
CH2Cl2
0
.
0
0
H
HO
O
H
O
O
 
 
 
 13C NMR of Compound 4.22 
AA-11-purealdehyde-C13
Acquisition Time (sec) 1.3582 Comment Std proton Date Nov 11 2008
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 30000 Original Points Count 31375 Points Count 32768
Solvent cdcl3 Sweep Width (Hz) 24125.45 Temperature (grad C) 25.000
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chloroform-d
7
7
.
2
3
H
HO
O
H
O
O
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Appendix D - ameter graphs 
Diameter graph of compound 4.11 
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 Diameter graph of compound 4.16  
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 Diameter graph of compound 4.10 
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 Diameter graph of compound 4.9 
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 Diameter graph of compound 5.1 
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 Diameter graph of compound 5.1 
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 Diameter graph of compound 5.2 
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 Diameter graph of compound 4.15 
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 Diameter graph of compound 5.3 
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 Diameter graph of compound (-)-2.9 
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 Diameter graph of compound 5.4 
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 Diameter graph of compound (+)-1.1 
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Diameter graph of compound (+)-1.1 
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